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The general introduction provides background information to the field of travel medicine 
from a historical, public and medical point of view.
Chapter one describes the effect of a malaria prevention programme and performance 
of self-diagnosis and standby treatment of malaria in long-term travellers to malaria 
endemic regions.
Chapter two describes the travel-health preparations and travel-related morbidity of 
kidney transplant recipients travelling to developing countries.
Chapter three reports on infectious complications in travellers with diabetes (insulin and 
non-insulin dependent), and their use of antibiotics in case of disease ocurrence.
Chapter four reports on the immune response in healthy elderly elicited by the live 
attenuated yellow fever vaccine. The response in elderly is compared to the response in 
younger vaccinees.
Chapter five addresses the intradermal Hepatitis B vaccination after topical application of 
an immunostimulant ointment, as a method to augment the immune response in 
previously non-responders to the vaccine.
Chapter six describes the non-inferiority of intradermally administered yellow fever 
vaccine at a reduced dose (0.1ml) compared the the conventional subcutaneous dose 
(0.5ml), in order to reduce the dose needed to elicit protective immunity.
Chapter seven focuses on the intradermal test dose of yellow fever vaccine in individuals 
with egg allergy who develop a local skin reaction to the vaccination.
Chapter eight reports on the immunity and safety of the intradermal inoculation route for 
pre-exposure primary and booster rabies vaccination with a purified chick embryo cell 
vaccine (PCECV).
The general discussion elaborates on the clinical perspectives of the studies concerning 
different types of travellers, on the immunology underlying the different routes of 
vaccination and different types of vaccines, and contemplates on future perspectives in 





General introduction – Travel medicine
In an epoch where every generation travels more frequently and at longer distances 
than the previous generation, with a mean increase of 30 million travellers per year from 
1995 until today [1], physicians throughout the world are confronted with new diseases. 
From the perspective of Western medicine, the import of highly contagious exotic 
infections remains an ominous but realistic threat, as shown by a Dutch patient who 
returned from Uganda carrying Marburg virus [2]. More than just a threat is the fact that 
approxmately 10% of travellers to developing countries experience a febrile illness, 
during or immediately after travel [3]. In absolute numbers, this implies that each year, 
roughly 4 million travellers appeal to specialised health care, either abroad or at home, 
because of systemic febrile illness, diarrhea or dermatologic disorders [4].
During the last decades, travel medicine has evolved into a distinct discipline of 
Infectious Diseases, eventhough transmission of infectious agents into vulnerable 
populations through travel has been well know for centuries. For example when the 
Spanish conquistadors invaded the Central and South American continents and 
annihilated (also by murdering) 95% of indigenous populations [5] . In fact, all major 
epidemics that have afflicted the human race have been spread internationally by 
travellers. Examples are the plague, which killed one third of the affected population, [6] 
throughout Europe between the fourteenth and eighteenth centuries, and syphilis, which 
is believed to have originally been imported into Europe from the New World by Spanish 
sailors [7]. Scientific medical publications in the field of travel medicine start to appear 
in the 1950’s with mainly topics on the impact of air and space travel on physical 
conditions and pre-existing illnesses, and individual reports of observed diseases 
during journeys (PubMed Database, MeSH terms “Travel Medicine”, approximately 
6300 hits). By the late 1960’s the first randomised controlled trial to investigate 
antimicrobial prevention of traveller’s diarrhea was reported [8], as well as case reports 
on imported infectious diseases by travellers, such as malaria [9]. In 1970, a novel 
perspective of travel medicine was introduced, in which travellers were defined as 
short-term travellers (vacational tourists), long-term travellers (e.g. expatriates) and 
immigrants and travellers visiting friends and relatives (VFRs) (those originating form 
tropical countries), among whom different risks of acquiring travel-related diseases 
could be distinguished [10]. Following closely on new travelling trends, specific norovirus 
outbreaks among cruise ship passengers were reported [11,12]. Since the 1990’s, the 
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number of scientific articles on Travel Medicine has increased almost threefold compared 
to the preceding decades (figure 1), implicating the increase of importance to and 
attention by the medical profession of this discipline of Infectious Diseases.
Hand in hand with travelling comes protection against travel-related diseases, which 
can be achieved on an individual and a population level. As preventive travel medicine 
covers multiple fields, from training to vaccination, individual and population-wide 
protection can be achieved on these different levels. A model to explain cumulative 
protective medical measures, and the occurrence of its failures, was proposed by 
James Reason as the “Swiss cheese” model [13]. According to this metaphor, in a 
complex system, hazards are prevented from causing human losses or illnesses by a 
series of barriers. Each barrier has unintended weaknesses or holes, giving the 
similarity with Swiss cheese (figure 2).
Defences, barriers, and safeguards occupy a key position in this system approach. 
By defining the barriers, and the (potential) holes, the system can be improved and the 
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Figure 1  Percentage of articles on travel medicine published  
 (PubMed Database, MeSH Term Travel Medicine, per decade), 
 according to the total number of scientific medical articles published 
(PubMed Database, total number of articles per decade).
13
hazards minimised, which can also be applied to travel medicine. This Swiss cheese 
model can be applied to the field of travel medicine, in which the slices and holes of the 
cheese are related to different aspects of protection against travel-related diseases in 
Table 1.
By applying the model on travel medicine, improvement of the system of protection 
against travel-related diseases can be achieved through knowledge on the following 
topics; 1. Epidemiology of travel-related diseases, 2. Morbidity and mortality of these 
illnesses in specific groups of travellers, 3. Adherence to travel health precautions, 
4. Immunological responsivity against vaccination, and 5. Availability of preventive 
measures, such as vaccines. The research described in this thesis addresses these 
various topics.
Epidemiology of travel-related disease with regard to specific populations  
of travellers
Several approaches to inventory the exact burden of these travel-related diseases have 
shown that the determination of the denominator (i.e. the number of persons exposed to 
a threat or disease) remains a challenge. A clinically relevant approach to investigate this 
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Figure 2  Swiss cheese model of how defences, barriers, and  safeguards may 
be penetrated by an accident trajectory [adapted from 13]. The slices 
of cheese are schematic and should either be positioned differently, or 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































burden is to monitor self-reported health problems after travelling to developing countries. 
However, with this approach, mild or self-limiting illnesses such as diarrhea, mild 
respiratory infections and skin disorders are either not picked up, or picked up less 
frequently. In addition, this approach is highly subject to population bias. 
Freedman et al. estimated the proportionate morbidity by diagnosis of self reported 
travel-related disease and geographic region among travellers returning from six 
developing regions of the world, by using the number of patients with a given diagnosis 
as the numerator and all ill travellers to a destination as a denominator [4]. Data of 30 
GeoSentinel sites, which are specialised travel or tropical-medicine clinics on six 
continents, contributed to clinician-based sentinel surveillance data on 17.353 ill 
returned travellers. Besides the limitations of this study, such as probable under-
representation of travel-related sexually transmitted diseases and infections with a short 
incubation period (e.g. dengue), it showed that the proportionate morbidity of diarrhea 
among returning travellers is highest in all developing regions visited (Southeast Asia, 
Central Asia, South America, Central America, Caribbean), except for Sub-Saharan 
Africa, where falciparum malaria accounts for the highest proportionate morbidity 
[figure 2 from ref 4]. Dengue occurs mostly in visitors to the Caribbean and Southeast 
Asia, cutaneous leishmaniasis in those who visit Central America and South America, 
and typhoid fever in travellers to south central Asia. TropNetEurop, a surveillance 
network of experts in Infectious disease and Tropical medicine throughout Europe, has 
reported similar trends [14]. Unfortunately, Freedman and colleagues have not 
analysed in more depth the contribution of the purpose of travel, a well-known risk 
factor for contracting infectious diseases during travelling. 
Bottieau and colleagues, alike the GeoSentinel group [4], investigated self-reported 
febrile episodes among returning travellers (N=1743), but additionally categorised 
these travellers into: Western travellers (natives of Western countries visiting the tropics 
for less than 6 months); expatriates (Western individuals residing for more than 6 
months in the tropics); natives of the tropics who have lived for more than 1 year in 
Europe and returning to their home country to visit friends and relatives (VFR travellers); 
and foreign visitors or migrants (natives of the tropics arriving for the first time in 
Europe) [3]. Falciparum malaria was more frequently diagnosed in expatriates, VFR 
travellers, and foreign visitors or migrants, whereas rickettsial infections, dengue, and 
acute schistosomiasis occurred almost exclusively in Western travellers and expatriates. 
Prevalence of HIV infection and tuberculosis was much higher in VFR travellers and 
foreign visitors or migrants. The epidemiology of travel-related diseases generated by 
these data is important for guiding post-travel diagnosis and empiric therapy as well as 
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for prioritizing pre-travel intervention strategies. In this thesis, the aim of reducing the 
risk of malaria in expatriate travellers is discussed in more detail (chapter 4).
Besides distinguishing travellers on the basis of the purpose of travel, they can be 
categorised according to their immune status. Immunocompromised travellers are 
more likely to experience severe effects of illness, and less likely to mount a significant 
response to vaccinations than those without immune disorders [15-21]. The divergent 
group of travellers with a compromised immunity comprises; 1. Patients on immune 
suppressive therapy such as solid organ or hematopoietic transplant recipients, 
patients with Crohn’s disease, colitis ulcerosa and rheumatic diseases, 2. Patients with 
human immunodeficiency virus (HIV) infection, 3. Asplenic travellers, 4. Patients with 
defective barriers such as skin or mucosal disorders or a reduced gastro-intestinal 
acid barrier [22]. Although the magnitude of the immune disorder is difficult to quantify, 
except for the use of the CD4+ T cell count in HIV patients, the overall health of immu-
nocompromised patients improves, and so does their motivation for travel along with 
the need for specific protective measures. In chapter 2 and chapter 3 of this thesis, the 
susceptibility of travelling solid organ transplant recipients and diabetics to travel-relat-
ed diseases and their precautions taken, are discussed in more detail.
Prevention of travel-related diseases by vaccination – protecting specific 
populations
The paradigm in vaccinology, which has existed since the development of vaccines, is that 
every population will mount comparable (protective) immune responses to similar vaccine 
doses and number of dose administrations. This approach has led to population-wide 
immunisations and hence the control of many infectious diseases, and should therefore 
always be pursued. However, with current advances in knowledge on individual variability 
in risk and morbidity of infectious diseases and in vaccine response, a more personalised 
approach could be strived for [23]. For the development of a personalised vaccination 
approach, the immune response in specific vulnerable groups must be inventoried and 
new vaccination methods, adjuvants and schedules should be investigated. 
Evident groups targeted by this approach would be the previously mentioned immuno-
compromised travellers, but also apparently healthy individuals can show a diminished 
response to vaccines. In these healthy persons, genetics, gender and age are 
well-known factors that can influence the response to specific vaccines [24]. 
The success of population-wide vaccination programs, suggests that interhuman 
genetic differences are negligible in the process of vaccine antigen processing, 
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presentation and lymphocytic response. However, complex interaction of the Human 
Leukocyte Antigens (HLA) and peptides derived from pathogens or vaccines are 
believed to play a role in the magnitude and breadth of the immune response [25,26]. 
HLA class II alleles influence the humoral response after vaccination, since antibody 
production is mediated by HLA class II-restricted CD4+ T-cell responses, except for 
polysaccharide antigen vaccines (e.g. pneumococcal vaccine) in which the response 
is T cell independent [27]. Indeed, for hepatitis B and measles vaccines, genetic 
profiles were found to be associated with persistent seronegativity or a low antibody 
response after vaccination [28-30]. The heritability of the immune response against 
hepatitis B vaccine is caused for 40% by genes within the MHC (Major Histocompatibil-
ity Complex), shown by higher intraclass correlations of MHC identical than MHC 
different dizygotic twins, and 60% by non-MHC genes [28]. Nevertheless, these genetic 
profiles do not exclusively account for the magnitude of the response. In the 
development of antibodies against hepatitis B vaccine, higher age, male gender and 
smoking also predispose for a lower antibody response [31,32].
In this thesis, two allegedly immunocompetent populations are investigated. The first 
group are individuals who failed to mount a protective immune response to the hepatitis 
B vaccine (chapter 5), expressed in antibody level. In these non-responders, the 
intrademal delivery of the vaccine antigen, along with an immune response modifier, 
was investigated in an attempt to induce a protective response. The second group are 
travellers of sixty years or older who received the live attenuated yellow fever vaccine 
(chapter 4). In the case of yellow fever vaccine, older age is associated with an 
increased susceptibility to serious adverse events which could hypothetically result 
from a diminished virus neutralising antibody response.
As the global population in Western countries is ageing, so is the travelling population. The 
elderly suffer from more frequent and severe infections than younger people [33], and this 
should increase the awareness in the elderly traveller and in those who give travel health 
advice. One of the main reasons for the increase in infections observed in the elderly is 
believed to be ‘immunosenescence’ [33], which refers to the immune system’s diminished 
function with age. Logically, if the elderly show an increased susceptibility to infections, 
their response to vaccines could be diminished, and this has indeed been found, e.g. in 
the case of influenza vaccination. In a review, the clinical vaccine efficacy in young adults 
was 70-90%, compared to an efficacy of 17-53% in the elderly vaccinated [34], depending 
on the circulating influenza strains. The phenomenon of immunosenescense is not yet well 
understood, but the following theories have been proposed: 1. Impaired antigen 
presentation, 2. Thymic involution leading to decreased naïve T cell production and a 
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decreased ability to respond to new antigens, 3. Reduced B cell production or isotype 
switching, resulting in low affinity antibody production, 4. Increased memory T cell numbers 
which restrict the diversity of the immune cell repertoire and 5. Ageing of the bone marrow 
stroma leading to decreased survival of plasma cells [35,36]. With more detailed knowledge 
on the development of the immune response to travel-related vaccines in the elderly, travel 
medicine could meet with the needs of this growing population. 
Prevention of travel-related diseases by vaccination – increasing vaccine 
dose availability
In the scope of a population-wide protection through vaccination, the aim is to create 
herd immunity in order to significantly reduce pathogen transmission and infection. Of 
all the goals formulated by the World Health Organisation (WHO) with respect to 
eradication of vaccine preventable diseases, only smallpox eradication has been 
achieved sofar [37]. Failure of eradication of infectious diseases through vaccination 
can be attributed to many factors. Evidently, political and financial reasons are the 
main hurdles to be taken, but from a scientific perspective other reasons can underly 
this failure. First, if the infectious agent has a non-human host, i.e. a zoonosis such as 
yellow fever, vaccination of all susceptible humans would still not eradicate the 
pathogen. Second, not all vaccines provide 100% protection against infection (e.g. 
vaccination with the capsular polysaccharide of Salmonella typhi (Vi) has a protection 
rate of 75% against typhoid fever in endemic populations) [38]. Third, immunisation is 
a human interference with nature, and people who believe this interference is wrong on 
religious or other grounds will refuse to be vaccinated, hampering eradication of the 
infectious agent. In the Netherlands, small outbreaks of poliomyelitis and measles 
occur on these grounds [39]. However, these reasons are probably secondary to the 
lack of resources to obtain the vaccine coverage that is needed for eradication. By 
reducing the vaccine dose needed for immunisation, vaccine stockpiles will last longer 
and costs will decrease, possibly leading to higher vaccine coverage.
A recently rediscovered possibility of vaccine dose reduction that receives much 
attention from vaccinologists, is vaccination in the skin [40-42]. The skin represents the 
outermost line of defense against mechanical impacts, temperature, UV-radiation, 
dehydration and pathogenic microorganisms. It is composed of three primary layers: 
the epidermis, the dermis and the subcutis (figure 3). 
The outer part of the epidermis consists of dead cells (stratum corneum), the inner part 
of live cells such as keratinocytes, melanocytes and, of special interest for immunisation 
purposes, dendritic cells which are named Langerhans cells (LC) after their discoverer 
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[44]. These professional antigen presenting cells (APC) account for only 1% of cells, 
but cover nearly 20% of the surface area due to their horizontal orientation and long 
protrusions [45]. The dermis is primarily composed of extracellular matrix, and like the 
epidermis	 contains	 dendritic	 cells	 (dermal	 dedritic	 cells	 –	 dermal	 DC),	 besides	
fibroblasts, macrophages and granulocytes. In the dermal layer reside the most 
superficial glands and lymphatic and blood vessels of the body. LC and dermal DC 
constantly monitor the (epi)dermal microenvironment by taking up antigen and 
processing it into fragments that can be recognised by effector cells of the adaptive 
immune system. LC have classically been thought to be essential for initiating T cell 
responses to cutaneous antigens, accounting for the success of intradermal vaccination 
[46]. However, recent data have also highlighted the importance of dermal DC in 
cutaneous immunity [47,48]. Zhao et al. investigated the contribution of vaginal APCs 
in immune induction to HSV-2 (Herper Simplex Virus), and revealed that only the 
CD11b+ dermal DCs, but not Langerhans cells, presented viral antigens to CD4+ T 
cells and induced Interferon γ (IFN)secretion. Following on these results, Allan et al. 
provided in vivo evidence that priming of HSV-specific CTLs (Cytotoxic T cells) after 
skin infection does not require antigen presentation by LCs. Although these results are 
confined to HSV and may not apply to other pathogens, they do undermine the 
hypothesis of overall dominance of LCs in an (epi)dermally initiated immune responses. 
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For immunisation purposes, both could be relevant, as both LC and dermal DC process 
and present the injected antigen to naïve T cells in the draining lymph nodes [49]. Itano 
and colleagues demonstrated that after subcutaneous inoculation of antigen, 
unprocessed antigen drains to lymph nodes within several hours and does not require 
cell-mediated transport [50]. DC that reside in the lymph node take up and process 
this antigen and then activate naïve T lymphocytes. A second wave of antigen is 
delivered to lymph nodes approximately 24 hours later by an influx of dermal DC that 
express high levels of the antigen. Although extensive T cell proliferation is induced by 
the first wave of antigen, complete CD4+ T cell differentiation requires the presence of 
dermal DC. [50]. 
LC and DC represent the principal APC under steady state condition, which is 
disrupted during cutaneous vaccination. The inflammatory state initiated by 
immunisation might induce influx of plasmacytoid DC into the site of injection, 
contributing to the induction of an adaptive immune response [51]. Based on these 
data, the success of intradermal vaccination is attributed to efficient vaccine antigen 
presentation to APC and hence T and B cells, whereas with subcutaneous or 
intramuscular	 vaccine	 administration,	 the	 probability	 of	 antigen	 –	 APC	 contact	 is	
lower. This hypothesis has recently been studied in mice, in which Virus-like particles 
(VLPs) of simian-human immunodeficiency virus (SHIV) were inoculated 
 intramuscularly, intraperitoneally, subcutaneously and intradermally. With an optical 
imaging approach to directly visualize the trafficking of the VLPs after immunisation, 
Cubas et al. showed convincingly that the intradermal immunisation led to the largest 
level of lymph node involvement for the longest period of time, which correlated with 
the strongest humoral and cellular immune responses [52].
Historically, the route of vaccine administration by needle, i.e. intradermal, subcutaneous 
or intramuscular, has been reached on arbitrary grounds. The first scientific evidence 
of vaccination was provided by Edward Jenner, an English doctor who in 1796 
successfully inoculated the content of a cowpox bulla -containing vaccinia virus- into 
the skin of a young boy, rendering him protected against a challenge with the human 
pox virus (variola) [53]. Almost 100 years later another vaccinology pioneer, Louis 
Pasteur, developed a post-exposure rabies vaccine, which was administered under a 
fold of the skin (i.e. subcutaneously) [54]. Apparently, intramuscular injection was 
initially not the standard immunisation route, and is still not the immunisation route for 
vaccines as Bacille Calmette Geurin (BCG) and vaccinia. Increased knowledge on 
vaccine-induced immunity, and enhanced laboratory techniques have contributed to a 
more ‘educated’ monitoring of immune response, although these measured responses 
often remain surrogates for protection against infection [55]. 
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In this thesis, the intradermal delivery of Hepatitis B vaccine (chapter 5), yellow fever 
vaccine (chapters 6 and 7) and rabies vaccine (chapter 8) is discussed, as a method 
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Falciparum malaria remains a major occupational illness that accounts for several 
deaths per year and numerous lost working days among the expatriate population, 
working or living in high-risk malarious areas. Compliance to preventive strategies is 
poor in travellers, especially business travellers, expatriates and long-term travellers.
Methods 
In this cross-sectional, web-based study the adherence to and outcome of a preventive 
malaria programme on knowledge, attitude and practices, including the practice of 
self-diagnosis and standby treatment (curative malaria kit, CMK) was evaluated in 
2,350 non-immune expatriates, who had been working in highly malaria endemic 
areas. 
Results 
One-third (N=648) of these expatriates visited a doctor for malaria symptoms and 
almost half (29 of 68) of all hospitalisations were due to malaria. The mandatory 
malaria training for non-immunes was completed by 92% of those who visited or 
worked in a high risk malaria country; 70% of the respondents at risk also received the 
CMK. The malaria awareness training and CMK significantly increased malaria 
knowledge [relative risk (RR) of 1.5, 95%CI 1.2-2.1], attitudes and practices, including 
compliance to chemoprophylaxis [RR=2.2, 95%CI 1.6-3.2]. Hospitalisation for malaria 
tended to be reduced by the programme [RR=0.4, 95%CI 0.1-1.1], albeit not 
significantly. Respondents who did not receive instructions on the rapid diagnostic 
test were two times [RR=2.3, 95%CI 1.6-3.3] more likely to have difficulties. Those 
who did receive instructions adhered poorly to the timing of repeating the test. 
Moreover, 6% (31 of 513) of those with a negative test result were diagnosed with 
malaria by a local doctor. 77% (N=393) of the respondents with a negative test result 
did not take curative medication. 57% (252 of 441) of the respondents who took the 
curative medication that was included in the kit did not have a positive self-test or 
clinical malaria diagnosis made by a doctor. 
Conclusions 
This survey demonstrated that a comprehensive programme targeting malaria 
prevention in expatriates can be effectively implemented and that it significantly 
increased malaria awareness.
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Introduction
Every year, Plasmodium falciparum infects 300 to 500 million persons, and kills between 
one and two million. Particularly sub-Saharan Africa, parts of South America and 
South-East Asia are affected. Falciparum malaria is also a major occupational illness 
that accounts for several deaths per year and numerous lost working days among the 
expatriate population, working or living in high-risk malarious areas. Approximately 1% 
of all non-immune travellers who acquire P. falciparum infection die [1].
Increasing awareness, personal protection measures against mosquito bites, chemo-
prophylaxis, and early diagnosis and treatment are the mainstay of prevention against 
falciparum malaria. Compliance to these preventive strategies is poor in travellers, 
especially business travellers, expatriates and long-term travellers [2]. Moreover, the 
diagnosis of malaria is often not immediately considered in returning travellers, 
resulting in treatment delay and subsequent higher morbidity [3]. 
In 2003, a preventive programme for international employees and contractors working 
in malaria endemic areas was set up by an oilfield service company to enhance 
awareness on the dangers of malaria, and to reduce its morbidity and mortality. The 
cornerstones of this preventive programme were a malaria awareness training 
programme and provision of a curative malaria kit, which contained dipstick-based 
strips for self-diagnosis and emergency standby medication for self-treatment of 
falciparum malaria. In an initial survey, this programme was rated very good to 
excellent by more than 60% of the respondents [4].
In this cross-sectional study by web-based questionnaire, the adherence to this 
preventive malaria programme, and the practice of self-diagnosis and standby 





The malaria prevention programme consists of the following components: 
1. Malaria training for non-immunes. This training was mandatory for all non-immune 
international oilfield service company employees. Any person who had left a malaria 
endemic country for more than six months was considered non-immune to malaria. 
2. Arrival packages were assigned to employees with high-malaria-risk destinations, 
according to the WHO malaria country definition [5]. A quiz was designed to 
enhance the awareness of expatriate workers on the risks of malaria and the 
possible preventive measures. 
3. At all malarious locations appropriate preventive measures were provided, 
including insecticide treated bed nets, routine malaria prophylaxis, insect repellents 
and insecticide treatments to kill mosquito larvae in company facilities and 
residences. 
4. Malaria hot line. A toll-free telephone line, staffed by multilingual doctors who were 
specialized in tropical diseases, was available 24 hours a day, seven days a week. 
5. A curative malaria kit (CMK) with hands-on training. This kit was developed to 
address emergency cases of suspected malaria in which an individual was more 
than 24 hours away from a medical centre. The kit consisted of forehead temperature 
strips, three dipstick-based, immunological antigen-capture self-tests for 
falciparum malaria (Paracheck Pf® or Core Malaria Pf®, depending on availability), 
and curative medication (Coartem®: artemether/lumefantrine). If the self-test was 
positive the infected person was instructed to start taking the curative medication 
(four tablets every morning and four tablets every evening for three days), and 
seek medical assistance as soon as possible. In case of a negative test result, the 
blood test was to be repeated 12 hours later. 
Web-based questionnaire 
To evaluate the malaria prevention programme, an e-mail invitation to answer a 
web-based questionnaire (NetQuestionnaires version NETQ 6.0, the Netherlands) 
was sent in July 2007 to 8,380 oilfield service company employees, who were 
registered as non-immune to malaria, and who might have travelled to, lived or worked 
in a malarious area in the last two years. The survey covered use of the programme in 
these preceding 24 months.
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The web-based questionnaire was accessible from July to September 2007 by a 
unique link per addressed employee, and could be opened only once. During this 
period, several reminders were sent to the employees who had not yet accessed the 
questionnaire. The answers to the questionnaire were analysed anonymously. Gender, 
age and country of birth was the only personal information requested.
Definitions 
Malaria was reported as 
1. ‘Doctor’s diagnosis of malaria’; diagnosed by a local doctor (not necessarily 
laboratory confirmed)
2. ‘Laboratory confirmed malaria’; diagnosed by a local doctor and confirmed by 
laboratory
3. ‘Presumptive malaria’; a positive self-test, or a clinically diagnosed or laboratory 
confirmed malaria. 
The following subgroups were defined:
- to analyse the effect of the malaria prevention programme on several aspects 
concerning knowledge, attitude and practices (KAP) of malaria: 
1. ‘Malaria Prevention Programme’ as receiving the training for non-immunes with 
or without CMK
2. ‘No Malaria Prevention Programme’ as receiving neither training nor CMK. 
- to analyse the effect of the CMK on malaria KAP: 
1. ‘CMK’ as receiving the training and the kit
2. ‘No CMK’ as receiving the training without the kit. 
Statistical analysis 
Continuous data were analyzed with Students t-test, categorical data with Chi-square 
test or Fisher’s exact test where appropriate. Corrected relative risk (RR) was calculated 
from the corrected odds ratio (OR) obtained by logistic regression. Corrected OR was 
recalculated into RR according to the following formula: RR=OR/((1-P)+(P*OR)), 
provided by Zhang and Yu [6], as the OR overestimates the RR when prevalence (P) 
exceeds 10%. Possible confounders for which was corrected by logistic regression 
are specified for all reported results. P values were provided for categorical data with 
more than two categories. Statistical analysis was performed using a computer- 




The web-based questionnaire was opened by 3,575 employees, giving a total 
response rate of 43%. Of these respondents, 2,552 reported to have travelled to 
malaria endemic countries in the past 24 months, of whom 2350 (92%) completed the 
questionnaire entirely. Analysis of the answers of all the respondents at risk and of 
those at risk who completed the questionnaire did not yield different results. Therefore, 
only the results of the completed questionnaires are reported. The mean time to 
complete the questionnaire was 12 minutes and 22 seconds. 
Study population 
The demographic characteristics of the studied population are listed in Table 1. 
The malaria countries visited are amongst those with the highest incidence of 
P. falciparum [6]; in descending order of frequency, the most visited countries were: 
Angola, Cameroon, Nigeria, India, Gabon, Sudan, Equatorial Guinea, Democratic 
Republic of Congo and Chad. Most respondents visited more than one endemic 
country; the median of endemic countries visited per respondent was 2 (range 1-105). 
Risk of malaria 
A comparison was made between the cumulative incidences (CI) of malaria according 
to work status (Table 2). The CI of acquiring malaria increased according to work 
status and thus according to time spent in malaria endemic countries. In addition, 
chemoprophylaxis use by long term travellers was significantly lower (29%) compared 
to that of rotators and visitors (both 62%) (p<0.001). In contrast to the increasing CI of 
malaria with a longer duration of stay, the CI of being hospitalised for malaria was 
similar in all groups.
Ninety percent of the respondents who reported to have had laboratory confirmed 
malaria acquired the disease in sub-Saharan Africa. Malaria was acquired in 
descending order of frequency in Sudan, Nigeria, Equatorial Guinea, Angola, Chad, 
Cameroon, Republic of Congo, Gabon, Ivory Coast, India, Benin, Somalia, Uganda 
and Peru. The considerable burden of malaria in this population was demonstrated by 
the fact that one-third (N=648) of all respondents visited a doctor for malaria symptoms 
and almost half (29 of 68) of all hospitalisations were due to laboratory confirmed 
malaria.
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Malaria prevention programme 
The mandatory malaria training for non-immunes was completed by 92% of those 
who visited or worked in a high risk malaria country. Overall, 70% of the respondents 
at risk also received the CMK (Figure 1). Seventy-five percent (N=1229) of respondents 
who received the CMK were instructed in how to use it, and all (98%) considered the 
instructions to be clear.
Multivariate analysis showed that respondents who were born in a malaria endemic 
country were two times less likely to receive the malaria prevention programme 
[RR 2.0, 95% CI 1.4-2.7]. In addition, women were less likely to receive the CMK [RR 
1.4, 95% CI 1.1-1.7]. The effect of the malaria prevention programme and the CMK on 
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Table 1  Demographic characteristics of study population
Demographic characteristics  N %
  (N total 2350)
Gender Male  2065 88
 Female 285 12
Age (yrs) mean  36 -
 (range) (19-63) 
Continent of birth African 733 31
 European 631 27
 South American 328 14
 Asian 301 13
 North American 174 8
 Arabic 102 4
 Oceanian 64 3
Country of birth Malaria endemic$ 1392 60
 Malaria non endemic 941 40
Working conditions Outdoor* 1278 54
 Indoor  1072 46
Work status Long term (>6 months) 1122 48
 Rotator 795 34
 Visitor 342 15
 Other (e.g. spouse) 91 4
Percentages may not add up to exactly one hundred due to rounding off. $ Malaria endemic country 
 according to the WHO (5). *Outdoor working  conditions include working on a land rig or with seismic 
crew, off shore, on another field location or on a marine vessel.
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malaria KAP was therefore corrected for these variables. The distribution of the 
programme was not influenced by work status, i.e. whether employees were long-term 
workers, rotators or visitors, neither by working indoors or outdoors.
Respondents receiving the malaria prevention programme reported a twofold higher 
use of malaria chemoprophylaxis (47% vs. 19%) and had significantly more knowledge 
about malaria. A similar effect was observed for those who only received the CMK. 
Those who did not receive the programme were twice as likely not to consider malaria 
as a threat, nor to take additional anti-mosquito measures (Table 3). 
Despite the increased use of chemoprophylaxis by the total group receiving the CMK, 
a small group (14%, N=226) thought that having the CMK made regular malaria 
 chemoprophylaxis unnecessary. The use of chemoprophylaxis in this group was 49% 
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Table 2  Cumulative incidence of malaria per 100 persons according to 
work status in 24 months. *p-value for malaria diagnosis was 
obtained by χ2-test and for hospitalisation with Fisher’s exact test. 
Those who responded to belong to the ‘other’ group (N=91), 
instead of the solicited groups, were excluded as their global time 
of possible exposure to malaria was unclear. 
  Cumulative incidence (%)
  of malaria in 24 months p-
   [95%CI]  value*
  Visitor Rotator Long term




 2.3 6.2 13.7 
<0.001
  [0.7-3.9] [4.5-7.9] [11.7-15.7]
 
Doctor’s diagnosis
 2.0 5.7 12.8 
<0.001
  [0.5-3.5] [4.1-7.3] [10.8-14.8]
 
Laboratory confirmed
 1.8 4.3 9.7 
<0.001




 0.6 1.6 1.5 
0.6
for malaria
  [0.0-1.4] [0.7-2.5] [0.8-2.2]
 
Laboratory confirmed
 0.6 1.6 1.2 
0.5
  [0.0-1.4] [0.7-2.5] [0.6-1.8] 
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in comparison to 60% of those who felt prophylaxis remained necessary with CMK 
use (p = 0.001).
Use of self-test
One-third (N=575) of the respondents who had received the CMK performed the 
malaria self-test contained in the CMK for presumptive malaria. Forty-nine test results 
were positive (defined as a positive test result at first or repeated testing), 508 negative 
and 18 invalid. Two-thirds (N=378) repeated the test, giving a similar result in 79% (19 
of 24), 99% (338 of 344) and 40% (4 of 10), respectively. Although it was instructed to 
repeat the test after 12 hours if the result was negative, only 55% (N=189) adhered to 
this instruction. 
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Figure 1  Distribution of the Malaria Prevention Programme in population  
at risk (N=2350). Numbers represent number of respondents 
 receiving this part of the programme. Training = Training for non-
immunes, CMK = Curative Malaria Kit.
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Fifteen percent of the respondents reported having difficulties in using the self-test. 
Among those, the most frequently reported difficulties were pricking the finger and 
placing the blood drop on the test strip (Table 4). 
Respondents who did not receive instructions with the self-test were two-times more 
likely to have difficulties [RR=2.3, 95%CI 1.6-3.3] and three-times more likely to have 
an invalid test [RR=2.9, 95%CI 1.0-8.5]. Respondents with difficulties were 30 times 
more likely to have an invalid test result [RR=29.6, 95%CI 8.2-106.4], after correction 
for possible confounding of receiving instructions. 
Use of medical care
Almost twice as many respondents with a positive result visited a doctor for malaria 
symptoms, and a positive test indicated a tenfold higher risk of being diagnosed with 
malaria. On the other hand, 6% (31 of 513) of those with a negative test result were still 
diagnosed with malaria by a local doctor, although this diagnosis was 1.5 times less 
likely to be confirmed by a laboratory (Table 5). 
When hospitalisation was employed as an indicator for severity of malaria, performing a 
test before visiting a doctor for malaria symptoms did not result in more severe malaria in 
comparison to immediately visiting a doctor (respectively 12%, and 14% hospitalisation in 
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Table 4  Difficulties with self-test contained in the CMK reported by 
 respondents who used the test. More than one difficulty could be 
reported per respondent. 
Difficulties with self-test  N (%)
Respondents reporting difficulties 
85 (15)
N performing self-test = 575
 
Difficulties Finger prick 50 (59)
N total =85 Placing blood drop 24 (28)
 Result interpretation 15 (18)
 Identifying lines 13 (15)
 Technical problem kit 12 (14)
 Instructions 10 (13)
 Adherence to waiting time 2 (2)
 Too ill to perform test 1 (1)
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those with doctor’s diagnosis of malaria, p = 1.0) (table 5). In addition, respondents in 
whom malaria was diagnosed despite a negative test result, had a similar hospitalisation 
rate (13%).
Standby emergency treatment 
One fifth (N=441) of the respondents took curative medication for malaria. The origin 
of the curative medication was mostly the CMK (39%) or a local hospital (35%). Ninety 
percent (N=44) of the respondent with a positive test result and 22% (N=115) of the 
respondents with a negative test result took curative medication.
Fifty seven percent (N=252) of respondents who took curative medication did not 
have presumptive malaria. The source of this inappropriately used curative medication 
was two times more likely to be the CMK than the medication used by those with 
presumptive malaria (50% vs. 25% respectively). 
Malaria prevention in long term travellers
Table 5  Influence of test performance and result (positive if first or  repeated 
test result was positive) on doctor visit and malaria diagnosis and 
hospitalisation.  
   CMK received




 Positive Negative RR RR# performed




40 233 1.8 1.8 177
malaria symptoms 





33 31 11.0  10.3  59
malaria 
(67) (6) [8.3-13.2] [7.4-12.8] (6)
N Yes (%)
Laboratory confirmed  
 
 
28* 18* 1.5   1.5   47*
malaria 
(85) (58) [1.1-1.7] [1.2-1.7] (80)
N Yes (%)
Hospitalisation for   
 
 
4* 4* 0.9   1.0   8*
malaria 
(12) (13) [0.2-2.9] [0.2-3.0] (14)
N Yes (%)
RR=Relative Risk. 
# RR is corrected for malaria endemic country of birth. 
* Denominator is respondents with a doctor’s diagnosis of malaria.
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Effect of the malaria prevention programme on the outcome of malaria 
1.1% (N=25) of the respondents who had received the malaria prevention programme 
was hospitalised for laboratory confirmed malaria in comparison to 3.7% (N=4) of 
those who did not receive the programme [RR=0.3, 95%CI 0.1-0.9]. However, when 
corrected for birth in a malaria endemic country the risk of hospitalisation was not 
significantly reduced [RR=0.4, 95%CI 0.1-1.1]. There was no significant reduction in 
hospitalisation for those who had received the CMK without training. 
Discussion
Falciparum malaria is a severe disease and international employees and contractors 
working in highly endemic malarious areas are particularly at risk. In this study, it was 
found that one per 200 employees per year was hospitalised because of laboratory 
confirmed malaria, and 90% of malaria was acquired in sub-Saharan Africa. The 
self-test was positive in 8% of the respondents. Malaria was also diagnosed by a 
medical doctor in 6% of the repondents with a negative test. The malaria awareness 
training and self-diagnosis and treatment had a significant positive effect on 
knowledge and attitude towards malaria prevention and doubled the use of malaria 
chemoprophylaxis. This study also suggests a reduction in hospitalisation for malaria, 
thus reducing malaria associated morbidity. 
Several limitations of this study require attention. First, not all employees responded 
to the invitation (response rate was 43%), possibly inducing a responder bias. This 
may have led to an overestimation of the uptake of the programme. On the other hand, 
some of the respondents did not or partly receive the programme, which allowed to 
draw seperate conclusions on the contribution of awareness training and CMK. 
Secondly, neither the result of the self-test nor the diagnosis of malaria by doctor or 
laboratory was confirmed by an independent test. Therefore, the accuracy of the inter-
pretation of the self-test result by these febrile expatriates remains unknown. However, 
the endpoint of malaria was considered to be equally (in)accurate in all respondents, 
meaning that no diagnosis bias was introduced.
This survey showed that sub-Saharan Africa continued to pose the highest risk for the 
acquisition of malaria, and that long term residents are at the highest risk to contract 
malaria, although they were not more likely to be hospitalized than rotators or visitors. 
This could reflect the experience long term travellers have with malaria, being more 
aware of its symptoms. 
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The present study confirmed that the compliance of expatriate workers to malaria 
prophylaxis was poor [7] and decreased with duration of stay [8]. Fifty-five percent of 
the respondents did not take malaria chemoprophylaxis; for comparison in travellers 
on vacation in high-risk areas this was 16% [2]. The availability of self-testing and 
standby treatment with CMK may offer non-compliant employees an additional safe 
guard against the serious consequences of falciparum malaria if proper medical care 
is not available. In addition, the introduction of the malaria awareness training and 
CMK significantly increased compliance to malaria prophylaxis. Despite this increased 
compliance, 14% of those who received the CMK thought that having the kit made 
regular chemoprophylaxis unnecessary. Although many of the respondents who felt 
this way actually did use prophylaxis. The importance of continuing prophylaxis use 
despite the availability of standby treatment warrants special emphasis in any 
educational programme. 
In experienced hands, the immunological antigen-capture self-test for P. falciparum 
histidine-rich protein-2 or lactate dehydrogenase has shown to be accurate and 
reliable diagnostic tests for P. falciparum infection [9]. However, the correct 
performance of these dipstick-based rapid tests in febrile travelers may vary from 
69% to 91% depending on whether prior instructions were given [10-12]. In the present 
study, 15% reported difficulties with performing the self-test, and the fact that not 
receiving CMK instructions was significantly associated with difficulties and invalid 
test results clearly underscores the need for proper instructions. Only 67% adhered to 
the instruction to repeat the self-test in case of a negative test result, and 55% adhered 
to the instructed time interval. The reason for non-adherence to these instructions is 
unknown. One possibility is that the self-test was not repeated because malaria 
symptoms had spontaneously resolved. It should be emphasized during the training 
that repeating the self-test within six hours after a first negative test result is unlikely to 
be useful as parasitaemia may still be too low to detect.
The introduction of a self-test for malaria aims at decreasing treatment delay in case 
of a positive test result in the absence of medical care, and at reducing the empirical 
use of standby treatment medication in case of fever and a negative test result. On the 
contrary, introduction of a self-test for malaria may increase patients’ delay and lead 
to more severe malaria in case of false negative test result. However, the hospitalisa-
tion rate of respondents with a negative test result who were subsequently diagnosed 
with malaria by a doctor was not significantly increased. This suggests that these 
patients did not have severe malaria more frequently. 
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Six percent of respondents who tested negative were still diagnosed with malaria. 
However, this diagnosis was less likely to be confirmed by a laboratory. It may reflect 
the possibility of overdiagnosis of malaria by a doctor, since there is anecdotal 
evidence that in Africa it is common practice to assume malaria, often irrespective of 
actual complaints [13]. The use of molecular diagnostics has the potential to overcome 
these limitations. When a finger prick for self-testing is performed we would recommend 
storing a few drops of blood on filter paper as well for PCR analysis for P. falciparum 
after returning home. This would enable future determination of true positive and true 
negative rates for self-testing and clinical diagnosis of falciparum malaria abroad. 
The use of a self-test had a clear effect on restrictive use of standby medication: 77% 
of the respondents who had a negative test result did not take standby medication. 
Standby treatment was used not only by respondents with a positive self-test or 
medical diagnosis of malaria, but also in 57% who did not have a diagnosis of malaria, 
a number which has also been reported by others [14, 15]. The CMK may have 
facilitated this inappropriate use, as the curative medication used by respondents 
without presumptive malaria originated in 50% from the CMK. This aspect will require 
future scrutiny; the improper use of self-treatment may result in unnecessary exposure 
to side-effects and in a delay of diagnosis and treatment of other potentially life 
threatening diseases. 
Conclusions
This survey demonstrates that, with proper instruction and training, a preventive 
malaria programme can contribute to the awareness of the risks of this disease. The 
components of this programme that deserve attention are the instructions on the 
performance of the self-test, the correct use of the curative medication and the need 
to seek medical care regardless of use of CMK. As it is impossible to make all 
travellers, irrespective of their purpose or duration of travel, adhere one hundred 
percent to every preventive measure, the contribution of the separate components 
which raise awareness and protection is cumulative. For those travellers considered 
to be exposed to higher risks of infection, such as expatriates, this malaria prevention 
programme certainly is such a component. Its strength lies in the multi-step design, 
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Improved health of solid organ transplant recipients has possibly led to increased 
travelling by this group. Since they are thought to be more susceptible to (travel-
related) infectious diseases, as a result of their immunosuppressive medication, a 
survey was performed to investigate their travel profile and occurrence of travel-
related diseases.
Methods
A cross-sectional, descriptive study was conducted among Dutch kidney transplant 
recipients visiting the nephrology outpatient clinic. 290 completed a questionnaire 
(Q1). Of these, 103 travelled to (sub)tropical regions in the past 5 years. A mailed 
questionnaire (Q2) concerning occurrence and severity of travel-related diseases was 
returned by 71 individuals. 
Results
Thirty four percent of the respondents had travelled outside Western Europe (WE) and 
Northern America (NA); 22% of these travellers did not seek pre-travel health advice. 
Transplant physicians were most frequently consulted for pre-travel advice (53%). Of 
the respondents travelling outside WE and NA 29% were ill during their most recent 
journey. Four of seventeen ill recipients (24%) were hospitalised, reflecting the high 
morbidity of travel-related disease in this patient group. 
Conclusion
Our data show that there is need for improvement of pre-travel healthcare, and 
suggest an important role for transplant physicians in providing adequate 
counselling.
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Introduction
Modern surgical techniques and immunosuppressive therapy have greatly improved 
the health of solid organ transplant (SOT) recipients resulting in an increased mobility 
to different parts of the world, including tropical or subtropical destinations. Because 
of the continuous need for immunosuppression, SOT recipients are more susceptible 
to travel-related diseases and opportunistic pathogens than immunocompetent 
travellers [1,2]. A Canadian study revealed that SOT recipients are relatively unaware 
of these travel-related risks [3]. We investigated the travel health knowledge, attitude 
and practices of Dutch kidney transplant recipients (KTX) regarding preventive 
measures, adherence to these measures and consequences of illness while staying 
abroad, in order to assess the travel-related risks and to improve travel care in this 
patient group.
Patients and methods
This cross-sectional, descriptive study was conducted at the nephrology outpatient 
clinic of the Leiden University Medical Centre (LUMC) in the Netherlands from December 
2004 until January 2005.
A questionnaire (Q1) was distributed to all kidney and kidney-pancreas transplant 
recipients while waiting for their routine visit to their transplant physician. Patients 
participated on a voluntary basis. Q1 focussed on demographics, on the medical 
history regarding organ transplantation, on information regarding travel of the past five 
years (destination, duration, purpose) and on pre-travel preparations. 
Patients who had travelled outside Western Europe (WE) received a second, more 
extensive questionnaire (Q2) by mail. Q2 assessed information on the most recent 
journey in the past five years (after transplantation) (destination, duration, purpose), on 
pretravel preparations, on medication taken during travel, on medical illnesses during 
travel and on its consequences. 
To evaluate preventive measures and morbidity according to medical hazard, 
destinations were categorised into countries with (VAC+) and countries without (VAC-) 
recommendations for vaccination according to Dutch national travel guidelines [4]. 
VAC- countries are those in Western Europe, the Northern Americas, New Zealand and 
Australia.
Statistical analysis was performed using a computer-assisted software package (SPSS 








A total of 290 of the approximately 400 individuals visiting the nephrology outpatient 
clinic completed Q1. Seventy-two recipients had their transplantation within the 
previous year. Six of the 72 recently transplanted SOT had travelled, of which 3 outside 
Western Europe (Curacao, Tunisia and Turkey). Since travelling is dissuaded during the 
first year after transplantation we excluded this patient group from further analysis 
(Figure 1). 
Q2 was sent to 94 of the remaining 218 patients who had travelled outside WE, and to 
an additional 9 patients that had responded to Q1 after the period of active recruitment 
(February 2005). Seventy-one of these 103 patients returned Q2 (70% response rate). 
Twelve questionnaires were excluded (patients were deceased, had moved, or had 
their last travel within WE) leaving 59 questionnaires eligible for analysis.
Responders (N=59) and non-respondents (N=32) to Q2 did not differ in terms of 
gender (p=0.5), age (p=0.3), transplant organ (p=0.4) and post-transplantation 
period (p=0.9). Demographic characteristics of the study population are listed in table 
1. Nine of 59 respondents to Q2 did not fill out their (immunosuppressive) medication. 
Usage of the following immuunosuppressive medication was reported (N=50): 
prednisone (95%), mycophenolate mofetil (47%), cyclosporine (42%), tacrolimus 
(27%), azathioprine (18%), mycophenolic acid (4%) and sirolimus (2%). Most KTX were 
on double (54%) or triple (42%) immunosuppressive therapy. 
Travel profile
The majority (80%) of the respondents to Q1 reported to have travelled outside the 
Netherlands (NL), 43% travelled outside WE, and 34% outside WE and the northern 
Americas (NA) in the previous five years. No differences in gender, age, transplant 
organ or mean time since transplantation were observed between travelling and non-
travelling respondents to Q1.
The mean duration of travel of the patients travelling outside WE (Q2, N=59) was 24.5 
+ 2.9 (s.e.m.) days. Regions visited by the travellers outside WE (Q1, N=94) were 
North America (23%), Africa (20%); North Africa, mostly Canary Islands (12%), and 
South Africa (8%), Eastern Europe (13%), Asia (12%) and Central America (11%), 




Figure 1  number of subjects enrolled in phase 1 (outpatient questionnaire, Q1) 
and phase 2 (mail questionnaire, Q2) of the survey.
Transplant patients in outpatient 
clinic in time of survey (±2 months) 
n=400 
Filled out questionnaires 
n=290 
Not filled out questionnaires 
n=110 
Transplanted organ > 1 year in situ 
n=218 
Organ < 1 year in situ 
n=72 
Travelled outside WE  
n=94 
Not travelled outside WE 
n=124 




KTX travelling outside WE   
n=103 




Travelled outside WE  
n=59 
Deceased, moved or 
travelled within WE 
n=12 
  Outpatient questionnaire (Q1)  
Mail questionnaire (Q2)  
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followed by the Caribbean (7%), Oceania (4%), South America (4%) and the Middle 
East (3%). In the Q2 population the major travel purpose was tourism (73%). Twenty 
four percent  visited friends and relatives (VFR), and 3% travelled for business. 
Travel Health Preparations
Pre-travel health information was sought by 5% (Q1; 4 of 80) of reponders travelling 
outside NL but within WE, 23% of travellers outside WE but within NA and 78% of 
travellers outside WE and NA (p<0.01). No statistical significant difference regarding 
gender, age, transplanted organ or time since transplantation was observed between 
respondents seeking pretravel advice and those not seeking advice (data not shown). 
Therefore, the data considering kidney and kidney pancreas transplant recipients were 
analysed as one group (KTX). 
Travelling KTX who sought pre-travel advice (Q2, N=37) mostly consulted their 
transplant physician (53%), followed by a specialised travel clinic (16%) or their general 
practitioner (14%).
Regarding purpose of travel, travel health advice was sought by 28 of 42 (67%) tourists, 
and by 7 of 15 (46%) VFR. Responders to Q2 and travelling to VAC+ countries (N=25) 
more frequently sought pretravel advice (80%) than Q2 respondents travelling to VAC- 
areas (N=34) (50%) (p=0.03).
Accuracy of advice on vaccine-preventable diseases
Of the travellers seeking advice and travelling to VAC+ regions, 15 respondents (79%) 
were vaccinated according to the national guidelines. The five unvaccinated individuals 
Travelling kidney transplant recipients
Table 1  Demographics of studied travelling kidney and kidney pancreas 
transplant recipients 
 Q1 (n=218)  Q2 (n=59)
 %  or mean range %  or mean range 
 (± s.e.m.)  (± s.e.m.)
gender (male) 60 - 64 -
age (yrs) 50.5 ± 0.8 23-79 50.5 ± 1.7 24-78
percentage kidney transplants 78 - 83 -
transplant organ in situ (yrs) 9.5 ± 0.5 1-37 9.5 ± 1.0 1-29
Q1 is the outpatient questionnaire, Q2 is the mail questionnaire which only the travellers outside 
 Western Europe (N=103) received. 
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travelled to Turkey (N=4) or Colombia (N=1). Four of these 5 obtained pretravel advice 
from their transplant physician.
Travel related diseases
Seventeen respondents to Q2 (29%; 95% CI 17-41) reported being ill during their most 
recent journey. Diarrhea was most frequently reported (44%; 95% CI 27-61, 14 of 32 
reported symptoms), followed by fever (19%; 95% CI 5-33) and symptoms of respiratory 
tract infection (16%; 95% CI 3-29). Nine of 14 of travellers with diarrhea took additional 
medication (mainly antidiarrheal medication) of which only 2 reported to have taken 
antibiotics. No statistical difference was observed in the development of illness according 
to the number of immunosuppressants taken by respondents (data not shown). 
Almost twice as many travellers visiting VAC+ destinations (40%; 95% CI 21-59) 
reported symptoms of disease compared to those with VAC- countries (21%; 95% CI 
7-35) however this difference did not reach statistical significance (p=0.1). A significant 
difference was seen in illness in KTX travellers reporting to have taken oral diabetic 
medication (80%; 95% CI 45-100 ill) compared to non-diabetic travellers (24%; 95% CI 
13-35 ill) (p=0.02).
Consequences of illness for KTX during travel are listed in table 2. Four of the ill 
recipients (24%; 95% CI 4-48) were admitted to the hospital because of: syncope 
during a diarrheal episode (N=1), Salmonella gastro-enteritis with transient renal failure 
(N=1), ulcerative lesions in mouth and throat accompanied by diarrhea and weight 
loss (N=1) and cellulitis of the lower limb (N=1). 
Chapter 2
2
Table 2  Type of medical care and absence from work due to travel-related 
disease in transplant recipients during travel outside Western Europe
 percentage of travellers time (days)  range
 becoming ill (N=17) (mean ± s.e.m.) (days)
Use of additional medication 64 - -
Contact physician on location 29 - -
Contact physician in NL 29 - -
Hospitalisation 24 25±16 1-56
Absence from work due to illness 29 38±16 4-92
NL = the Netherlands. 
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Discussion
In this survey, 75 of 218 respondents had visited a (sub)tropical destination in the past 
five years and tourism was the main reason for travelling. At least one in five immuno-
compromised travellers failed to obtain pre-travel health advice for these medically 
more hazardous destinations. In addition, there is room for improvement of the 
accuracy of advice on vaccine-preventable diseases. For example, 21% of travellers 
seeking information did not receive active or passive immunisation against hepatitis A 
while they should have, nor was immunoprotection confirmed by hepatitis A serology 
(data not shown). Furthermore, one third of the KTX travelling to VAC+ and one fifth 
travelling to VAC- countries acquired a travel-related illness. Diabetic KTX travellers 
were most at risk. Finally, we found that almost a quarter of the ill travellers were 
hospitalised compared to less than 1% hospitalisation of ill, short term healthy travellers 
to the tropics [5].
Some potential limitations of this survey require comment: 1) we analysed travel 
behaviour of the last five years to reduce recall bias; 2) the number of kidney transplant 
recipients visiting friends and relatives (VFR) may be underestimated due to a language 
barrier resulting in failure to return the mailed questionnaire (Q2). In general, VFR are 
reported to be at greater risk of acquiring travel-related diseases [6].
Although very few studies have investigated practices, travel-related risks and 
complications experienced by solid organ transplant recipients travelling, the findings 
are surprisingly similar [3,7]. In the retrospective, descriptive study of mainly kidney 
and liver transplants recipients by Boggild et al. tropical destinations accounted for 
48% of all travel; 34% travelling outside NA and WE failed to seek pre-travel advice, 
and in 78% the transplant physician was the source of information [3]. Of the travellers 
who became ill 56% had travelled to the tropics. In the retrospective, descriptive study 
of heart transplant recipients by Kofidis et al. travelling overseas was associated with 
a 45% complication rate in comparison to 22% for European destinations [7]. 
To conclude, we would like to make the following suggestions for improvement of travel 
care in this patient group. 1) transplant physicians have a central role in raising awareness 
of the risks and precautions for foreign travel after solid organ transplantation. A number 
of web links provide general information on risks and recommended preventive health 
measures [8]. For more specific advice referral to a specialised travel medicine centre is 
recommended. 2) As in non-compromised travellers, gastrointestinal and respiratory 
Travelling kidney transplant recipients
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tract infections were most frequently reported [9]. Diarrhea can lead to dehydration and 
may compromise renal function and increase toxicity of immunosuppressive medication 
[8]. Only 14% of respondents with diarrhea started self-treatment with antibiotics. 
Therefore, emphasis should be put on the importance of prompt self-treatment with 
antibiotics to reduce duration and severity of the diarrhea. 3) Finally, the need for 
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Diabetic travellers to the (sub)tropics are thought to have symptomatic infectious 
diseases more often and longer than non-diabetics. Evidence for this is needed. This 
study evaluates whether diabetic travellers are at increased risk of symptomatic 
infectious diseases.
Methods 
A prospective study was performed between October 2003 and February 2008 among 
adult medication-dependent diabetic travellers, with their non-diabetic, non-immune-
suppressed travel companions serving as matched controls. Thus, diabetics and 
controls were assumed to have comparable exposure to infection. Data on symptoms 
of infectious diseases were recorded by using a structured diary.
Results  
Among 70 insulin-dependent diabetics, the incidence of travel-related diarrhea was 
0.99 per person-month, and the median number of symptomatic days 1.54 per month. 
For their 70 controls, figures were 0.74, and 1.57, respectively (p>0.05). Among 82 
non-insulin-dependent diabetics, incidence was 0.75, and the median number of 
symptomatic days was 1.68. For their 82 controls, figures were 0.70, and 1.68, 
respectively (p>0.05). As for other symptoms, no significant travel-related differences 
were found between diabetics and controls.
Only 17% of diabetic travellers with diarrhea used their standby-antibiotics.
Conclusions  
Medication-dependent diabetic travellers to (sub)tropical destinations do not have 
symptomatic infectious diseases more often or longer than non-diabetics. Although 
the incidence of metabolic dysregulation among diabetic travellers should be 
assessed in more detail, routine prescription of stand-by antibiotics against 
uncomplicated travellers’ diarrhea is probably not useful, in particular not for NIDD. 
Self-treatment should be reserved for more complicated diarrhea.
Infectious diseases in diabetic travellers
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Introduction
In recent years, the number of travellers to (sub)tropical countries has increased 
dramatically [1], including those with pre-existing medical conditions such as diabetes. 
Due to improved awareness and support for diabetic travellers, their number probably 
will continue to rise [2,3].  
Travelling to the (sub)tropics may complicate an underlying medical condition and may 
require special considerations and advice. For example, it has been suggested that 
diabetic travellers have a higher risk of metabolic dysregulation and symptomatic 
infectious diseases [4-6]. Dutch travel guidelines thus recommend that diabetics taking 
insulin or oral anti-diabetic medication should be prescribed stand-by antibiotics for 
treatment of diarrhea while in the (sub)tropics [7]. British guidelines likewise advise to 
consider prescribing a course of antibiotics for diabetic travellers [8]. However, data on 
the association of diabetes mellitus with tropical infections, and on the benefits of 
preventive and therapeutic measures are lacking. Even evidence for a causal relation 
between diabetes and domestic infections is limited and inconsistent [9]. 
The exact number of diabetics who visit the (sub)tropics is not known. In a study 
published in 1991, 0.4% of 2445 travellers to a developing country who visited a travel 
clinic had insulin-dependent diabetes mellitus [10]. Since then, the prevalence of 
diabetes, both insulin-dependent and non-insulin-dependent, has increased. Annually, 
about ninety million persons travel to the (sub)tropics from North America and Europe 
[11], where diabetes prevalence is about 2.8% [12]. Assuming that diabetics travel as 
frequently as non-diabetics, an estimated 2.5 million diabetics travel annually from 
North America and Europe to (sub)tropical destinations. 
In order to improve travel advice for this substantial group, we conducted a prospective 
study with matched controls to see if diabetics are more susceptible to symptomatic 
infectious diseases than non-diabetics. We also studied the usage of antibiotics for 
stand-by treatment of diarrhea among diabetics. 
Methods
Study population
A prospective study with matched controls was performed among travellers who 
attended the travel clinics of the Public Health Service Amsterdam or the Leiden 
University Medical Centre  between October 2003 and February 2008. All  medication- 
dependent diabetics 18 years or older were eligible if planning to travel to one or more 




companion, who was within 10 years of their own age. Thus, the control group was 
comparable for travel destination, travel duration, and exposure. Tropical or subtropical 
destinations were defined as those with moderate to high risk on hepatitis A according 
to the World Health Organization [13].
Insulin-dependent diabetes (IDD) was defined as diabetes mellitus requiring daily 
insulin treatment, with or without additional oral anti-diabetics. Non-insulin-dependent 
diabetes (NIDD) was defined as diabetes mellitus requiring only oral anti-diabetics.   
Survey methods and definition of symptoms
A standard questionnaire was used to collect data on socio-demographics and medical 
history. Diabetics and controls were asked to fill out a structured diary about symptoms of 
infectious diseases, from the day they visited the travel clinic (up to 4 weeks before departure), 
until 2 weeks after return from travel. Data were collected before departure to gain information 
about baseline symptoms, and for 2 weeks after return to encompass incubation periods of 
the most (acute) travel-related infectious diseases. In the results section, the term ‘travel- 
related’ refers to the period of travel itself and the two weeks thereafter. 
Recorded in the diary were any episodes of fever, diarrhea, vomiting, rhinitis, cough, 
and signs of skin infection; consultation with a doctor; and whether the diabetics used 
the stand-by antibiotics or other medication. Fever was defined as a self-measured 
body temperature of 38.5 degrees Celsius or more. Diarrhea was defined as loose or 
watery stools. Rhinitis was defined as nasal discharge or congestion. Cough could be 
dry or productive. Signs of skin infection included redness or (itching) rash, swelling, 
tenderness, and/or pus-like drainage. The diary also provided for recording non-in-
fectious symptoms and signs, such as dysregulation of blood glucose level. Diabetics 
monitored blood glucose levels at their own discretion. 
All diabetics were prescribed ciprofloxacin (500 mg 2 times a day for 3 days), to be 
used as immediate self-treatment in case of traveller’s diarrhea, according to the 
Dutch national guidelines on travel advice [7].
Power-analysis showed that 70 pairs were needed to prove a diarrhea outcome ratio 
of 2 or more, with α = 0.05 and power = 80%.
This study was approved by a medical ethics committee. All participants gave their 
informed consent. 
Statistical Analysis
For non-independent, non-matched characteristics, McNemar’s statistic testing was 
performed (SPSS for Windows release 15.0, SPSS Inc., Chicago, USA). A p-value 
< 0.05 was considered to be statistically significant.
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A random effects Poisson regression model was used to calculate incidence rates 
and accompanying incidence rate ratios (IRR). Incidence rate was defined as the 
number of symptom onsets divided by the sum of symptom-free days for all individuals 
during a specific time period. A random effects logistic regression model was used to 
calculate median number of symptomatic days and accompanying odds ratios. 
Median number of symptomatic days equals an individual’s probability to have a 
symptom per day. It was calculated to compare the disease burden between the 
diabetics and non-diabetic controls. In order to express results in units per month, 
numbers per day were multiplied by 30.  
The random effects model takes into account two levels of correlation: 1) diabetics 
and their travel companions had more or less the same exposure, and thus are not 
independent; 2) for incidences, there may be repeated episodes of a symptom within 
an individual; for numbers of symptomatic days, presence of symptoms over the days 
within an individual are correlated. IDD and NIDD were analyzed separately. 
For estimation of the parameters, a Bayesian approach was used, starting with non-infor-
mative priors. Posterior distributions were obtained by Markov Chain Monte Carlo 
methods, using the WinBUGS program [14,15]. Three chains were generated, based on 
different sets of baseline values. Parameter estimates are the medians of the posterior 
distributions. The range from the 2.5% to the 97.5% quantile is used to quantify the 
uncertainty in the parameter estimates. This range can be interpreted as a 95% confidence 
interval and will be referred to as such. If 1 is not included in the 95% confidence interval 
of a ratio, the ratio can be considered statistically significant (p<0.05).
Results
During the study period, 210 diabetics planning to travel with a non-diabetic, non-
immune-suppressed companion were eligible for inclusion: 93 IDD, and 117 NIDD. Of 
these 210 eligible pairs, 58 (28%) did not participate, citing lack of time (34%), lack of 
interest (57%) or reasons unspecified (9%). The remaining participants all provided a 
completed diary.
Characteristics of the study sample
The study sample comprised 70 IDD and their 70 controls, plus 82 NIDD and their 82 
controls. Of these 152 pairs, 137 (90%) were included at the Public Health Service 
Amsterdam, and 15 (10%) at the University Medical Centre Leiden. Table 1 shows the 




Sixty-four IDD (91%) and 70 NIDD pairs (85%) matched for country of birth; only 8 IDD 
(11%), and 12 NIDD pairs (15%) matched for gender (data not shown). The IDD more 
often had cardiovascular disease and dyslipidemia than their controls (p<0.05). There 
was no difference in the use of gastric acid inhibitors. The NIDD more often had 
non-ischemic cardiovascular disease and dyslipidemia than their controls (p<0.05). 
Their use of gastric acid inhibitors seemed more frequent, but not significantly.
Incidence rates and number of symptomatic days between diabetics and 
their controls
Table 2 shows the travel-related symptoms by prevalence, incidence rate, mean 
duration among symptomatics, and median number of symptomatic days per 
symptom for IDD and their travel companions. The figure in Table 2 shows the 
accompanying incidence rate ratios (IRR) and odds ratios (OR) on a logarithmic scale. 
Likewise, table 3 shows the results for NIDD and their controls.
IDD and controls
The prevalence of travel-related diarrhea was 44% among IDD and 41% among 
controls. The incidence rate of travel-related diarrhea was 0.99 per person-month 
versus 0.74; the IRR showed no significant difference. The median number of days 
with diarrhea was 1.54 per month among IDD, comparable to controls.  
Diarrhea outcome measures before travel showed no significant differences between 
IDD and controls (p>0.05) (data not shown). 
Diarrhea incidence rate and median number of symptomatic days were higher during 
travel than before travel, for both IDD and their controls (p<0.05) (data not shown). 
The IDD and controls did not significantly differ in travel-related incidence rates and 
median number of symptomatic days for vomiting, fever, cough, rhinitis, and signs of 
skin infection. Nor did they differ pre-travel, except that the median number of days 
with cough was lower among IDD (p<0.05) (data not shown). 
Travel-related and pre-travel outcome measures did not differ significantly, except that cough 
among IDD increased after departure in incidence rate and median number of symptomatic 
days (p<0.05), although confidence intervals approximated 1 (data not shown). 
NIDD and controls
The prevalence of travel-related diarrhea was 39% among NIDD and 43% among 
controls. The incidence rate was 0.75 per person-month versus 0.70; the IRR showed 
no significant difference. The median number of days with diarrhea was 1.57 per 
month among NIDD, comparable to controls.  
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Pre-travel diarrhea incidence rate and median number of symptomatic days were 
higher for NIDD than controls (p<0.05) (data not shown). 
Diarrhea incidence rate and median number of symptomatic days were higher during 
travel than before travel for both NIDD and controls (p<0.05) (data not shown). 
Travel-related incidence rates and median number of symptomatic days for vomiting, 
fever, cough, and rhinitis were comparable between both groups. The travel-related 
incidence rate and median number of days for signs of skin infection were higher among 
NIDD than among controls. However, these measures also differed before travel (data 
not shown) and showed no significant increase after departure (data not shown).
Before travel, incidence rate and median number of symptomatic days for vomiting 
were higher for NIDD than controls (p<0.05) (data not shown). 
Travel-related and pre-travel outcome measures did not differ significantly, except 
that rhinitis and vomiting among controls increased after departure in both incidence 
rate and median number of symptomatic days (p<0.05) (data not shown). 
Treatment and doctor consultation
Only 6 out of 31 IDD with diarrhea (19%) used the stand-by antibiotics. Effect on the 
duration of diarrhea was unclear due to small numbers. Seven (23%) used loperamide 
or activated carbon, and 3 (10%) used oral rehydration solution. Of 29 controls with 
diarrhea, 10 (34%) used loperamide or activated carbon, and 1 (3%) used oral 
rehydration solution (not statistically different from IDD). 
Only 5 out of 32 NIDD with diarrhea (16%) used the standby antibiotics. Effect on the 
duration of diarrhea was unclear due to small numbers. Nine diabetics (28%) used 
loperamide or activated carbon, and 1 (3%) used oral rehydration solution. Of the 35 
controls with diarrhea, 12 (34%) used loperamide or activated carbon, and 1 (3%) 
used oral rehydration solution (not statistically different from NIDDs). 
As to the use of other medication (antibiotics, antipyretics, and anti-inflammatory 
drugs) and doctor consultations, both IDD and NIDD were comparable to their 
controls.
Dysregulation of blood glucose 
Of 70 IDD, 3 (4.3%) reported dysregulation of blood glucose levels during travel. A 
69-year old woman had two hypoglycemic episodes, of which one coincided with 
non-febrile diarrhea, for which she took stand-by antibiotics. A 47-year old man had a 
2-day episode of hyperglycemia without fever or diarrhea. A 25-year old woman had 
2 alternating hypo- and hyperglycemic episodes, of which one coincided with 
























































































































































   




























   


























































































   


































   

























































   





































   
































   

























   





































































































   


































   















































   
























   




































   



























   

































   



























   







































    
                    
   































     
  
   











































   














































   

















































   









































   


































   


































   





































































































































































































































































































   
   
   
   































































   
   
   
   






































































   
   
   
   

































































   
   
   
   





































































   
   
   
   































































   
   
   
   









































































   
   
   
   
































































   
   
   
   








































































   
   
   
   































































   
   
   
   
















































































   
   
   
   


































































   
   
   
   





















































































































































































































































































































































   
   
   
   































































   
   
   
   






































































   
   
   
   

































































   
   
   
   



































































   
   
   
   
































































   
   
   
   









































































   
   
   
   

































































   
   
   
   








































































   
   
   
   































































   
   
   
   















































































   
   
   
   






























































   
   
   
   






























































































































































Of 82 NIDD, 2 (2.4%) reported dysregulation of blood glucose levels during travel. 
A 63-year old woman had one hyperglycemic episode, coinciding with non-febrile 
diarrhea, for which she did not take stand-by antibiotics. A 47-year old woman had a 
4-day episode of hyperglycemia without fever or diarrhea.
Discussion
This is the first prospective study evaluating whether medication-dependent diabetic 
travellers to the (sub)tropics are at increased risk for developing symptomatic 
infectious diseases. Although we hypothesized that they would have symptoms more 
often and longer than non-immune-suppressed non-diabetics, no differences in trav-
el-related diarrhea, vomiting, fever, cough, or rhinitis were found. The NIDD had signs 
of skin infection more often than controls, unrelated to travel. A higher incidence rate 
and burden of non-travel-related signs of skin infection among type 1 and 2 diabetics 
has been reported before, irrespective of insulin use [9,16]. Why we found increased 
risk for skin infection only among NIDD and not IDD, may reflect differences in age, 
exposure, or unknown co-morbidity, such as pre-existing skin disease, carriage of 
Staphylococcus aureus, peripheral neuropathy, or microvascular disease [9,17].   
Before travel, disease burden of cough seemed to be lower among IDD than controls. 
This coincided with a higher prevalence of asthma or chronic obstructive pulmonary 
disease among the controls, although the difference was not statistically significant 
(p>0.05). 
Before travel, outcome measures for diarrhea and vomiting were higher among NIDD 
than controls. The increased diarrhea might be explained by medication, as the oral 
anti-diabetic metformin is known for such gastro-intestinal side effects [18]. Also, 
diarrhea has been associated with metabolic dysregulation. In a retrospective popu-
lation-based survey including 423 IDD and NIDD and more than 8000 controls, non-
travel-related diarrhea was more prevalent among diabetics than controls, with an OR 
of 2.06 (95% confidence interval 1.56 - 2.74) after adjusting for age and sex [19]. That 
study linked poorer levels of self-reported glycemic control with a higher prevalence 
rate of diarrhea.
Our study design had distinctive strengths. Structurally specified data were obtained 
prospectively and on a daily basis. Data collection started before departure (median 
15 days) to gain insight into pre-existing symptoms. It continued until 2 weeks after 
return from travel to encompass incubation periods of the most (acute) travel-related 
infectious diseases. With a travel companion serving as a matched control, situational 
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specifics for diabetics and non-diabetics were comparable, which minimized any 
differences in exposure to infectious agents between the two groups. Diabetics and 
controls also matched in age and country of birth. They did not match for gender or 
for cardiovascular disease and dyslipidemia. However, prospective studies on travel-
related infectious diseases found no association of symptoms of infectious diseases 
and gender [20,21], and we are not aware of any association with cardiovascular 
disease or dyslipidemia. 
The prevalence of diabetes among visitors of our clinic was 3.1%, comparable with the 
general population [12]. Also, age and male-female ratio of our diabetic subjects were 
comparable with the general diabetic population. Participants’ travel destinations 
were equally distributed across the four (sub)tropical regions. Their median travel 
duration of 20 days corresponded well with the median travel duration of the average 
traveller [22,23]. Thus, the study sample can be considered representative, and 
results can reasonably be applied to the average diabetic traveller to a (sub)tropical 
country.
This study has some limitations. Sample size may not have been large enough to 
detect small differences. Secondly, although the diary provided information on 
symptom duration, it did not distinguish mild symptomatology from severe. For 
example, diabetics could have had more bowel movements or more water loss. 
Thirdly, diabetics and controls differed in counseling and prescription; some diabetics 
did use the stand-by antibiotics. Therefore, the data may be skewed toward seeing 
less differences in outcome measures between both groups. 
Metabolic dysregulation was minimal among our diabetics: 4.3% among IDD and 
2.4% among NIDD. A retrospective, descriptive cohort study among IDD performed in 
1996-1997 reported that 68% of 19 IDD travellers to tropical destinations had metabolic 
dysregulation [4]. Moreover, it found that 55% of those IDD reported dysregulations 
more frequently during travel than at home. This suggested that travel to the tropics is 
a risk factor for metabolic dysregulation. However, data were collected retrospectively, 
by telephone interviewing, and the study size was small and comprised only IDD. 
Finally, with improvements in the quality and use of insulin preparations and treatment 
schedules [5,24,25], diabetics might now be more aware and more compliant with 
anti-diabetic therapy, including its adjustments to travel-related alterations in eating 
habits, physical exertion, climate, and circadian rhythm.
Nevertheless, the prevalence of metabolic dysregulation in our subjects, may be un-
derestimated, because regular testing of blood glucose levels during travel was not 




Aside from such limitations, our findings represent diabetics who sought pre-travel 
health advice. One may assume that they had a more than average health awareness, 
particularly having received travel advice and knowing the objectives of the study. 
As to usage of stand-by antibiotics, it was carefully explained to all diabetics. Its 
importance was emphasized by an experienced travel health expert, and by means of 
information leaflets. Nevertheless, 83% of all diabetics with diarrhea did not use this 
treatment, even in the case of metabolic dysregulation. Of 152 stand-by antibiotic 
courses provided, 141 (92.8%) were not used. Moreover, NIDD did not experience 
hypoglycemias, only hyperglycemias. Indeed, hypoglycemia is uncommon when 
using only oral anti-diabetics [26]. Thus, routine prescription of stand-by antibiotics to 
prevent hypoglycemia during uncomplicated diarrhea is probably not useful. For IDD, 
monitoring blood glucose more frequently, and adjusting insulin dosage and diet 
accordingly, are probably more helpful in minimizing the impact of diarrhea or fever on 
metabolic dysregulation. Stand-by antibiotics may be useful for diabetic travellers to 
areas where health facilities are lacking or for complicated cases, for example 3 or 
more unformed stools per 24 hours with accompanying symptoms such as fever, or 
blood in stools.  The merits of this definition could not be assessed in this study.
In conclusion, this study showed that medication-dependent diabetic travellers to 
(sub)tropical destinations do not have travel-related symptoms of diarrhea, vomiting, 
fever, cough, rhinitis, and signs of skin infection more often or longer than non-
diabetics.
The incidence of metabolic dysregulation among diabetic travellers should be 
assessed in more detail, but our findings indicate that routine prescription of stand-by 
antibiotics against mild, uncomplicated travellers’ diarrhea is probably not useful, in 
particular not for NIDD. Self-treatment could be of value for travellers to remote areas 
or for cases of complicated diarrhea. 
Infectious diseases in diabetic travellers
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Yellow fever vaccine (YF-17D) can cause, although rarely, serious adverse events 
(SAEs). The mechanism of these SAEs is poorly understood. Older age has been 
identified as one of the risk factors for developing such events. We investigated the 
adaptive immune response against YF-17D in elderly subjects, to elucidate the 
mechanism of SAEs.
Methods
Young volunteers (age range 18-28 yrs, N=30) and elderly travellers (age range 60-81 yrs, 
N=28) were vaccinated with YF-17D from the same vaccine batch. Neutralising 
antibody titres and plasma YF-17D RNA copy numbers were measured at day 5 after 
vaccination. Following vaccination, adverse events were documented in a diary during 
3 weeks.
Results
Ten days after vaccination seroprotection (80% virus neutralisation in plaque assay by 
minimally diluted serum) was attained by 77% (23/30) of the young participants and 
by 50% (14/28) of the elderly (p = 0.03, Chi-square test). At day 10, the younger 
participants had a Geometrical Mean Titres (GMT) of 0.18 IU/ml, ten-fold higher than 
the GMT in the elderly (0.017 IU/ml) (p = 0.004). At day 14 the GMT also differed 
(respectively 4.8 IU/ml and 2.7 IU/ml, p = 0.035). Seroprotection was attained by all 
participants (young and elderly) by day 14. At day 5, viraemia was more common in 
the elderly (18%) than in the younger participants (3%). Viraemia was associated with 
fever but not with the time to seroprotection. The elderly participants reported fewer 
mild adverse events.
Conclusion
We found that elderly subjects (age ≥60 yrs) had a slower antibody response against 
yellow fever vaccine after primovaccination. We hypothesize that this allows attenuated 
virus to cause higher viraemia that may result in severe disease. 
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Introduction
The live attenuated 17D yellow fever vaccine is regarded as one of the safest and most 
effective vaccines [1]. However, it can cause fatal adverse events in immunocompro-
mised individuals [2]. A hampered immune response allows the vaccine virus to 
replicate unrestrictedly, leading to vaccine-associated disease that resembles wild 
type yellow fever (yellow fever vaccine associated viscerotropic disease, YEL-AVD). 
YEL-AVD is fatal in 50% of cases [3]. In the last decade, a series of these serious and 
sometimes fatal adverse events following yellow fever vaccination appeared in the 
literature [4-10]. The risk of YEL-AVD increases with a history of thymectomy [11], male 
gender [12] and old age. For vaccinees of 60-69 years, this risk is estimated to be 
1.1:100.000 doses and for vaccinees of ≥70 years it is 3.2:100.000, a 4.4 and 13.4 fold 
higher risk than for young adults [13]. 
The higher risk of YEL-AVD in elderly travellers has led to a more restrictive policy 
towards vaccinating travellers older than 60 years [14,15]. In this group the risk of serious 
adverse events following vaccination is weighed against the risk of infection, using 
disease surveillance data of the WHO and reports of yellow fever outbreaks.
The biological mechanism for the association between adverse events and older age 
has not yet been elucidated [3]. The innate and adaptive immune response wanes with 
age [16]. However, yellow fever neutralising antibody (NA) levels are equal in elderly and 
young vaccinees at 30 days following vaccination [17]. Although the immune response 
eventually leads to equal NA levels, it may be that the response develops more slowly 




This study was conducted to determine whether the adaptive immune response to 
yellow fever vaccine is slower to develop in persons of 60 years or older compared 
with younger persons (18-40 years). The humoral response to yellow fever vaccination 
was measured by Plaque Reduction Neutralisation Test (PRNT). Yellow Fever 17D 
(YF-17D) viraemia after vaccination was quantified by real time PCR (qRT-PCR). In 




Study design and Participants
In this prospective controlled observational trial, participants were recruited at the 
Travel Clinic of the Leiden University Medical Centre, and Municipal Health Centres of 
Leiden and The Hague. Healthy volunteers aged between 18 and 40 years were 
eligible for inclusion into the control group. Participants in the control group did not 
need to have an indication for yellow fever vaccination. Healthy travellers aged 60 
years or above, who had an indication for yellow fever vaccination based on their 
travel destination (National Coordination Centre for Travelers’ Health, LCR) [18], were 
eligible for the study group. 
Those who had previously received yellow fever vaccine, those who had a 
compromised  immunity due to underlying illness or immunosuppressive medication 
and	–in	the	young–	those	who	were	pregnant	were	excluded.	The	study	was	carried	
out between April 2008 and April 2009. Vaccinations were administered at the Travel 
Clinic of the LUMC.
Yellow fever vaccine
The live, attenuated, 17D vaccine used in this study was manufactured on embryonated 
chicken eggs according to WHO regulations and stored according to manufacturer’s 
guidelines. All administered vaccines originated from the same vaccine lot (Stamaril, 
Lot no B5355, Sanofi Pasteur, France). The vaccine was administered subcutane-
ously in the deltoid region of the right arm. 
Data collection
At the time of inclusion, data on demographic characteristics of the participants were 
obtained. Blood samples for the determination of neutralising antibodies (NA) and 
YF-17D viraemia were collected before (day 0), and 3, 5, 10, 14 and 28 days after 
vaccination. Peripheral Blood Mononuclear Cells (PBMC) for determination of cellular 
immunity were collected at day 0 and 14.
Participants were asked to document local and systemic adverse events after 
vaccination in a three-week diary. Solicited symptoms were: erythema, pain and 
swelling at the site of injection, fever and myalgia. 
Constant virus – varying serum dilution Plaque Reduction Neutralisation Test 
(PRNT)
The tests were carried out in 6-well plates (Corning Inc., USA) using a slightly modified 
technique described originally by De Madrid and Porterfield [19]. Briefly, approximately 
6 x 105 Vero cells/mL were seeded per well in 6−well plates and cultured to obtain a 
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confluent monolayer. Sera were complement inactivated at 56°C for 1 hour. Prevac-
cination sera were tested in 1:16 dilution, to which 100 plaque forming units (PFU) of 
17D-YF were added. Postvaccination sera were tested in two-fold dilutions starting 
from 1:4 to 1:1024. One hundred PFU of YF−17D virus were added to each serum 
dilution. All test sera were assayed in duplicate. After 1 hour incubation on ice, the 
mixtures of virus and serum were added to the Vero cell monolayers and incubated for 
1 hour at 37°C. An overlay of 2 x DMEM and 2% agarose was added. After 5 days of 
incubation at 37°C, the overlay was discarded and cell monolayers were stained with 
crystal violet. Plaques were counted by eye. Virus neutralisation (VN) was calculated 
for each serum dilution (i) with the following formula: VN(i) = 100 x (number of PFU in 
diluted postvaccination serum / number of PFU in pre-vaccination serum (in a 1:16 
dilution)). The serum dilution at which log10 neutralisation index 0·7 (80% VN) occurred 
was taken as endpoint, as this corresponds to the generally accepted definition of 
protection [20]. A reference serum, obtained from the National Institute for Biological 
Standards and Control (http://www.nibsc.ac.uk/) was used for quantification of 
International Units per milliliter (IU/mL). In our hands a 0.7 log10 plaque reduction in 
1:10	diluted	serum	corresponds	 to	a	 titre	of	0.5	 IU/mL	 [95%CI:	0.3–0.8	 IU/mL]	 [21].	
Similar values have been found by others [22]. Geometrical Mean Titres (GMT) were 
compared between the two groups.
Flow cytometry  
PBMC samples were thawed and allowed to rest overnight in RPMI supplemented 
with 10% fetal calf serum (Gibco, Breda, The Netherlands). After washing, cells were 
incubated with ViVid Live/Dead stain (Invitrogen, Breda, The Netherlands) for 10 
minutes at 4°C before staining with the following antibodies: CD3-APC-Cy7, CD4-Alexa 
700, CD8-Am Cyan, CD45RA-PE-Cy5, CCR7-PE-Cy7 (all BD Biosciences, Breda, the 
Netherlands) and CD19-Pacific Blue and CD14-Pacific Blue (Biolegend, ITK 
Diagnostics, Uithoorn, the Netherlands) for 30 minutes at 4°C. Cells were acquired on 
a LSRII flowcytometer using FACSDiva Software (BD Biosciences) and analysed 
using FlowJo Software (TreeStar, Ashland, Oregon, USA). Analysis was performed by 
gating on lymphocytes, followed by selection of live cells that were not CD14 or CD19 
positive. Subsequently, CD3+ T cells were selected and samples were gated for 
CD4+CD8- cells and CD8+CD4- cells before analyzing memory subpopulations.
Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
Viral RNA was isolated from 200 μl plasma using a MagNa Pure LC Total Nucleic Acid 




synthesized with 10 μl elute (200μl total) in a Tprofessional ThermoCycler (Biometra, 
Germany), and quantitative reverse transcription-PCR (qRT-PCR) of YFV RNA was 
performed in a BioRad i-cycler IQ™ real-time PCR detection system (BioRad, 
Veenendaal, The Netherlands). The following YFV specific primers and probe were 
used [23]:
YFV-1 (forward)  AATCGAGTTGCTAGGCAATAAACAC 
YFV-2 (reverse)  TCCCTGAGCTTTACGACCAGA
YFV-P (probe)   FAM-ATCGTTGAGCGATTAGCAG-BHQ
FAM (6−carboxyfluorescein) was used as 5’-reporter dye and BHQ (Black Hole 
Quencher) as 3’-quencher dye. In order to quantify YFV RNA, log10 dilutions of in vitro 
transcribed RNA standards were included as standard curves. RNA copy numbers 
were calculated with the standard curves from Cycle threshold (Ct) values to compare 
viraemia in both groups quantitatively.
Ethics
The protocol and consent forms were approved by the Dutch Central Committee of 
Human Research (CCMO) and by the Medical Ethical Committee of the Leiden 
University Medical Centre (LUMC) in the Netherlands. The trial was registered under 
NTR1040 and ISRCTN42180653, (http://irsctn.org). Written informed consent was 
obtained from each participant prior to inclusion. 
Statistical methods
Power calculations were based on an expected 80% virus neutralisation of 95% in the 
control group and 66% in the elderly group at day 14, based on previous observations 
at the Travel Clinic (unpublished data). With an α of 0·05 and a β of 0·2, 26 participants 
per group were needed to confirm a significant difference under these assumed 
conditions. To take into account a possible lost to follow up of 15%, 30 participants 
were included per group.
The Student’s t-test was used for comparison of the Geometrical Mean Titres (GMT) 
at which 80% virus was neutralised between the control group and elderly vaccinees. 
Where appropriate, Chi-square tests were used, and Wilcoxon’s test for non-paramet-
rical distributed numerical data. Statistical analysis was performed using a computer-
assisted software package (SPSS version 16.0, SPSS Inc., Chicago, IL).




We enrolled 60 volunteers. None of the participants withdrew prematurely. In 2 elderly 
participants, virus neutralisation already occurred at day 0, meaning that these 
persons had been vaccinated against yellow fever previously (Figure 1). These two 
were excluded from further analysis. Baseline characteristics of the study population 
are given in table 1. Gender and possible previous exposure to flaviviruses did not 
differ between the groups (Table 1).
Chapter 4
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Figure 1  Inclusion of study population. Two participants in the group  
of ≥ 60 yrs had neutralising antibodies before vaccination.  
These were excluded from analysis. Ab = Antibodies, PBMC = 
Peripheral Blood Mononuclear Cells, RT-PCT = Real Time - 
Polymerase Chain Reaction, PV = Post-vaccination.
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Neutralising antibody response
At day 3 and 5 after vaccination, no neutralising antibodies were found (data not 
shown). Ten days after vaccination seroprotection was attained by 77% (23/30) of the 
young participants and by 50% (14/28) of the elderly group (p = 0.03, Chi-square 
test). This result is also reflected in the height of the antibody concentration (Figure 2). 
At day 10, the younger participants had a GMT of 0.18 IU/ml, ten-fold higher than the 
GMT in the elderly participants (0.017 IU/ml) (p = 0.004). At day 14, seroprotection 
was attained by all participants (young and elderly). The GMT at day 14 still differed 
significantly between the young and the old (respectively 4.8 IU/ml and 2.7 IU/ml, p = 
0.03). At 28 days after vaccination there was no longer a significant difference in the 
GMT between the younger and older group (resp. 13.3 IU/ml and 9.0 IU/ml, p = 0.1). 
Female gender or recent travel to flavivirus endemic countries did not result in a 
significantly different virus neutralisation titre in either group (data not shown).
Vaccine safety
Participants reported the occurrence and duration of adverse events after yellow fever 
vaccination in a 3−week diary. In younger vaccinated participants vaccination evoked 
redness and swelling at the site of inoculation more frequently and for a longer period 
than in the elderly participants. Although not significant (with α = 0.05), adverse 
events occurred more frequently and earlier (respectively 1.3 and 5.3 days after 
vaccination) in the younger participants compared to the elderly group. 
Yellow fever vaccine virus RNA
YF-17D viraemia was measured by qRT-PCR at day 5. The detection limit was 1300 
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Table 1  Demographic characteristics of the study population 
                                  Participants
Demographic
  Young (18-40 years) Elderly (≥ 60 years) p-valuecharacteristics
 N = 30 N = 28
Females (%)  22 (73) 20 (71) 0.9
Age (years)
 Median 21 66 -
 IQL range 20-22.5 65-69 -
 Range 18-28 60-81 -
Flavivirus $ N yes (%)  8 (27) 8 (29) 0.9
$ Flavivirus = possible flavivirus encounter in past five years defined as travelled to flavivirus endemic  
destination
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copies/ml. At day 5 viraemia was detected in more elderly (18%) than young participants 
(3%) (p = 0.05, Fisher’s Exact Test). The one young participant with viraemia did have 
a protective antibody titre at day 10. Of the six elderly people with viraemia, two had 
attained seroprotection by day 10 (33%) compared with 12 of 22 (55%) of those without 
detectable viraemia. In the seven participants with detectable viraemia at day 5, the 
GMT was 0.3 IU/ml (95% CI  0.1 to 0.8) at day 10, 8.6 IU/ml (95% CI 5.6 to 13.1) at day 
14 and 16.5 IU/ml (95% CI 10.9 to 24.8) at day 28. In those without detectable viraemia 
the GMT was 0.05 IU/ml (95% CI 0.03 to 0.07) at day 10, 3.3 IU/ml (95% CI 2.8 to 3.7) 
at day 14 and 10.5 IU/ml (95% CI 9.1 to 12.0) at day 28. P-values for the difference in 
GMT between those with and those without viraemia were 0.14 for the comparison at 
day 10, 0.06 at day 14 and 0.33 at day 28. 
Viraemia was associated with fever. Of the six participants with detectable viraemia, 
three (50%) had self-reported fever compared with 4 of 47 (9%) who did not have 
detectable viraemia (p = 0.03, Fisher’s Exact Test), The mean number of days between 
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Figure 2  Geometric mean titres (GMT) of yellow fever antibodies in 
 participants with a measurable antibody response at 10, 14 and  
28 days after vaccination. No antibodies were measured at day 3 
and 5 after vaccination. * p=0.03, ** p=0.004. GMT were analysed 
with non-parametric test (day 10) and Student’s t-test (day 14 
and 28). Error bars represent 95%CI.
86
the vaccination and start of symptoms did not differ between those with and those 
without viraemia (respectively 3.7 and 3.5 days). Myalgia and injection site reactions 
were not associated with viraemia (data not shown). 
T-cell subsets
We investigated the percentage of naïve, central memory (CM), effector memory (EM) 
and terminally differentiated effector memory (TEMRA) cells in the CD4+ and CD8+ T 
cell subsets at baseline (day 0). Previous publications have shown that naïve cells are 
relatively more numerous in younger persons, and that the percentage of more dif-
ferentiated T cells (EM and TEMRA) is augmented in elderly persons [24]. This was 
confirmed in our population (Figure 3). The increased percentage of naïve cells in the 
younger participants, compared with the elderly, was more pronounced in the CD8+ 
than in the CD4+ T cell subset. In addition, the elderly group had a higher percentage 
of CD8+ effector T cells. Irrespective of age, no correlation was found between the 
percentage of naïve T cells and either anti-YF17D GMT or viraemia. 
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Table 2  Solicited adverse events after primary and booster YF-17D  
vaccination. Safety of vaccination expressed in various parameters
                                    Participants
Adverse event
  Young  Elderly p-value 
  N=30  N=28
Local  Erythema N yes (%) 8 (27)  2 (7) 0.05
  Mean N days (s.e.m.) 3.4 (±0·8)  2.0 (±1·0) 0.4
 Swelling N yes (%) 3 (10)  1 (4) 0.3
  Mean N days (s.e.m.) 2·7 (±1·2)  2·0 (-) 0.8
 Pain N yes (%) 3 (10)  2 (7) 0.7
  Mean N days (s.e.m.) 1·7 (±0·7)  2·0 (±0·0) 0.7
Systemic  Myalgia N yes (%) 12 (40)  6 (21) 0.1
  Mean N days (s.e.m.) 2·3 (±0·5)  2·3 (±0·2) 0.9
 Fever N yes (%) 3 (10)  4 (14) 0.6
  Mean N days (s.e.m.) 6·3 (±3.8)  3·0 (±4.0) 0.4
 (N days after vaccination) 1.3 (±1.3)  5.3 (±0.3) 0.09




We demonstrated that in elderly persons (≥ 60 years) the initial humoral response to 
yellow fever vaccine lags behind that of younger vaccinees. GMT of neutralising 
antibodies were significantly lower at 10 and 14 days after vaccination but not at 28 
days. Five days after vaccination viraemia was more common in the elderly. Viraemia 
was associated with having a fever but was not associated with the time to sero-
protection.
These results may offer a biological explanation for the increased susceptibility to 
YEL-AVD in old age. Immunological senescence leading to an impaired ability to clear 
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Figure 3  Percentage of T lymphocyte subsets in the study population, 
 divided in CD4+ and CD8+ subsets. Young and elderly  participants 
were compared with respect to their naïve, central memory (CM), 
effector memory (EM) and terminally differentiated effector memory 
cells (TEMRA) at day 0 (before vaccination) 
with Student’s t-test. ** p ≤ 0.001.
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the vaccine virus has been put forth as a possible reason for increased risk of YEL-AVD 
in elderly people [17]. In a retrospective study of two large clinical trials of two YF-17D 
vaccines from different manufacturers, involving a total of 4,532 subjects, neutralising 
antibody responses at 30 days after vaccination were equivalent in younger and 
elderly subjects. Due to the retrospective nature, early responses (i.e. < 30 days after 
vaccination) could not be compared and were assumed to be equal in both groups. 
Our results show that this assumption needs to be modified.
We observed a striking resemblance with respect to the occurrence of adverse events 
between the previous analysis of yellow fever vaccination in elderly subjects and our 
study (AE) [17]. Overall, the incidence injection site adverse events was lower in 
elderly than in younger subjects. If injection site reactions are a result of immune 
activation, observing less adverse events in elderly subjects could reflect a weaker or 
slower immune response in elderly people. Similarly, this line of argumentation is 
consistent with the later onset of adverse events in the elderly compared with the 
younger subjects (5.3 versus 1.3 days).
Neutralising antibodies are the gold standard for monitoring the immune response 
against yellow fever vaccine. This has in part a biological reason. In vitro, the antibodies 
inhibit viral replication. In vivo, passively immunised primates are protected against 
challenge with wild-type yellow fever [25]. Therefore, the delayed humoral response in 
the first two weeks after vaccination in the elderly could enable augmented virus 
replication. Whether this hampered antibody response coincides with an impaired 
cellular immune response remains to be studied. 
In the elderly, an impaired innate and acquired immunity [26,27] is generally held 
responsible for the increased susceptibility of the elderly to infections, and reduced 
ability to respond to vaccines [28]. Clinical examples of this hampered response 
against vaccines are the influenza vaccine, with an efficacy between 70% and 90% in 
those under 65 years of age, but of 30% to 40% for those over 65 years of age [29], 
the pneumococcal polysaccharide vaccine [30] and hepatitis B vaccines [31]. On a 
cellular level, it has been shown that the subset of naïve T lymphocytes decreases 
dramatically with age (possibly due to thymic involution), together with an increase of 
effector T cells, which we also demonstrated in our study population. This altered 
distribution of lymphocytes at specific differentiation stages may restrict the diversity 
of the immune cell repertoire, leading to a diminished response to neoantigens, like 
yellow fever vaccine [27,28]. 
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Beside the immunosenescence in elderly subjects, other hypotheses on the 
mechanism of YEL-AVD have been postulated. For example, it is possible that the 
vaccine virus reverts or mutates to a more virulent form. However, extensive genetic 
analyses of the viral strains extracted from patients with YEL-AVD do not provide 
evidence to support this hypothesis [3]. The hypothesis of host genetic susceptibility 
for developing YEL-AVD seems more plausible. Pulendran and colleagues found a 
heterozygous CCR5Δ32 mutation in a patient who suffered from YEL-AVD [32]. Since 
the prevalence of heterozygosity of the CCR5Δ32 mutation in the general population is 
15% [33] and the occurrence of YEL-AVD among yellow fever vaccinees is significantly 
less [13], other host factors (e.g. immunosenescense) must also play a role in the 
development of YEL-AVD [34]. On the other hand, milder forms of YEL-AVD might 
occur more frequently, but might not be severe enough to be published, thus 
introducing publication bias. In addition to the hypothesis of genetic susceptibility, 
recently discovered genetic host factors, including complement protein C1qB and 
eukaryotic translation initiation factor 2 alpha kinase 4- (an orchestrator of the 
integrated stress response) predicted YF-17D CD8+ T cell responses with up to 90% 
accuracy. A B-cell growth factor, TNFRS17, predicted the neutralising antibody 
response with up to 100% accuracy [35]. 
Although occurrence of YEL-AVD is very rare, fear of this adverse event could reduce 
utilisation of yellow fever vaccine. An “International Laboratory Network for Yellow 
Fever Vaccine-Associated Adverse Events” has been established in 2008, to 
complement the USA and the European Yellow Fever Vaccine Safety Working Groups 
[36]. Its goal is to determine the pathogenesis of severe adverse events following 
yellow fever vaccination through systematic and coordinated laboratory evaluation of 
reported cases. With this study, we contribute to this goal. A greater understanding of 
the pathogenesis of YEL-AVD may lead to new approaches to prevent this serious 
complication. One possibility may be to inject much less vaccine virus in a more im-
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Five to ten percent of immunocompetent persons fail to develop a protective immune 
response to hepatitis B vaccination, and are defined non-responders (NR). We 
investigated the immune response to intradermal hepatitis B vaccination after 
pre-treatment of the skin with the TLR7 agonist imiquimod. 
Methods
Twenty-one non-responders (anti-HBs < 10IU/L after at least 6 intramuscular hepatitis 
B vaccinations) were randomly assigned to the control group (N=11) or the experimental 
group (N=10). Participants in both groups received 3 intradermal vaccinations with 
5μg HBsAg (0.125mL) at 0, 1 and 6 months. In the experimental group, the dermal site 
of injection was pre-treated with 250 mg imiquimod ointment. Anti-HBs antibodies 
were determined at 0, 1, 2, 6 and 7 months.
Results
In both study groups, 70% of the participants developed a protective immune response 
(anti-HBs ≥ 10IU/L), after the 3rd intradermal vaccination.
Conclusion
The  application of imiquimod on the skin prior to intradermal vaccination did not 
enhance the humoral response to hepatitis B vaccine. However, irrespective of 
imiquimod application, 70% of the NR who had not responded to 6 previous 
intramuscular vaccinations, developed a protective immune response with high affinity 
antibodies after 3 ID hepatitis B vaccinations with 5 µg HBsAg.
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Introduction
The immune response to the injected hepatitis B surface antigen (HBsAg) can vary 
greatly in healthy subjects [1]. Whereas most healthy vaccinees develop an adequate 
antibody response, defined as an anti-hepatitis B surface antigen (anti-HBs) titre of 
≥100 IU/L, five to ten percent of immunocompetent persons fail to develop a protective 
immune response and never reach an anti-HBs titre exceeding 10 IU/L; these are 
defined as non-responders (NR) [2]. True NR, defined as NR to 2 series of hepatitis B 
vaccinations	 are	 presumed	 unlikely	 to	 develop	 adequate	 anti–HBs	 titres	 with	 further	
vaccine doses, although no thorough research has been performed to confirm this [3].
The protective efficacy of hepatitis B vaccination is directly related to the induction of 
anti-HBs antibodies [4-6]. An antibody titre of ≥10	IU/L	measured	1–3	months	after	the	
administration of the last dose of the primary vaccination series is considered to be a 
reliable marker of immediate and long-term protection against infection, and those 
who have an anti-HBs titre of ≥10 IU/L are considered to have protective immunity. 
Non-responsiveness to the vaccine has major implications for health care workers 
and sexual partners of HBV carriers in low endemic countries. In terms of biological 
mechanisms, non-responsiveness to hepatitis B vaccination has been associated 
with the presence or absence of specific of MHC alleles. The most pronounced 
associations with non-responsiveness were with excess of HLA-DR3, -DR7, -DQ2 and 
-DP11 and with absence of HLA-DR1, -DR5, -DR2, -DQ5 and -DP4 [7-8]. Other char-
acteristics correlated with an inadequate anti-HBsAg response are; higher age, 
obesity, male gender, and cigarette smoking [9-11]. 
Several strategies to increase the immune response to the hepatitis B vaccine in NR 
have been investigated, and comprise of an additional series of standard vaccinations, 
vaccination of  HBsAg combined with other antigens or additional adjuvants [12-14], 
or alternative routes of administration. The most commonly chosen strategy is to give 
an additional series (1 to 3 vaccinations) of conventional intramuscular vaccinations, 
leading to seroconversion in 61% of the revaccinated [15]. 
Another alternative to enhance immunogenicity in NR would be to administer hepatitis 
B vaccine in the dermal layer of the skin, instead of injecting intramuscularly. Although 
the intradermal (ID) vaccination route has shown to elicit slightly lower antibody 
responses in healthy subjects [16-22], in hepatitis B vaccine low responders (anti-HBs 
of 10-100 IU/L) and NR, the ID vaccination  yielded slightly higher antibody titres 





In this study, we combined the ID vaccination route with local stimulation of dermal 
antigen presenting cells as a new approach to obtain a protective antibody response 
in true hepatitis B vaccine NR. Imiquimod (Aldara) activates antigen presenting cells 
(APCs) through the toll-like receptor 7 (TLR7) and is registered for the treatment of 
(genital) warts and basal cell carcinoma. 
Methods
Objectives
This study was conducted to determine whether in NR to hepatitis B vaccination, 
pre-treatment of the injected skin with a TLR stimulant (Aldara, one sachet (250mg) 
applied on 20cm2 skin) before ID hepatitis B vaccination (5μg; 0·125 mL) would elicit 
a higher antibody response compared to ID vaccination (5μg; 0·125 mL) without 
pre-treatment of the skin. Efficacy of vaccination was determined by serum anti-HBs 
antibody measurement.
Study design and Participants
The protocol and consent forms were approved by the Medical Ethical Committee of 
the Leiden University Medical Centre (LUMC, The Netherlands; protocol P05.187), 
and registered in the Dutch Trial Register (#NTR1043). Written informed consent was 
obtained from each participant. 
Healthy volunteers of 18 years and older with a history of at least 2 series of hepatitis 
B vaccination (one series comprises 3 vaccinations of at least 10µg HBsAg per 
vaccination) and no postvaccination antibody titre of ≥10 IU/L, were eligible for 
inclusion. Participants were recruited via the University Medical Centres of Leiden and 
Utrecht (the Netherlands). Records of previous hepatitis B vaccinations and antibody 
responses were obtained. We excluded volunteers with a compromised immunity due 
to underlying illness or immunosuppressive medication, pregnant volunteers and 
those with (possible) autoimmune disorders. The study was carried out between May 
2007 and October 2008. Subjects were randomly assigned to the experimental (with 
imiquimod pretreatment of the injected skin) or control (without pre-treatment of the 
injected skin) group. Randomisation was performed with the use of sealed envelopes 
containing the vaccination code balanced through in permuted blocks of 4. 
Hepatitis B vaccine
The hepatitis B vaccine used in this study, HBVAXPRO 40μg HBsAg/mL, is a 
recombinant vaccine with alum adjuvant, manufactured by Sanofi Pasteur MSD (Lot 
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no ND37720) and stored according to manufacturer’s guidelines. Multiple dosages 
(maximally 4) were obtained from one vial for ID vaccination. One ID vaccination of 
0·125mL contained 5μg HBsAg.
Vaccination and data collection
At the time of inclusion, data on demographic and clinical characteristics of the 
participants were obtained. Participants received 0·125mL hepatitis B vaccine 
(equivalent to 5µg HBsAg) intradermally on the dorsal side of the right forearm at 0, 1 
and 6 months. This vaccination site enables careful monitoring of possible adverse 
events. The quality of the ID injection was defined by the diameter of the arisen 
cutaneous wheal (adapted from the tuberculin skin test) [http://www.cdc.gov/tb/pubs/
Mantoux/part1.htm (accessed 27th of March 2009)], with 6 mm being the lowest 
acceptable diameter. In the experimental group, a square surrounding 20 cm2 (equal 
of 7·9 square inches) was marked on the dosal side of the forearm. The participant 
applied the content of one sachet of Aldara (5g, 50mg/g) to the marked surface on 
the skin. This is the advised dosage per application for the treatment of skin lesions. 
After the ointment was taken up by the skin (in approximately 3 minutes), the vaccine 
was injected in the centre of the marked area. The oinment was removed by the 
participant by washing after 6 hrs. In the control group, the vaccine was administered 
without pre-treatment of the skin. 
Blood samples were collected before vaccination (time point 0), and at 1, 2, 6 and 7 
months. In the first blood sample (at time point 0) HBsAg and anti-HBcore antibodies 
were measured as control for infection with HBV. 
Participants were asked to document clinical symptoms (local and systemic) after 
vaccination in a four-week diary. Solicited symptoms were; erythema, pain and 
swelling at the site of injection, fever and myalgia. Severity of adverse events was 
documented	as	–	(absent),	+/-	(mild),	+	(moderate)	or	++	(severe).	
Anti-HBs detection
Anti-HBs titres were assessed by the ARCHITECT Anti-HBs assay (Abbott Laboratories, 
Chicago, IL, USA) according to the manufacturer’s instructions, and were expressed 
in International Units (IU)/L .
Anti-HBs avidity determination
Avidity of anti-HBs antibodies was measured in duplo by adding 0M (PBS), 2M, 4M 
and 6M urea to the serum of non-responders who mounted an antibody concentration 




index was calculated as the ratio of anti-HBs with 6M urea (dilution 1:1) to anti-HBs in 
PBS (dilution 1:1). As a control, the avidity index of healthy responders (anti-HBs ≥ 50 
IU/l after 3 hepatitis B vaccinations) was measured. The antibody concentration had 
no effect on the avidity index, measured by diluting serum (2-, 5- and 10-fold) in the 
presence of 6M urea (data not shown). In five study participants who mounted a 
protective response anti-HBs avidity was determined longitudinally throughout the 
course of the 3 intradermal vaccinations, to envisage the process of avidity 
maturation. 
HLA  allele determination
Study participants were typed for HLA-DRB1, -DQB1 en DPB1 as described previously 
[25], in the European Foundation of Immunogenetics (EFI)-accredited HLA laboratory 
of the Department of Immunology and Haematology, LUMC, the Netherlands. Briefly, 
DNA was isolated using a commercially semi-automated beads based assay 
(Chemagen,  Baesweiler, Germany). The HLA-DRB and DQB typing was performed 
with a reversed approach of the PCR/SSOP technique and HLA-DPB1 were determined 
with a commercially available beads-based hybridization assay (Tepnel, Stanford, CT. 
USA).  The interpretation of the raw data was carried out with computer assisted 
analysis software [26].
Statistical methods
Power calculations were based on an expected seroconversions (anti-HBsAg titre ≥10 
IU/L) of 60% in the experimental group [15] and 10% in the control group. With an α of 
0·05 and a β of 0·2, the sample size is 10 participants per group. To take into account 
a possible lost to follow up of 30%, we aimed to include 13 participants per group.
To correct for skewing of the data, antibody concentrations after experimental and 
control ID vaccination were log-normalised. Differences between vaccination groups 
were investigated under the hypothesis that a change from baseline of each endpoint 
was identically distributed within each of the two vaccination groups against the 
alternative that median change-from-baseline within one vaccination group differed 
from the other group. The hypothesis was tested using the non-parametric Wilcoxon’s 
test. Moreover, differences in antibody titres before and after first and second 
intradermal vaccination with or without imiquimod pretreatment were tested using 
analysis of variance on the log-transformed data. Where appropriate, Chi-square test 
or Fisher’s exact test was used. Statistical analysis was performed using a computer-
assisted software package (SPSS version 14.0, SPSS Inc., Chicago, IL).




Forty of the 70 non-responders from our database responded to the letter of invitation 
to participate, of whom 19 chose not to participate due to the travel distance to either 
of the two university hospitals (Leiden or Utrecht). Ten participants were included in 
the experimental group and eleven in the control group. One participant in the control 
group withdrew after the second vaccination due to local pigmentation at the site of 
vaccination. The data of this person were included in analysis per time point. The total 
inclusion was stopped at 21 instead of 26, as the calculated number of participants 
(10 per group) was reached and no further withdrawal occurred. Characteristics of the 
participants are given in table 1. Hepatitis B surface antigen and anti-HBcore was 
undetectable in all participants. 
Vaccine administration
The mean diameter of the cutaneous wheal that appeared after intradermal vaccination 
(total N=62) was 10.4 mm, with a range of 8-14 mm. 
Topical Imiquimod application and anti-HBs response
The anti-HBs titre was measured at each vaccination and one month after each 
vaccination. Evaluation of the overall anti-HBs antibody responses before and after 
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Table 1  Demographics and vaccine history of study population
Characteristics




Sex (female) (%) 6 (60) 5 (45) 0.5
Age (years) (IQR) 39 (26-52) 36 (23-47) 0.6
BMI (kg m-2) (IQR) 25.4 (22-28) 25.2 (22-27) 0.9
Smoking N (%) 3 (30) 3 (27) 1.0
Total HBsAg (μg) before inclusion (mean) (IQR) 78 (60-75) 62 (60-60) 0.3
Time since last HB vaccination (years) (IQR) 1.7 (0-4) 4.1 (1-9) 0.1
Median anti-HBs titre after last IM vaccination (IU/L) (IQR) 2.3 (0.0-6.0) 2.0 (0.0-5.7) 1.0
Median anti-HBs titre at start trial (IU/L) (IQR) 0.1 (0.0-5.6) 0.0 (0.0-1.0) 0.4
P-values were calculated with χ² -test, Fisher’s exact test, Wilcoxon or Student’s t-test where 
 appropriate. HBsAg = Hepatitis B surface antigen. BMI = Body Mass Index. IM = Intramuscular.  
IQR = Interquartile range. No significant differences were found between the imiquimod and control 
group (p-values > 0.1). 
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the vaccinations revealed the development of antigen-specific humoral responses 
after vaccination in most of the volunteers, the overall height of which did not depend 
on pre-treatment with imiquimod (Figure 1). Boosting of the responses by a third 
vaccination 6 months after the first two was observed, and again, did not differ 
between the experimental and control group. Responders with high anti-HBs remained 
good responders throughout the study, and those with low anti-HBs remained low 
responders.
When a seroconversion of anti-HBs ≥ 10 IU/L was taken as an endpoint, no difference 
was measured in the time of achievement of this seroconversion in the imiquimod and 
the control group (figure 2) (Logrank test, p = 0.8). One month after the last vaccination, 
7 of 10 (70%) of the experimental group and 8 of 11 (73%) of the control group 
developed an anti-HBs titre ≥ 10 IU/L (p = 0.9, Fisher’s exact test).
Intradermal hepatitis B vaccination of non-responders
Figure 1  Serologic response (anti-HBs) according to time of vaccination
Intradermal vaccinations were performed at 0, 1 and 6 months. Bars represent medians.  
Anti-HBs titres of 0.00 were recoded into 0.12 in order to appear in the figure. Each dot represents 
one participant, dots can overlap.
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Avidity of anti-HBsAg antibodies
In healthy responders to the hepatitis B vaccine, avidity maturation occurs during the 
vaccination series [27]. Since the participants in our study had at least 6 vaccinations 
to which they did not mount a protective response, we measured the avidity of anti-HBs 
antibodies of those in whom the additional ID vaccinations did induce an antibody 
response of ≥ 30 IU/l (N=7). The avidity index (anti-HBs in 6M urea / anti-HBs in PBS) 
of these previous non-responders was 0.72 (95%CI 0.61-0.93). The avidity index of 
healthy controls (N=9) in whom 3 intramuscular hepatitis B vaccinations induced an 
anti-HBs ≥ 50 IU/l was 0.60 (95%CI 0.35-0.85). Anti-HBs avidity after the first ID 
vaccination did not differ from the anti-HBs avidity after the last ID vaccination (data 
not shown). Apparently, in this group of previous non-responders, no avidity maturation 
occurred but instead, the anti-HBs response immediately showed high avidity, 
comparable to that in healthy vaccinees after a primary vaccination series.
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Figure 2  Cumulative percentage of participants achieving an anti-HBs titre 
of ≥10 IU/L
Arrows indicate intradermal vaccinations. Imiquimod N = 10, control N = 11.
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Responding vs. non-responding participants
To gain more insight in the development of a protective serologic response in the 
study population, several known associations were investigated. These were: sex, 
age, weight, smoking, and history of hepatitis B vaccination. After multivariate analysis, 
increased age was associated with non-response in this trial (Table 2).
Distribution of HLA alleles associated with antibody response after Hepatitis 
B vaccination
Both study groups were comparable with respect to HLA-DR and HLA-DP distribution. 
Alleles strongly associated with a non/poor response (DR3, DR7, DP11) [9] were present 
in 13 of 21 participants (6 in the imquimod group and 7 controls); alleles strongly 
associated with a high response (DR1, DR5, DR2, DPB1*0401) were present in 
4 participants (2 in the experimental group and 2 controls). The comparison between 
the median anti-HBs antibodies titres of the different HLA-groups is reported in table 3.
Adverse events
Participants reported adverse events in a four-week diary after each vaccination. 
At any time point, the application of imiquimod did not elicit any additional local 
erythema or tenderness, nor any systemic symptoms, except myalgia after the 1st 
vaccination (table 4). However, the ID vaccination of the vaccine did induce local 
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Table 2  Demographics and history of hepatitis B vaccination of study  
population according to serologic response after ID vaccination
Characteristics
 Responder NR uni multi 
(≥10 IU/L) (<10 IU/L) variate variate
 N=15 N=6 p-value p-value
Sex (male) (%) 5 (33) 5 (83) 0.06 -
Age (years) (mean) (IQR) 31 (22-45) 52 (49-58) 0.001 0.02
BMI (kg m-2) (mean) (IQR) 24.8 (21-27) 26.5 (24-29) 0.4 -
Smoking N (%) 6 (40) 0 (0) 0.1 -
Total HBsAg (μg) before inclusion (mean) (IQR) 64 (60-60) 84 (60-120) 0.4 -
Time since last HB vaccination (years) (IQR) 2.2 (0-3) 4.8 (1-10) 0.1 -
Anti-HBs titre after last IM vaccination (IU/L) (IQR) 2.4 (0.0-6.3) 0.0 (0.0-5.3) 0.5 -
Anti-HBs titre at start trial (IU/L) (IQR) 0.1 (0.0-4.3) 0.0 (0.0-0.0) 0.007 0.6
P-values were calculated with χ² -test, Fisher’s exact test or Student’s t-test where appropriate.  
NR = Non-responder. BMI = Body Mass Index. IM = Intramuscular. IQR = Interquartile range.  
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erythema in approximately 80%, swelling in 75% and pruritus in 30% of participants. 
In 11 of 21 participants, the first and second vaccination were still visible as a 
pigmented area at the time of the last blood sampling.
Severity	 of	 local	 adverse	 events	 was	 documented	 as	 –	 (absent),	 +/-	 (mild),	 +	
(moderate) or ++ (severe), according to participants’ experience. There was no 
difference between the control and experimental group in regard to the severity of the 
adverse events. The participants who reported redness and swelling experienced 
these events as mild (66%), moderate (32%) and severe (2%).
Discussion
In this study, application of the TLR7 agonist, imiquimod, on the skin prior to intradermal 
vaccination did not enhance the humoral response to hepatitis B vaccine in previously 
hepatitis B vaccine NR. However, irrespective of imiquimod application, 70% of these 
‘true’ NR developed a protective immune response after 3 ID hepatitis B vaccinations 
with 5 µg HBsAg. This is the first study demonstrating the induction of a protective 
immune response to additional intradermal hepatitis B vaccinations in individuals who 
did not respond to 6 previous vaccinations. The presence of high avidity antibodies 
after the first dose  suggests that the previous vaccinations did induce the development 
of a small number of antigen specific lymphocytes, although not enough for a 
measurable antibody response.
Although the number of participants in this study is low, the 70% seroprotection rate 
obtained in this group of NR, who were consecutively enrolled without further selection, 
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Table 3  Comparison of the peak antibody titre (within one participant during 
the study) between groups determined by HLA alleles associated with 
high of low response to hepatitis B vaccination [9]









 mentioned, high response: DR1, DR5, DR2, and/or DPB1*0401.  
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strongly suggests that similar protection rates may be reached in unselected groups 
of NR.  Whether the ID route of HBs-antigen delivery is superior to the intramuscular 
route remains uncertain, as we have not included a control group of participants who 
received a similar low vaccine dose intramuscularly. The local adverse events induced 
by the ID delivery of the vaccine (with aluminiumhydroxide as adjuvant) were perceived 
as mild to severe, and one participant withdrew because of sustained pigmentation at 
the site of vaccination. The etiology of this adverse event may be due to local 
granuloma formation in response to the aluminum adjuvant present in the vaccine. No 
systemic reactions occurred. If ID hepatitis B vaccination is pursued for research or 
clinical purposes, we suggest to vaccinate in a less visible site than the forearm, e.g. 
in the shoulder or back. 
The lack of a beneficial effect of imiquimod on the immune reactivity to the vaccine in 
our study was unexpected. Several publications support the local immune boosting 
effect of imiquimod. For instance, Aldara, with imiquimod as its active substance, is 
registered for the treatment of (genital) warts and basal cell carcinoma, and has 
recently been shown effective in the treatment of vulvar intraepithelial neoplasia (VIN) 
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Table 4  Adverse events after ID hepatitis B vaccination with or without 
 pre-treatment with imiquimod of the vaccinated skin
                                   Vaccination preceding adverse events
   (month) 
Adverse event
  0 1 6 
  IMQ CON IMQ CON IMQ CON
Local Erythema % 90 73 89 73 90 80
  N days (mean) 19 27 20 23 18 20
 Swelling % 70 73 89 73 70 70
  N days (mean) 10† 25† 15 22 16 19
 Pain % 20 0 11 9 10 0
  N days (mean) 5 - 10 1 5 -
 Pruritus % 30 27 33 18 40 20
Systemic Myalgia % 40† 0† 22 9 0 0
  N days (mean) 3 - 4 5 - -
 Fever % 0 0 0 0 10 0
  N days (mean) - - - - 1 -
Number of days are calculated for those who reported this adverse event. IMQ = Imiquimod 
 (experimental) group, CON = Control group. † p<0.05 with Fisher’s exact test or Student’s t-test.  
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[28]. After treatment with imiquimod, the antigen is processed and presented to cells 
of the adaptive immune system leading to clearance of the virus and subsequent 
clearance of the lesions [29]. In addition to functional maturation [30], imiquimod 
induces migration of dendritic cells from the dermis to draining lymph nodes [31,32]. 
Subcutaneous administration of imiquimod as vaccine adjuvant simultaneously with 
the antigen of interest, has shown to induce enhanced responses towards the 
administered antigen [32,34], However, ID vaccination combined with imiquimod as 
an adjuvant in mice, failed to increase the response towards the injected antigen [33]. 
In that study, imiquimod was topically applied for 24 hours before vaccination, possibly 
decreasing the density of local APCs at the time of vaccination. For this reason, we 
applied the imiquimod ointment immediately prior to vaccination. We assumed that 
simultaneous administration of imiquimod and antigen would allow for an enhanced 
antigen presentation, but a poor penetration of imiquimod through the skin may have 
disturbed this timing. Perhaps a more frequent application of the ointment would have 
enhanced its effectivity [35]. Secondly, if the hampered immune response in non-re-
sponders is due to a defect on the level of T cells or B cells instead of dysfunctional 
antigen presentation [36], stimulating APC would be less likely to enhance the antibody 
production. Finally, although in animal models imiquimod (administered either 
topically or systemically) has demonstrated adjuvant activity in vaccines using 
antigenic peptides [37], proteins [38], and DNA [39], the immunostimulating effect of 
imiquimod in clinical setting was most evident in HPV infection [28,40]. It is possible 
that HPV infection downregulates a specific aspect of the immune reponse, which is 
specifically upregulated by imiquimod. This would imply that the immunostimulating 
effect is virus or antigen specific. 
The unexpected high rate of seroprotection observed in this study population places 
the hypothesis of the ‘true’ non-responder who will never respond to the hepatitis B 
vaccine into a new perspective. On the other hand, the ID vaccination route has shown 
to be a potential vaccination route for several vaccine antigens [41] and could also 
have contributed to the high rate of seroprotection with high avidity antibody response 
in these NR. The beneficial effect of the ID route of hepatitis B vaccination in NR 
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Implementation of yellow fever vaccination is currently hampered by limited supply of 
vaccine. An alternative route of administration with reduced amounts of vaccine but 
without loss of vaccine efficacy would boost vaccination programmes.
Methods
A randomised, controlled, non-inferiority trial was conducted in a Dutch university 
centre between August 2005 and February 2007. A total of 155 primary vaccinated 
and 20 previously vaccinated volunteers participated. Participants were randomly 
assigned in a 1:1 ratio to receive intradermal (i.d.) vaccination with live attenuated 
yellow fever 17D vaccine at a reduced dose (1/5th; 0·1 mL) or the conventional 
subcutaneous (s.c.) vaccination (0·5 mL). Antibody neutralisation titres were 
determined at 2, 4 and 8 weeks and 1 year after vaccination by counting the reduction 
in virus-induced plaques in the presence of serial serum dilutions. Adverse events 
were documented in a 3-week dairy. Viraemia was measured 5 days after 
vaccination.
Results
From 2 weeks up to one year after vaccination, the maximum serum-dilution at which 
80% of the virus plaques were neutralised, which indicates protection against yellow 
fever, did not differ between those given a reduced i.d. dose or standard s.c. dose of 
vaccine. In all cases the WHO standard of seroprotection (i.e. 80% virus neutralisa-
tion) was reached (in 77/77 and 78/78, respectively). Similar results were found in the 
previously vaccinated individuals. Viraemia was detected in half of the primary 
vaccinated participants, which was not predictive of serological response. In 
revaccinees no viraemia was detected.
Conclusions
Intradermal administration of one fifth of the amount of yellow fever vaccine 
administered subcutaneously results in protective seroimmunity in all volunteers. 
Albeit this vaccination route should enable vaccination of five-times as many 
individuals at risk for disease, these results should now be confirmed in field studies 
in areas with potential yellow fever virus transmission to change vaccination policy.
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Introduction
Yellow fever is a re-emerging viral hemorrhagic febrile illness in tropical and sub-tropical 
areas of Africa and remains a major health threat in South-America. It is estimated to 
affect 200.000 individuals annually of whom approximately 30.000 die worldwide [1]. 
The virus is transmitted by infected Aedes mosquitoes, and may cause a wide 
spectrum of disease, from mild symptoms to severe illness accompanied by fever, 
hepatic and myocardial injury, renal failure, hemorrhage, and even death. There is no 
curative treatment for yellow fever, making vector control and vaccination essential 
ingredients in the prevention of yellow fever morbidity and mortality.
Although this flavivirus has never emerged in Asia, the Asian continent is considered 
vulnerable to future introduction of the virus, because of the presence of a large 
susceptible human population, the presence of the urban vector and increasing 
international travel [2]. Also Western countries may be at risk: for instance, in the 
Netherlands, the Aedes albopictus mosquito was introduced via imported bamboo 
from China, and its capability of transmission of flaviviruses is currently under 
investigation.
Thus, there is a potential risk for large epidemics of urban yellow fever now that 
migration of people from rural areas may introduce the virus into areas of high human 
population density, such as large African and South-American cities. During yellow 
fever epidemics in non-immune populations, case-fatality rates may be as high as 
50% [3]. In case of simultaneous outbreaks in megacities the current emergency 
stockpile of yellow fever vaccine of 6 million doses will not be sufficient to protect the 
large populations from the disease [4].
Yellow fever vaccination is the single most important and effective means to prevent 
the occurrence of yellow fever, and carries a low risk of serious adverse events. The 
live-attenuated 17D vaccine provides protective immunity within one to two weeks in 
95% of those vaccinated [5]. The World Health Organization (WHO) therefore strongly 
recommends to include yellow fever vaccination in at-risk countries, as part of the 
routine childhood immunisation program. However, hampered by a limited vaccine 
supply, this recommendation has not yet been acted upon as epidemic emergencies 
have priority. Besides mass immunisation campaigns in response to epidemic 
outbreaks and planned routine childhood immunisation programmes, yellow fever 
vaccination is used for preventive immunisation of travellers to endemic regions [6]. 




there is an urgent need to find alternatives for the current standard  of yellow fever 
vaccination, i.e., the subcutaneous administration of 0·5 mL 17D vaccine.
In general, the route of administration of a particular vaccine, e.g., intramuscular, 
subcutaneous or intradermal, appears to have been reached at arbitrary historical 
grounds. For the yellow fever vaccine, subcutaneous administration of 0·5 mL followed 
the initial human trials in which yellow fever 17D (YF−17D) vaccines were first put to 
extensive use. However, for some vaccines already, for instance rabies, hepatitis B 
and influenza vaccines, the classical subcutaneous or intramuscular routes have 
been challenged by the apparent efficacy of intradermal administration using 
appreciably smaller amounts of vaccine [7-10]. The safety and efficacy of this route of 
administration has not been addressed for the yellow fever vaccine. Interestingly, 
already in 1943, at the dawn of yellow fever vaccine development, Fox and colleagues 
observed an immune response after intradermal administration of the YF−17D vaccine 
[11]. However, the population investigated was small and the method used to assess 
antibody responses is irreconcilable with current definitions of seroprotection 
formulated by the WHO. Furthermore, scarification experiments with yellow fever 
vaccine conducted in the 1950s revealed a lower response rate when compared to 
subcutaneous inoculation [12,13].
In this study we investigate the efficacy of intradermal inoculation of yellow fever 
vaccine at one fifth the amount given subcutaneously, as a potential strategy to reduce 
costs and increase vaccine coverage in areas with limited amounts of vaccine 
available for mass vaccination as well as for travellers to these areas. Furthermore, to 
elucidate requirements for the induction of an effective immune response to yellow 
fever vaccination we assessed antibody responses in relation to post-vaccination 
viraemia in both primary and revaccinated individuals.
Methods
Objectives
This study was conducted to determine whether reduced dose i.d. yellow fever 
vaccination (1/5th; 0·1 mL) would be as efficacious and safe as the conventional s.c. 
vaccination (0·5 mL). Efficacy of vaccination was measured by virus neutralisation 
plaque reduction assay.
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Study design and Participants
Healthy volunteers of 18 years and older were eligible for inclusion. We excluded 
volunteers with a compromised immunity due to underlying illness or immunosup-
pressive medication, pregnant volunteers and those with chicken egg allergy. The 
study was carried out between August 2005 and February 2007. Subjects were 
randomly assigned by the investigator (AHR) to either receive intradermal (i.d.) 
(experimental vaccination group) or subcutaneous (s.c.) (conventional vaccination 
group) yellow fever vaccination. Randomization was performed with the use of sealed 
envelopes containing the vaccination code balanced through in permuted blocks of 
10 each. Vaccinations were administered at the travel clinic of the LUMC by the 
investigators who were trained in both methods of vaccine administration.
In the experimental vaccination group, participants received 0·1 mL YF−17D vaccine 
intradermally on the dorsal side of the right forearm. The syringe which was used for 
i.d. administration is identical to the syringe used for administration of tuberculin in the 
Mantoux test. The quality of the i.d. injection was defined by the diameter of the arisen 
cutaneous wheal (adapted from the tuberculin skin test) [14], with 6 mm being the 
lowest acceptable diameter. The conventional vaccination group received 0·5 ml 
YF−17D vaccine subcutaneously in the right upper deltoid region.
17D Yellow Fever Vaccine
The live, attenuated, 17D vaccine used in this study was manufactured on embryonated 
chicken eggs according to WHO regulations and stored according to manufacturer’s 
guidelines. All administered vaccines originated from the same vaccine lot (Stamaril, 
Lot no Y5597, Sanofi Pasteur, France). A single vaccination dose of 0·5 ml contained 
approximately 3·5 x 104 plaque forming units (PFU), measured in two randomly selected 
vials. Multiple dosages (maximally 4) were obtained from one vial for i.d. vaccination. 
After reconstitution, vials were stored at 4°C and discarded after maximally 4 hours.
Data collection
At the time of inclusion, data on demographic and clinical characteristics of the 
participants were obtained, including information on possible flavivirus exposure 
(defined as travel to a flavivirus endemic country) in the 5 years prior to entering the 
study and previous yellow fever vaccination. Blood samples were collected in all (155) 
primary vaccinated participants before vaccination, and 4 and 8 weeks after 
vaccination. An additional blood sample was collected 2 weeks after vaccination in 55 
primovaccinees (the last 55 consecutive subjects entering the study) to investigate 




Extra ethylenediamine tetraacetic acid (EDTA) blood samples were collected 5 days 
after vaccination in the first 24 consecutive primovaccinees entering the study.
In 20 previously vaccinated participants blood was drawn before vaccination, and 5 
days and 2 weeks after booster vaccination (figure 1). Approximately one year after 
vaccination, one additional blood sample was taken from all participants who could 
be contacted (96 participants). A financial compensation was given for every blood 
sample collection at completion of the study. None of the participants withdrew 
prematurely.
Participants were asked to document clinical symptoms (local and systemic) after 
vaccination in a three-week diary. Solicited symptoms were; erythema, pain and 
swelling at the site of injection, fever and myalgia. Severity of adverse events was 
documented	as	–	(absent),	+/-	(mild),	+	(moderate)	and	++	(severe).
Constant virus – varying serum dilution Plaque Reduction Neutralisation Test 
(PRNT)
The tests were carried out in 6-well plates (Corning Inc., USA) using a slightly modified 
technique described originally by De Madrid and Porterfield [15]. Briefly, approximately 
6 x 105 Vero cells/mL were seeded per well in 6−well plates and cultured to obtain a 
confluent monolayer. Sera were complement inactivated at 56°C for 1 hour. Prevac-
cination sera were tested in 1:16 dilution, to which 100 PFU of 17D-YF were added. 
Postvaccination sera were tested in two-fold dilutions starting from 1:16 to 1:512. 100 
PFU YF−17D virus were added to each serumdilution. All test sera were assayed in 
duplicate. After 1 hour incubation on ice, the mixtures of virus and serum were added 
to the Vero cell monolayers and incubated for 1 hour at 37°C. An overlay of 2 x DMEM 
and 2% agarose was added. After 5 days of incubation at 37°C, the overlay was 
discarded and cell monolayers were stained with crystal violet. Plaques were counted 
by eye. Virus neutralisation (VN) was calculated for each serum dilution (i) with the 
following formula: VN(i) = 100 x (number of PFU in diluted postvaccination serum / 
number of PFU in pre-vaccination serum (in a 1:16 dilution)). For comparison of i.d. 
and s.c. vaccination, serum dilution at which log10 neutralisation index 0·7 (80% VN) 
occurred was taken as endpoint, as this corresponds to the generally accepted 
definition of protection [16].
Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
RT−PCR of YF−17D was performed at the department of Virology of the Erasmus 
Medical Centre according to Nijhuis and colleagues [17]. Briefly, viral RNA was 
isolated and reverse transcribed (Taqman Reverse Transcription Reagents, Applied 
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Biosystems International). cDNA synthesis was performed in a J Mini Gradient Thermal 
Cycler (BioRad, Netherlands) for real-time PCR, the following YF specific primers and 
probe were used [18]:
YFV-1 (forward) AATCGAGTTGCTAGGCAATAAACAC 
YFV-2 (reverse)  TCCCTGAGCTTTACCAGA
YFV-P (probe)  FAM-ATCGTTGAGCGATTAGCAG-BHQ
with FAM (6−carboxyfluorescein) as 5’-reporter dye and BHQ (Black Hole Quencher) 
as the 3’-quencher dye. Real-time PCR was monitored on ABI Prism 7500 Seq. 
Detection System (Applied Biosystems International). Cycle threshold (Ct) values 
were used to compare viraemia in i.d. and s.c. groups quantitatively.
Ethics
The protocol and consent forms were approved by the Medical Ethical Committee of 
the Leiden University Medical Centre (LUMC), the Netherlands (ISRCTN46326316). 
Written informed consent was obtained from each participant. 
Statistical methods
Power calculations for primovaccinees were based on a one-sided non-inferiority 
according to Armitage P., et al. [19], formula 18.5, with a maximally acceptable 
difference (δ) of 0·04 between the experimental and conventional vaccination group, 
α of 0·05, β of 0·2 and a π (overall probability of positive response) of 0·99 [5], which 
makes σ2 = 0·0099. The number of participants needed to confirm non-inferiority of 
low dose i.d. vaccination under these assumed conditions are 77 per group. For the 
antibody response in previously vaccinated individuals receiving a booster vaccination, 
basic descriptive statistics are used. It was anticipated that the small number in this 
subgroup would not allow a definite conclusion concerning non-inferiority and no 
power calculation was performed. Twenty previously vaccinated persons were 
included to monitor possible trends in interference of neutralising antibodies in yellow 
fever vaccination. Paired t-test was performed to calculate their increase in neutralisa-
tion after booster vaccination and linear regression was used to calculate influence of 
circulating antibodies on booster vaccination. Neutralising capacity of sera after i.d. 
and s.c. vaccination were compared with Student’s t-test. Where appropriate, 
Chi-square tests were used, and Wilcoxon’s test for non-parametrical distributed 
numerical data. Statistical analysis was performed using a computer-assisted software 






We enrolled 175 volunteers from August 2005 to February 2007 (figure 1). Baseline 
characteristics of the study population are given in table 1.
Concerning the accuracy of i.d. vaccine delivery, the mean diameter of the cutaneous 
wheal measured after vaccination was 8 mm (range 6-10 mm), indicating that all 
(N=87) i.d. vaccination wheals met the minimal requirement for acceptable size.
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Figure 1  Flow chart of study participants
Included study participants from August 2005 until February 2007. PV = post vaccination. 
RT−PCR = Reverse transcriptase polymerase chain reaction. Wks = weeks and yr = year.
175 Included 
155 Primovaccinees 20 Revaccinees 
77 serology           
4 and 8 wks PV 
28 serology         
2 wks PV 
13 RT-PCR           
5 days PV 
10 RT-PCR             
5 days PV 
9 serology              
2 wks PV 
37 serology          
± 1 yr PV 
8 serology              
± 1 yr PV 
78 subcutaneous 10 intradermal 
77 adverse event 
diary 3 wks PV 
10 adverse event 
diary 3 wks PV 
77 intradermal !10 subcutaneous 
10 serology              
2 wks PV 
7 serology              
± 1 yr PV 
78 serology           
4 and 8 wks PV 
44 serology          
± 1 yr PV 
10 RT-PCR             
5 days PV 
10 adverse event 
diary 3 wks PV 
78 adverse event 
diary 3 wks PV 
27 serology         
2 wks PV 
11 RT-PCR           
5 days PV 
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Vaccine efficacy
Four weeks after vaccination, 80% virus neutralisation (VN) at the least diluted serum 
(dilution of 1:16) was achieved by 77 of 77 of the intradermally and by 78 of 78 of the 
subcutaneously vaccinated primovaccinees. The percentage of VN in both study groups 
was linearly correlated to serum dilution at all time points measured (data not shown). 
Ninety percent neutralisation was achieved by 70 of 77 (91%) and by 69 of 78 (89%), 
respectively. Plotting of neutralisation indices against serum dilution showed similar 
kinetics of i.d. and s.c. vaccination at all measured time points (data not shown). This 
allowed us to compare the serum dilution at which 80% of yellow fever was neutralised, 
which is similar in both groups at all time points measured (figure 2).
No difference in percentage of virus neutralisation was measured in either (i.d. or s.c.) 
group between male and female participants, nor between recent travel to flavivirus 
endemic countries or not (data not shown).
Neutralising capacity of 1:16 diluted prevaccination serum of previously vaccinated 
participants ranged from 2% to 97% reflecting the wide range of years since their last 
YF vaccination (0·5 to 18 years). The mean percentage of VN by the least diluted 
serum before vaccination in the i.d. group was 77% (range 51%−97%) and in the s.c. 
group was 74% (range 2% - 97%). All revaccinees reached protective neutralisation 
immunity 2 weeks (19/19) and 1 year (15/15) after vaccination.
Both the i.d. and the s.c. group of revaccinated participants showed a significant rise 
in VN after booster vaccination. The mean increase in percentage of neutralisation by 
serum (dilution 1:16) before and 2 weeks after vaccination in the i.d. vaccinated 
participants was 18% (95% CI; 8%−28%) and 20% (95% CI; 4%−36%) in the s.c. group 
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Table 1  Comparability of intradermally and subcutaneously vaccinated groups
                                   Vaccine administration
Participants
  Intradermal Subcutaneous p-value
Primovaccinees N Female (%) 56 (73) 65 (83) 0·1
 Mean age (range) 27 (18-61) 25 (19-70) 0·2
 Flavivirus$ N yes (%) 33 (43) 26 (33) 0·3
Revaccinees N Female (%) 7 (70)  8 (80) -
 Mean age (range) 30 (20-50) 34 (21-48) 0·4
Age and gender distribution in primary (77 i.d., 78 s.c.) and booster (10 i.d., 10 s.c.) vaccinated 
 populations. YF-17D = yellow fever vaccine virus. $ Flavivirus = possible flavivirus encounter in past 
five years defined as travelled to flavivirus endemic destination.
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(data not shown). To investigate the influence of prevaccination neutralising antibody 
titre on postvaccination VN, pre- and post vaccination serum dilutions at which 80% 
VN occurred were plotted (figure 3). In linear regression analysis, an increase in post-
vaccination VN correlated significantly with a higher prevaccination antibody titre 
(coefficient 0.54, p=0·02). Thus, the presence of circulating neutralising antibodies in 
this population did not inhibit a booster response.
Viraemia was measured by RT-PCR 5 days after vaccination in 24 primovaccinees and 
all revaccinees (N=20). In the latter no YF-17D RNA was detected in the blood. The 
percentage of primary vaccinated subjects positive for YF virus detection was 
comparable in the i.d. (7 of 13, 54%) and s.c. (5 of 11, 45%) group, as were the mean 
Cycle threshold (Ct) values (35·86 cycles and 37·52 cycles, respectively).
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Figure 2  Protective virus neutralisation after intradermal or subcutaneous 
vaccination against yellow fever
Comparison of reciprocal serum dilutions at which 80% of yellow fever virus is neutralised in  
constant	virus	–	varying	serum	dilution	test	after	intradermal	and	subcutaneous	YF	vaccination	 
in primary vaccinated participants (n=155). Bars represent 95% Confidence Intervals (CI).  
Virus neutralising capacity of serum in both groups was performed at similar time points but  
indicators are juxtaposed for visual enhancement. VN = virus neutralisation.
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No difference was measured in the serum dilution at which 80% VN occurred 4 weeks 
after vaccination between those with and those without viraemia, irrespective of the 
route of vaccine administration (figure 4).
Vaccine safety
Participants reported duration and severity of adverse events after yellow fever 
vaccination in a 3−week diary. In primary vaccinated participants i.d. vaccination 
evoked redness and swelling at the site of inoculation more frequently and for a 
significantly longer period than after s.c. vaccination (p<0·001). Itching at the site of 
injection was also reported more by i.d. vaccinated primovaccinees (p=0·02). The s.c. 
vaccinated primovaccinees reported significantly longer pain at the site of injection 
Chapter 6
6
Figure 3  Pre- and post vaccination virus neutralising capacity of serum of 
previously vaccinated participants
Pre- and postvaccination (2 weeks) serum dilutions at which 80% VN occurred in previously 
 vaccinated participants. When 80% VN was not reached by the least diluted serum (1:16), samples 
were defined as <16 (reciprocal serum dilution). VN = Virus neutralisation.
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(p=0·03), and more s.c. primary vaccinated participants reported myalgia (p<0·01) 
(table 2). In previously vaccinated participants, a similar trend of adverse events was 
monitored except for myalgia.
The severity of adverse events due to vaccination, which was reported on a 4-level 
scale (-, +/-, +, ++), did not reveal a difference in experienced discomfort (both local 
and systemic) between the i.d. and s.c. group. Of the reported adverse events, 2/3rd 
was experienced as mild (+/-) and 1/3rd as moderate (+). No i.d. vaccinated and 3 s.c. 
participants rated their events as severe (++).
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Figure 4  Virus neutralising capacity of YF-RNA negative and positive sera
Comparison of reciprocal serum dilutions, of serum obtained 4 weeks after vaccination,  
at which 80% VN occurred between positive and negative YF-17D RNA detection by RT-PCR in 
primary  vaccinated participants (N=24). Bars represent the median reciprocal serum dilution.  
VN = Virus neutralisation.
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Discussion
Intradermal administration of 1/5th of the conventional yellow fever vaccine dose was 
non-inferior to standard subcutaneous vaccination of the full dose as far as protective 
immune response and safety is concerned: at 2, 4 and 8 weeks after administration, 
as well as one year later, the titres of yellow fever-neutralising antibodies were identical 
in individuals being primary vaccinated intradermally or subcutaneously. Both i.d. and 
s.c. administration of the vaccine resulted in protective seroimmunity in all subjects. 
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Table 2  Solicited adverse events after primary and booster YF-17D vaccination
 Primary vaccination Booster vaccination
  (N=155) (N=20)
Adverse event
  Intradermal Subcutaneous Intradermal Subcutaneous 
  N=30 N=28
Local  Erythema N yes (%) 63 (82) 25 (32) 6 (60) 1 (10)
  Mean N days  4·3 (±0·5) 1·1 (±0·2) 3·2 (±1·0) 1·0 (±0·9)
  (s.e.m.) 
 Swelling N yes (%) 52 (68) 9 (12) 6 (60) 0 (0)
  Mean N days  2·6 (±0·4) 0·3 (±0·1) 2·6 (±0·9) -
  (s.e.m.) 
 Pain N yes (%) 6 (8) 15 (19) 2 (20) 0 (0)
  Mean N days  0·1 (±0·06) 0·6 (±0·2) 0·2 (±0·1) -
  (s.e.m.) 
 Severity  N +/- (mild) 39 15 3 -
  N + (moderate) 24 9 2 2
  N ++ (severe) - 1  -
Systemic  Myalgia N yes (%) 12 (16) 27 (22) 1 (10) 1 (10)
  Mean N days  0·4 (±0·1) 0·7 (±0·1) 0·1 (±0·1) 0·7 (±0·7)
  (s.e.m.) 
 Fever N yes (%) 4 (5) 8 (10) 0 (0) 0 (0)
  Mean N days  0·1 (±0·03) 0·2 (±0·06) - -
  (s.e.m.) 
 Severity N +/- (mild) 9 17 - -
  N + (moderate) 3 8 1 1
  N ++ (severe) - 2 - -
Safety of vaccination expressed in various parameters. Severity of adverse events could be graded 
with - (absent), +/- (mild), + (moderate) and ++ (severe). S.e.m. = standard error of the mean.
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Finally, the kinetics of the immune response were similar in both groups with 
neutralising antibody responses peaking at 4 weeks after vaccination.
Several aspects of this study require comment. First, assuming 99% seroprotection 
after primary vaccination in both groups, the population size in this study does not 
allow to detect differences less than 4% between the experimental (i.d.) and 
conventional (s.c.) vaccination groups. However, the numbers are sufficient to reliably 
measure a log 0·7 virus neutralising capacity in at least 95% of those vaccinated 
intradermally, which meets the minimal required percentage of seroprotection after 
vaccination, as defined by the WHO [20]. Second, the viral dose contained in the trial 
vaccine was 3·5 x 104 PFU/0·5mL, which is equivalent to approximately 5 x 103 Mouse 
Lethal Dose (MLD)50 (21). A fivefold reduction of vaccine dose for i.d. delivery then still 
contains the minimal potency requirement (1 x 103 MLD50) as defined by the WHO 
[20], meaning that the results of this study cannot exclude that s.c. vaccination with 
0·1 mL dose might be protective. Several lines of evidence however suggest that this 
may not be the case. More than sixty years ago Fox and colleagues verified the 
protective efficacy of human serum from vaccinees in a mouse challenge model and 
observed that at a similar vaccine dose, sera from intradermally injected subjects 
were more efficacious than sera of those injected subcutaneously [11]. Additionally, 
0·1 mL s.c. delivery of a live attenuated chimeric flavivirus vaccine against Japanese 
encephalitis in non-human primates resulted in a 7−fold lower neutralising antibody 
response compared to 0·1 mL i.d. delivery by micro needle [22]. Finally, this study has 
been performed in healthy adult volunteers who represent travellers to and not 
individuals living in an area of potential yellow fever transmission. This study should 
be repeated in a population living in a yellow fever endemic area, to account for 
differences in skin tissue composition, possible interactions by cross-reactive 
antibodies against other flaviviruses, and possible decreased immune response due 
to malnutrition or chronic parasitic infections.
In regard to the reproducibility of these results, the significant variation in viral load 
between YF-17D vaccine batches is of importance. The batches generally contain 
5-50 times the minimal required potency dose to account for possible loss during 
storage and transportation [5]. The YF-17D batch used in this study contained five 
times the minimal required potency dose, and is therefore at the low side of the batch-
variability in viral vaccine load. Intradermal YF-17D vaccination with other batches will 
thus yield similar results, as no other batch is likely to contain less virus particles.
Correct i.d. vaccination is technically more demanding than subcutaneous or 
Intradermal yellow fever vaccination
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intramuscular vaccination. By introducing a minimal diameter cutoff of the cutaneous 
wheal following i.d. vaccination, we allowed to control for proper i.d. delivery of the 
vaccine. To our opinion, this simple test is a valuable tool to ensure correct i.d. 
vaccination. 
Local adverse events such as erythema and swelling were reported to occur longer in 
the i.d. vaccinated group. This is consistent with other intradermally administered 
vaccines [7,8], and might represent the inflammatory reaction due to activation of 
local immunomodulating cells. To our opinion this increased duration of local adverse 
events will not be a reason to renounce the new cost-effective method of yellow fever 
vaccination investigated, as they were not experienced as more severely than the 
adverse events in the s.c. group. Evidently, adverse events with a frequency beneath 
1/77 after low dose i.d. vaccination could not be detected in this study.
The participants who had been previously vaccinated against yellow fever all showed 
seroprotection after booster vaccination, irrespective of their pre-booster VN capacity, 
implying that circulating neutralising antibodies did not interfere with the induction of a 
booster response. Furthermore, this study shows that detectable YF−17D replication as 
evidenced by viraemia in the week after vaccination, was not required for induction of a 
booster response, which is consistent with previous findings by Reinhardt et al. [23].
The enhanced efficiency of the i.d. route of vaccination may be explained by direct 
targeting of antigen presenting cells (APCs) in the dermis and epidermis. Despite the 
possibility of YF−17D replication in dendritic cells [24], Palmer and colleagues found 
this replication to be restricted due to rapid processing of the virus [25]. Together with 
the fact that despite the lower vaccine dose the number of intradermally vaccinated 
participants in which viraemia was measured was not reduced, it is likely that an even 
more reduced vaccine dose (than fivefold reduction) administered i.d. could induce a 
protective immune response. 
The findings of this study have the following practical implications: 1) in case of an 
outbreak of urban yellow fever or vaccine shortage for travellers to endemic areas, i.d. 
administration of yellow fever vaccine will allow immunisation of at least four times as 
many individuals as s.c. vaccination with the same limited vaccine supply, 2) provided 
that these results can be confirmed in field studies in areas with potential yellow fever 
virus transmission, the i.d. vaccination strategy could be implemented in routine 




launched by the WHO and UNICEF to envisage the immunisation of 48 million people 
in 12 high-risk countries between now and 2010 [26], 3) finally, these results suggest 
that travellers with a possible history of egg allergy in whom an i.d. test dose of 0·1 ml 
YF−17D vaccine yielded a strong local urticarial reaction do not need further 
vaccination, but this should always be checked by virus neutralisation tests.
Intradermal yellow fever vaccination
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Persons with a history of egg allergy are susceptible to developing a strong urticarial 
or anaphylactic reaction to the yellow fever vaccine. Therefore, in these persons a test 
dose (1/5th of the coventional dose) is administered intradermally, in order to monitor 
the local skin reaction.
Methods
The neutralising antibody response after the yellow fever vaccine (YF-17D) skin test 
was measured in 7 egg allergic persons in whom further vaccination was abandoned 
because of a strong local urticarial reaction to the YF-17D vaccine test dose. 
Results
We found that this test dose of 0.1 mL of YF-17D vaccine was sufficient to induce a 
protective antibody response in all 7 subjects. 
Conclusion
Intradermal injection of 1/5th dose of the yellow fever vaccine appears to be sufficient, 
in non-allergic as well as allergic persons, and non-inferior to the subcutaneous 
full dose.
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Introduction
The yellow fever vaccine is considered to be one of the most effective and safe 
vaccines since its development in the 1930’s. Mild adverse reactions such as 
low-grade fever, myalgia, and local redness or tenderness at the site of injection occur 
in 10-30% of vaccinees, 2 - 6 days after vaccination [1]. More serious adverse events, 
such as yellow fever vaccine-associated neurotropic disease (YEL-AND) or 
viscerotropic disease (YEL-AVD), have been reported, but are very rare (0.3-0.4 per 
100.000 administered doses) [2]. In addition to these adverse events that are typically 
related to viral replication, anaphylactic reactions probably triggered by the hydrolysed 
porcine gelatin or egg proteins present in the vaccine, have been reported with a risk 
of 0.8 per 100.000 doses [3]. 
Because the yellow fever 17D vaccine strain (YF-17D) is propagated on embryonated 
chicken eggs, a history of acute hypersensitivity to eggs or egg products is a con-
traindication to vaccination. If a subject with a probable history of egg allergy is 
planning on traveling to an area with a significant risk for contracting yellow fever a 
test dose of the vaccine can be given under close medical supervision. According to 
the Dutch guidelines of the National Coordination Centre for Travelers’ Health a test 
dose of 0.1 mL of YF-17D vaccine (1/5th of the normal vaccine dose) is administered 
intradermally, and a control dose of 0.1 mL physiologic saline (0.9% NaCl) is injected 
intradermally in the contralateral arm [4]. The test is read after 30 minutes. If the 
diameter of the cutaneous wheal of the test dose is less than 2 times the diameter of 
the saline control, the skin test is considered negative and the remaining 0.4 mL of 
vaccine is administered subcutaneously. In case of a positive skin test, further 
vaccination is abandoned [4].
In 1943, Fox and colleagues observed a protective immune response after intradermal 
administration of the YF-17D vaccine [5]. However, the population investigated was 
small and the methods used to assess antibody responses are irreconcilable with 
current definitions of seroprotection as formulated by the WHO. We have recently 
shown that intradermal vaccination with 0.1 mL YF-17D vaccine induced protective 
neutralising antibody levels in healthy volunteers [6]
To ascertain this protective response also occurs after the YF skin test in egg allergic 
individuals, we measured the neutralising antibodies in 7 persons in whom further 
vaccination was abandoned because of a strong local urticarial reaction to the YF-17D 





Serum samples of immunocompetent individuals who had received the yellow fever 
vaccine test dose in our hospital since 2000 (start of registration), and who developed 
a positive skin reaction were tested. Serum of 7 of 11 registered patients with a positive 
skin test could be obtained. The live, attenuated, YF-17D vaccine that was used 
(Arilvax, Medeva, Belgium, or Stamaril, Sanofi Pasteur, France) was stored according 
to manufacturer’s guidelines. Administration of the test dose (performed as described 
previously [6]) and close medical observation of the subjects was performed at the 
outpatient travel clinic of the Leiden University Medical Centre (LUMC). One individual 
was hopitalised for observation during the procedure because of the anticipated risk 
of anaphylaxis.
Neutralising	 antibodies	 were	 measured	 by	 constant	 virus	 –	 varying	 serum	 dilution	
Plaque Reduction Neutralisation Test (PRNT), using a slightly modified technique 
originally described by De Madrid and Porterfield [7]. Briefly, sera were complement 
inactivated at 56°C for 1 hour. Postvaccination sera were tested in two-fold dilutions 
starting from 1:16 to 1:512. One hundred Plaque Forming Units (PFU) of YF−17D virus 
were added to each serum dilution. All test sera were assayed in duplicate in 6-well 
plates. Virus neutralisation (VN) was calculated for each serum dilution (i) according 
to the following formula: VN(i) = 100 - (number of PFU in diluted postvaccination 
serum / number of PFU in medium)*100. The highest serum dilution at which at least 
80% virus neutralisation occurred (a log10 neutralisation index of 0·7) was taken as 
endpoint, as this corresponds to the generally accepted definition of protection [8]. 
A reference serum, obtained from the National Institute for Biological Standards and 
Control (http://www.nibsc.ac.uk/) was used for quantification of the antibody response 
in International Units per milliliter (IU/mL). In our hands a 0.7 log 10 plaque reduction 
in	 1:10	 diluted	 serum	 corresponds	 to	 a	 titre	 of	 0.5	 IU/ml	 [95%CI	 0.3	 –	 0.8	 IU/ml]	
(unpublished data). Similar values have been found by others [9].
Results 
The characteristics of the vaccinated individuals, their skin reaction and antibody 
response to the vaccine test dose are given in table I. Similar to our findings in healthy 
volunteers, we found that the test dose of 0.1 mL of YF-17D vaccine was sufficient to 
induce a protective antibody response in all 7 subjects with egg allergy (Table 1), with 
a mean concentration of 5.3 IU/ml [99% CI 2.0-8.6 IU/ml]. No adverse reactions 

















































































































































































































































































































































































































































































































































































































































































additional to the local wheal formation were observed in the individuals at the 
outpatient clinic. The hospitalised patient developed a sensation of swelling of the 
tongue that responded to treatment with antihistamines. 
Discussion 
Travellers with egg allergy in whom vaccination was abandoned after the YF-17D test 
dose are very likely protected by the test dose. Apparently, the wheal-and-flare 
formation within 30 minutes after vaccine administration did not affect the formation of 
neutralising antibodies against yellow fever virus. The effect of mast cell degranulation 
on viral entry and replication remains unknown and could be important for the 
response to intradermal yellow fever vaccination. It has been shown recently that 
locally activated mast cells can actually enhance the immune response to a vaccine 
antigen [10]. 
Although all 7 egg allergic individuals were protected against yellow fever, the sample 
size of this study is too small to conclude that documentation of this protection by 
virus neutralisation test is no longer needed. Post-vaccination testing would no longer 
be required if 100% success rate of intradermal test dose vaccination would be 
achieved in 72 egg allergic individuals, corresponding to the lower boundary of the 
95% confidence interval of the percentage of individuals who should be protected 
after YF-17D vaccination according to the WHO. In conclusion, these results show 
that, similar to healthy (non-allergic) individuals [6], subjects with a history of egg 
allergy in whom an intradermal test dose of 0.1 mL YF−17D vaccine yielded a strong 
local urticarial reaction, are able to develop a protective immune response and do not 
need further vaccination.
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Pre-exposure vaccination of persons at risk with intradermally administered reduced 
dose cell culture rabies vaccines remains controversial in low-enzootic countries. 
Methods
In a prospective clinical trial of adult volunteers (N=25), we studied the immune 
response to purified chick embryo rabies cell vaccine (PCECV) administered 
intradermally at a reduced dose (0.1mL) in a three-dose schedule (0, 7 and 21 days). 
In 10 subjects, immunogenicity of intradermally administered one-dose booster 
vaccination with 0.1 mL PCECV was investigated. 
Results
All participants were seroconverted 3 weeks after primary and 1 week after booster 
vaccination, (antibody titre >0.5 EU/mL, measured by enzyme linked immunosorbent 
assay). Local adverse events such as erythema and swelling were moderate and 
transitory. 
Conclusion
The intradermal vaccination route offers an efficacious and cost-reducing strategy to 




Rabies virus is transmitted through contact of saliva of a rabid animal with a person’s 
mucosa or a skin lesion. Infection results in an encephalitis for which currently no 
antiviral treatment is available [1]. Because of the almost invariable fatal outcome after 
infection, medical care facilities in high-enzootic areas and travel clinics in non- or 
low-enzootic areas focus on prevention by vaccination either before a potential or 
shortly after a possible exposure. Individuals eligible for vaccination are the exposed 
population living in or travelling to enzootic areas, or persons who may be exposed to 
rabies by nature of their occupation [2]. 
Pre-exposure vaccination, which consists of a three-dose schedule on day 0, 7 and 
21 (or 28), induces long-lasting memory, eliminates the need for rabies immuno-
globulins (RIG), and reduces the number of days of post-exposure vaccination in case 
of possible exposure to the virus from five to two.
In areas where high rabies virus transmission occurs, intradermal (i.d.) pre- and 
post-exposure vaccination against rabies with a reduced vaccine dose is a widely 
accepted, safe, efficacious and cost-reducing strategy to increase the accessibility of 
more expensive cell culture rabies vaccines, and to phase out the use of nerve tissue 
rabies vaccines [3-6]. In travel clinics in non- or low-enzootic countries, pre-exposure 
rabies vaccination takes up an important and relatively expensive part in the prevention 
of travel-related diseases. Low-budget long term travellers such as backpackers at risk 
are more inclined to opt for pre-exposure rabies vaccination if vaccine costs are low. 
However, western travel clinics are hesitant to implement the i.d. administration of cell 
culture rabies vaccine with a tenfold reduced dose for pre-exposure prophylaxis. 
Several reasons could underlie this reluctance to vaccinate more economically: 
1) intramuscular (i.m.) vaccination results in higher antibody titres when compared to 
i.d. administration, even though it has been shown with several cell culture derived 
rabies vaccines that antibody titres induced by i.d. vaccination with 1/10th of the i.m. 
dose reach adequate levels as defined by the World Health Organization (WHO) 
[2, 3, 7-10], 2) i.d. vaccination is technically more demanding than the i.m. route, thus 
requiring a more trained staff, 3) i.d. rabies vaccination can induce more local adverse 
events than i.m. vaccination [7, 8, 11] and 4) not all official advisory institutions agree 
on the interchangeability of i.d. administration of the different cell culture rabies 
vaccines; i.e., human diploid cell vaccine (HDCV), purified chick embryo cell vaccine 
(PCECV), purified duck embryo vaccine (PDEV) and purified Vero cell rabies vaccine 




HDCV for i.d. administration and the WHO advocates the i.d. application of any cell 
culture rabies vaccine, provided that the country adopting this i.d. regimen repeats 
immunogenicity studies with the selected vaccine in their own population [12, 13]. 
In the setting of pre-exposure prophylaxis, we investigated the efficacy and safety of 
pre-exposure i.d. primary (three-dose schedule of 0.1 mL) and booster (one dose of 
0.1 mL) rabies vaccination with PCECV, in an adult population. 
Methods
Study design
Travellers of 18 years and older, with an indication for pre-exposure rabies vaccination 
according to Dutch medical travel guidelines [14] were eligible for inclusion. 
We excluded volunteers with a compromised immunity due to underlying illness or 
immunosuppressive medication, travellers taking chloroquine or hydroxychloroquine, 
pregnant travellers and those allergic to chicken eggs. Written informed consent was 
obtained from each participant. The protocol and consent forms were approved by 
the Medical Ethical Committee of the Leiden University Medical Centre (LUMC) 
(protocol number P05.093), the Netherlands. The study was carried out between 
August 2005 and July 2007. Vaccinations were administered at the travel clinic of the 
LUMC by the medical travel consultants who were trained in methods of i.d. vaccine 
administration.
Subjects received 0.1 mL PCECV i.d. in the dorsal side of the right forearm in a 3-dose 
schedule (0, 7 and 21 days, one vaccination each time). This site of administration 
was chosen in order to be able to distinguish between adverse events of i.d. rabies 
vaccination and other vaccines administered in the deltoid muscle, in case of multiple 
vaccinations for travel purposes. Additionally, the i.d. vaccination in the dorsal side of 
the forearm facilitated the monitoring of adverse events by the participants (compared 
to the deltoid region). The syringe that was used for i.d. administration is identical to 
the syringe used for administration of tuberculin in the Mantoux test. The quality of the 
i.d. injection was defined by the diameter of the arisen cutaneous wheal (adapted 
from the tuberculin skin test), with 6 mm being the lowest acceptable diameter [15]. 





The PCECV used in this study contained ≥2.5 IU/mL of Flury low egg passage 
(Flury-LEP) rabies strain that was grown in chick embryo fibroblasts, inactivated by 
β–propionolactone,	and	purified	by	density	gradient	centrifugation	(Rabipur, Novartis 
Vaccines and Diagnostics GmbH & Co KG, Marburg, Germany). Multiple doses 
(maximally 8) were obtained from one 1.0 mL vial (0.1 mL per i.d. vaccination). 
After reconstitution, vials were stored at 4°C and discarded after maximally 8 hours.
Data collection
At the time of inclusion, data on demographic and clinical characteristics of the 
participants were obtained. Blood samples were collected in all primary vaccinated 
participants before vaccination (day 0), and 3 weeks after their last vaccination (day 
42). Rabies vaccination was offered for free and a financial compensation was given 
for every blood sample collection at completion of the study. 
Participants were asked to document local and systemic symptoms after each 
vaccination in a diary. In case of swelling at the site of injection the maximum diameter 
was documented by the participant.
Antibody detection against rabies
Antibody titres against rabies were measured using a commercial in vitro diagnostic 
ELISA (PLATELIA™ RABIES II kit, Bio-Rad, France) according to manufacturer’s 
instructions. Briefly, a 96-well microplate coated with rabies glycoprotein was used. 
This viral envelope protein is responsible for the induction of neutralising antibodies 
[16]. The enzymatic conjugate consisted of a protein A from Staphylococcus aureus 
coupled with peroxidase. Positive controls, which are calibrated against WHO 
standards, allowed the quantitative determination of anti-rabies antibody titre in the 
serum, which were expressed as Elisa Units (EU) per mL.
The ELISA PLATELIA™II rabies test reaches 98.6% sensitivity and 99.4% specificity in 
comparison to the virus neutralisation assay, the rapid fluorescent focus inhibition test 
(RFFIT). There is a strong concordance between the two methods as demonstrated 
by the linearity of the correspondence between titres obtained by PLATELIA™ RABIES 
II	and	those	by	RFFIT	in	the	range	0–4	IU/mL	(r2  = 0.94), and the cut-off level of 0.5 
EU/mL corresponds to the internationally recommended 0.5 IU/mL threshold [17]. 
Statistical analysis
Student’s t-test was performed to compare geometrical means of antibody titres and 




between antibody titres after primary and titres after booster vaccination, and between 
the occurrence of adverse events and the height of the antibody response were analyzed 
by Pearson correlation on logarithmically transformed antibody titres. Calculation of the 
population size was based on a pilot study we performed preceding this study. In order 
to show immunogenicity in all participants (with α = 0.05 and 1-Δ = 80%) expressed as 
an antibody titre above 0.5 EU/mL, 25 participants were to be included, taking into 
account a withdrawal of 20%. Statistical analysis was performed using a computer- 
assisted software package (SPSS version 12.0, SPSS, Inc., Chicago, IL).
Results
Demographical characteristics of study cohort
Twenty five participants with a median age of 25.5 years (range 22-59 yrs) were 
included to receive the primary i.d. vaccination series. Nine of these primary vaccinated 
participants were male. Ten participants could be contacted after 1.5 years for the 
revaccination. Their median age was 24.5 years (range 23-59 yrs) at time of inclusion, 
and two of these participants were male.
Intradermal vaccination
The mean diameter of the arisen cutaneous wheal measured after vaccination was 
8 mm (range 7-10 mm), indicating that all i.d. vaccinations (N=85) were performed 
correctly according to our standard.
Immunogenicity after primary and booster vaccination
Primary i.d. vaccination with PCECV in a three-dose 0.1 mL regimen induced antibody 
titres ≥0.5 EU/mL in 25/25 participants. Booster vaccination with one dose 0.1 mL PCECV 
induced protective titres in 10/10 participants (table 1). The geometric mean titre (GMT) 
after booster vaccination was significantly higher when compared to the GMT following 
primary vaccination (p = 0.02), indicating a good anamnestic response. Half of the 
boostered participants showed an antibody titre above 30 EU/mL (table 1), which is 
considered predictive for a longer duration of seroconversion after i.m. vaccination [17]. 
Correlation between immunogenicity after primary and booster vaccination
The divergent antibody responses to primary and even more to booster vaccination 
(ranges	2.9	–	52.4	EU/mL	and	3.9	–	94.0	EU/mL,	respectively),	allowed	to	investigate	
if a high immunologic response after primary vaccination could predict a high 
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response after booster vaccination. However, no correlation was observed (coefficient 
= 0.2, p = 0.6) (data not shown) when logarithmically transformed antibody titres 
after primary vaccination were plotted against the titres after booster vaccination. This 
lack of intra-individual consistency as far as the height of the antibody response after 
vaccination is concerned, is demonstrated by the multiple crossing lines (figure 1).
Safety of primary and booster vaccination
Local erythema and swelling at the site of injection occurred in 96% of participants 
after primary vaccination and in all subjects after booster vaccination. A trend towards 
more severe local adverse events was documented after booster vaccination, e.g. a 
mean diameter of swelling twice the diameter after primary vaccination (table 2).
In addition, we investigated if the severity of adverse events corresponded with the 
height of the vaccine induced antibody response. For primary as well as for booster 
vaccination, no correlation was found between the severity of adverse events and the 
height of the antibody titre (correlation coefficients of 0.06, p = 0.8 and 0.2, p = 0.6, 
respectively) (data not shown). 
Discussion
Reduced dose intradermal pre-exposure vaccination with PCECV resulted in protective 
antibody titres in all primary and revaccinated healthy adult volunteers. This finding is 
consistent with a study performed in children aged 5 to 8 in Thailand by Kamoltham 
Chapter 8
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Table 1  Immunogenicity after (3-dose) i.d. primary and (1-dose) i.d. booster 





















      EU/mL EU/mL
Primary  Day 0 0.0 - - - 0/25 -
	 Day	42	 10.7	 2.9	 52.4	 8.3	–	13.1	 25/25	 4/25
Booster		 Day	550		 0.9	 0.2	 2.5	 0.0	–	3.4	 8/10	 0/10
	 Day	7	PB	 4.8	 0.9	 19.0	 2.1	–	7.5	 10/10	 0/10
	 Day	14	PB	 23.9	 3.9	 94.0	 21.2	–	26.6	 10/10	 5/10
Booster vaccination was performed approximately 1.5 years after primary vaccination  
(day 550, or day 0 PB). PB = post booster vaccination
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et al., in which the efficacy of i.d. PCECV vaccination has been shown with a simulated 
two-dose booster vaccination post-exposure schedule [19]. 
In addition, the i.d. booster after 1.5 years resulted in an antibody titre above 30 EU/
mL in half of the participants, reflecting the possibility of a long-lasting immune 
response. According to Strady et al. [18] these ‘good responders’ have an almost 
100% probability of staying protected during the following 10 years. This is of 
importance for those at continuous risk of exposure to rabies virus. Consistent with 
the population boostered intramuscularly with HDCV or PVRV by Strady et al., i.d. 
booster with PCECV elicited poor and good responders (figure 1). This dichotomy was 
Intradermal rabies vaccination
Figure 1  Correlation between antibody response after primary and booster 
vaccination within participants (N=10)
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not observed after primary vaccination and may therefore be attributed to a difference 
in induction of memory after primary vaccination. 
The population size of this study was adequate to demonstrate the immunogenicity of 
primary and booster i.d. vaccination with 0.1 mL PCECV, but insufficient to determine 
differences between adverse events after primary and booster vaccinations. 
Chapter 8
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Table 2  Adverse events after i.d. primary and i.d. booster vaccination (day) with 
PCECV. Lymph node swelling ocurred in the ipsilateral axilla
   Vaccination preceding adverse events
Adverse event
  Primary vaccination (day) Booster vaccination 
 
  0 7 21 
Local Erythema n/N 24/25 24/25 24/25 10/10
  N days (mean) 4.6 5.5 4.3 6.6
	 	 95%	CI	of	mean	 3.8	–	5.4	 3.9	–	7.1	 3.2	–	5.4	 5.8	–	6.4
 Swelling n/N 22/25 20/25 21/25 10/10
  N days (mean) 4.3 4.9 4.3 5.5
	 	 95%	CI	of	mean	 3.3	–	5.3	 3.1	–	6.7	 2.7	–	5.9	 3.9	–	7.1
  Diameter (mm) 17.0 15.1 20.3 40.1
	 	 min	–	max	(mm)	 0	-	40	 0	-	45	 0	-	80	 5	-	100
	 	 95%	CI	of	mean	 11.7	–	22.3	 8.5	–	21.6	 9.7	–	30.9	 18.7	–	61.5
 Pain n/N 4/25 4/25 6/25 2/10
  N days (mean) 0.5 0.5 0.7 0.6
	 	 95%	CI	of	mean	 0.0	–	1.0	 0.0	–	1.0	 0.2	–	1.2	 0.0	–	0.9
 Pruritus n/N 12/25 3/10
Systemic Myalgia n/N 2/25 2/25 1/25 1/10
  N days (mean) 0.3 0.3 0.2 0.3
	 	 95%	CI	of	mean	 0.0	–	0.7	 0.0	–	0.7	 0.0	–	0.6	 0.0	–	0.9
 Fever n/N 0/25 1/25 1/25 0/10
  N days (mean) 0.0 0.0 0.1 0.0
	 	 95%	CI	of	mean	 -	 -	 0.0	–	0.3	 -
 Lymph 
 node  n/N  2/25  1/10
 swelling 
Overall severity of adverse events* +/- + + +
Range of severity of adverse events* − to + − to ++ − to ++ +/- to ++
Severity	of	adverse	events	was	documented	as	–	(absent),	+/-	(mild),	+	(moderate)	or	++	(severe),	
 according to participants experience. *Severity concerned local adverse events.
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Furthermore, no comparison was made with intramuscularly vaccinated participants 
since i.d. and i.m. rabies vaccinations have previously been compared with other 
vaccines than PCECV [4, 7-11]. 
Local adverse events occur more frequently after i.d. than after i.m. vaccination, as 
has been demonstrated with various vaccines such as influenza [20, 21], yellow fever 
(unpublished data), and also with rabies vaccine [7, 8, 11]. Because the local adverse 
events after i.d. PCECV administration may hamper the acceptance of this vaccination 
route, recipients should be informed on the occurrence of transitory local erythema 
and swelling. Systemic symptoms such as myalgia and fever have not been reported 
more frequently after i.d. vaccination with PCECV [7]. In our experience adverse 
events are seldom a reason for vaccinees to discontinue the i.d. vaccination.
The severity of adverse events was not correlated with the height of the antibody 
response after primary as well as booster vaccination. Neither does the antibody level 
after primary vaccination predict the response to booster vaccination, implying that 
poor or good responders to rabies vaccine cannot be identified until boostered. 
Although widely used for Mantoux testing and BCG vaccination, i.d. vaccination is 
technically more demanding. To ensure correct i.d. vaccination, we introduced a 
minimal cut-off diameter of the cutaneous wheal following i.d. vaccination. If the wheal 
does meet not the required diameter; vaccination should be repeated.
In conclusion, the findings of this study have the following practical implications: 1) up 
to eight times as many individuals can be vaccinated intradermally with 0.1 mL PCECV 
compared to i.m. vaccination. By clustering travelers who will be at risk of exposure to 
rabies virus, travel clinics in low enzootic countries can adopt this method of economic 
pre-exposure vaccination without changing their vaccination schedule 2) introduction 
of the diameter cut-off for the wheal after i.d. vaccination allows for control of i.d. 
vaccine delivery, and 3) the cost-saving strategy should further encourage 
pre-exposure immunisation in high-enzootic countries, where focus on rabies 
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General introduction – Travel medicine
Global travel has increased dramatically during the past decades, with an estimated 
growth at approximately 6% per year [1]. Inversely proportional to this increase is a 
reduction of geographic barriers to pathogens, hence increased potential for spread 
of infectious diseases. The traveller nowadays comprises a wide variety of individuals 
with accompanying ways of travelling, requiring a diverse approach to protection 
during his or her journey, of which several aspects are addressed in this thesis.
According to the Swiss cheese model proposed by James Reason [2], cumulative 
protective medical measures (barriers) prevent hazards from causing human losses 
or illnesses. As noted in the introduction of this thesis,  this model can be applied to 
travel medicine, to improve protection against travel-related diseases through 
knowledge on the following topics; 1. Epidemiology and prevention of travel-related 
diseases, 2. Morbidity and mortality of these illnesses in specific groups of travellers, 
3. Adherence to travel health precautions, 4. Immunological responsivity upon 
vaccination, and 5. Availability of preventive measures, such as vaccines. In table 1, a 
schematic application is given of the model to (travel) health care, corresponding with 
the topics investigated and discussed in this thesis.
Prevention of travel-related disease with regard to specific populations of 
travellers
Chapter 1
In chapter 1 we describe how indeed travellers’ knowledge and attitude can be influenced 
with a training programme. Long term travellers are notorious non-compliers to malaria 
prophylaxis [3], which is confirmed by our study population (47% took malaria chemo-
prophylaxis) compared to 84% of short term travellers on vacation in high-risk areas [4]. 
The study of a malaria prevention programme among 2,350 employees working at an 
oilfield service company showed that a carefully designed malaria awareness training 
including self-diagnosis and treatment had a significant positive effect on knowledge and 
attitude towards malaria prevention and doubled the use of malaria chemoprophylaxis 
(47% of respondents who followed the programme vs. 19% who did not). The relative 
success of this malaria prevention programme has led to the implementation of the 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































A realistic approach of protection against malaria for long term travellers, considering 
the low usage of chemoprophylaxis even after intensive training, would be to prescribe 
chemoprophylaxis only for the first 2-3 months of their stay abroad. In that period they 
will get acquainted with local healthcare, and know what to do in case of illness. The 
availability of self-testing and standby treatment for malaria may offer these travellers 
an additional safe guard against the serious consequences of falciparum malaria 
infection, provided that they are properly instructed, by means of hands on training. In 
line with the Swiss cheese model, this malaria prevention programme comprises 
separate components that raise awareness and protection, in which a missed step is 
pre-empted by the next.
Correct performance of dipstick-based rapid diagnostic tests for falciparum malaria in 
febrile travellers may vary from 69% to 91% depending on whether prior instructions 
were given [5-7]. Implementation of the malaria prevention programme not only 
improved knowledge and attitude on malaria but also allowed us to investigate the 
contribution and drawbacks of the use of rapid diagnostic test for P. falciparum by the 
target population, although we have no control for the result of the test. When a finger 
prick for self-testing is performed we strongly recommend storing a few drops of 
blood on filter paper for PCR analysis for P. falciparum after returning home, to enable 
determination of true positive and true negative rates for self-testing and clinical 
diagnosis of falciparum malaria abroad. This additional information would overcome 
the major limitation of the study as described in chapter 1, which is that the diagnosis 
of malaria remains subject to what the participants report.
Chapter 2
In chapter 2, we describe the study of travelling kidney transplant recipients, in which 
we found that the majority (80%) travelled outside the Netherlands, 43% travelled 
outside Western Europe (WE), and 34% outside WE and the northern Americas. 
At least one in five travellers failed to obtain pre-travel health advice for medically 
more hazardous destinations, defined as destinations for which at least hepatitis A 
vaccination is required (VAC+). In addition, one in five travellers seeking information 
did not receive active or passive immunisation against hepatitis A while they should 
have, nor was immunoprotection confirmed by hepatitis A serology. Furthermore, 
one-third of the kidney transplant recipients travelling to VAC+ and one-fifth travelling 
to VAC- countries acquired a travel-related illness, and almost a quarter of the ill 
travellers needed to be hospitalised. This is a dramatic disease burden, compared to 
less than 1% hospitalisation of ill, immunocompetent travellers to the tropics [8]. 
Summary and discussion
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In respect to self-treatment, only 14% of responders with diarrhea reported to have started 
self-treatment with antibiotics. In conclusion, it is clear that there certainly is room for 
optimizing care of this vulnerable group. Travel health specialists should deliberate 
with the traveller’s other specialists to develop an appropriate travel advice [9].
Several limitations of this study have been discussed in chapter 2. Although our 
findings were very similar to those found by other researchers [10], the major drawback 
is the retrospective, observational study design. To meet with the need for prospective 
studies in immunocompromised travellers the study described in chapter 3 was 
designed by the municipal health centre of Amsterdam and performed in cooperation 
with the Travel Clinic of the Leiden University Medical Centre. This prospective, 
controlled study was set up to investigate the burden of travel-related diseases in all 
immunocompromised travellers seeking advice at the travel clinic. Inclusion of 
travellers using immunosuppressive medication, HIV-infected subjects, asplenic 
travellers, diabetics and travellers with inflammatory bowel disease together with their 
healthy travel partner allowed for adjustment of exposition to pathogens while abroad. 
Inclusion of diabetic travellers was met in 2008, and the analysis of the development 
of infectious diseases is described in chapter 3 of this thesis. Inclusion of otherwise 
(non-diabetic) immunocompromised travellers is ongoing, and results of the travel-
disease burden for these groups will be published when numbers needed to include 
are reached.
Chapter 3
The main result of the study described in chapter 3 is the lack of difference in 
prevalence of  travel-related diarrhea between prospectively monitored medication 
dependent diabetic travellers and their healthy travel-partner (respectively 44% and 
41%).  Also the prevalence of vomiting, fever, cough, or rhinitis did not differ. This 
result was unexpected, as in a retrospective population-based survey including 423 
insulin dependent diabetics (IDD) and non-insulin dependent diabetics (NIDD), and 
more than 8000 controls, Bytzer et al. found a significantly higher prevalence of non-
travel-related diarrhea among diabetics (adjusted OR 2.06, 95%CI 1.56 - 2.74) [11]. 
Travelling has also been associated with metabolic dysregulation in 68% of IDD [12], 
and in the study by Bytzer et al., the increased prevalence of symptoms was correlated 
with poorer levels of glycemic control [11]. The prevalence of metabolic dysregulation 
found in our study was low: 4.3% among IDD and 2.4% among NIDD, possibly due to 




Another prominent result is the fact that in spite of specific instructions, 83% of all 
diabetics with diarrhea did not use their stand-by antibiotic treatment, not even in the 
case of metabolic dysregulation (in 2 out of 3 diabetics with diarrhea). Considering 
that 93% of stand-by antibiotics were not used, makes stand-by treatment cost-inef-
fective. Frequent blood glucose monitoring, adjustments in medication (insulin 
dosage) and diet are probably more helpful in minimising the impact of diarrhea or 
fever on metabolic dysregulation. The conclusion of this study is that the advice to use 
antibiotics for stand-by treatment of travellers’ diarrhea is poorly adhered to, and 
probably not efficacious, and should therefore not be routinely recommended to 
diabetics, or prescription should be restricted to those in whom metabolic dysregulation 
is expected, with strict instructions on when to start antibiotics. With respect to the 
kidney transplant recipients who similarly failed to use their prescribed antibiotics, it 
should be stressed that they do benefit from the use of antibiotics in case of diarrhea, 
reflected by the high morbidity of travel-related diseases reported in chapter 2. These 
results clearly show the difference in immune compromised state and subsequent 
susceptibility for serious infectious diseases.
Prevention of travel-related diseases by vaccination – protecting specific 
populations
Chapter 4
As the baby boomer’s generation retires, many will have time and money to travel 
abroad. These elderly travellers are vulnerable to the effects of travel-related stress, 
transportation environments, foreign disease, temperature extremes, and acute 
illnesses [16]. With cardiopulmonary, renal and immunological functions declining 
with longevity, health care professionals are responsible for counselling these elderly 
travellers on travel preparation (itinerary, medication and insurance), air travel, safety, 
sun and heat, insect precautions, food and water precautions, and vaccinations. 
The immune response to vaccines in elderly can be impaired [17], and may 
subsequently increase the susceptibility to acquire (travel-related) infectious diseases. 
In chapter 4 we investigate the immune response against yellow fever vaccine in 
elderly with respect to the increased risk to serious adverse events. 
We demonstrate that in elderly subjects (≥ 60 years), the initial humoral response 
against yellow fever vaccine is hampered, compared to 40-year younger vaccinees. 
Significantly lower anti-YF-17D antibody titres are measured at 10 and 14 days after 
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vaccination in the elderly, but not at 28 days. To our opinion, this may offer a biological 
explanation for the higher susceptibility to yellow fever vaccine associated viscerotropic 
disease (YEL-AVD) with increasing age. The yellow fever vaccine contains live 
attenuated virus that replicates in order to induce an immune response. In general, 
the viraemia can be detected in 50% of vaccinees and peaks on the 5th day after 
vaccination [18]. YF-17D viraemia is about 5 log10 lower than viraemia induced by wild 
type YF virus (1.7 log10 PFU/ml versus 6-8 log10 PFU/ml) [19], reflecting the attenuation 
of the vaccine strain. An impaired immune response in the first 10 days after vaccination 
could give ground to a higher YF-17D viraemia, possibly leading to YEL-AVD. The fact 
that impaired immunity is a risk factor for YEL-AVD is shown by case reports of this 
fatal condition in immunocompromised persons; HIV [20] and post-thymectomy [21].
The measured difference in antibody response between the younger en elderly 
subjects is subtle, and could be the reason why it was not picked up by analyzing the 
response at 30 days post vaccination [22]. Other mechanisms, such as host genetic 
susceptibility could also play a role in the development of YEL-AVD, as suggested by 
a recently found heterozygous CCR5Δ32 mutation in a patient with YEL-AVD [23]. 
Although not investigated in regard to YEL-AVD, other genetic factors are associated 
with humoral and cellular response against yellow fever vaccine, and could also play 
a role in the development of adverse events [24]. Since the condition of YEL-AVD is 
extremely rare, the development is likely to be multifactorial [25], e.g. a combination 
of immunosenescence, CCR5 mutations and other yet to be discovered risk factors. 
Taken together our results described in chapter 4 and those of Monath et al. [22], 
indicate that elderly travellers can be adequately protected against yellow fever by 
vaccination. All subjects showed seroprotection at day 14 after vaccination. 
Nonetheless, concern about inducing a serious, possibly fatal event by vaccination 
remains. Since the first cases of YEL-AVD were published, the WHO has strongly 
advised to weigh the risk of vaccination against the risk of acquiring yellow fever. In 
the daily practice, this means that severely immunocompromised individuals (HIV 
infected with CD4 cell counts <200/ml, rheumatologic, transplant or inflammatory 
bowel disease patients using immunosuppressive medication and patients with a 
history of thymectomy) are advised not to visit endemic areas. Mildly immunocompro-
mised, including elderly, are vaccinated if they visit yellow fever endemic or transitional 




The possible role of the immune response lagging behind in the development of 
YEL-AVD in elderly calls for new approaches to prevent YEL-AVD in elderly who need 
protection against yellow fever because of their travel destination. In Chapter 6 we 
obtained equal protective immune response by intradermal injection of a reduced 
dose of yellow fever vaccine compared to the conventional vaccine dose injected in-
tramuscularly [26]. However, if intradermally injected antigens indeed elicit higher 
immune responses because they are directly targeted towards the antigen presenting 
cells (APC) in the skin, injecting even lower amounts of vaccine virus may induce an 
antibody response without inducing a detectable viraemia.  Unfortunately, in animal 
experiments, ageing is associated with a lower density of Langerhans cells (LC), a 
population of antigen presenting cells in the skin [26]. Whether this also applies to 
dermal dendritic cells in humans is unknown. 
Another possibility is the injection of inactivated YF-17D, as suggested by Gaspar et 
al. [28]. The 17DD virus (104 PFU/dose) was inactivated by hydrostatic pressure, and 
inoculated subcutaneously in mice on days 0, 15 and 30. As expected, neutralising 
antibody titres measured 2 weeks after each vaccination were significantly lower 
(respectively 10-fold, 4-fold and 10-fold) in the mice vaccinated with the inactivated 
vaccine compared to the live vaccine. Forty-five days after the first vaccination the 
mice were challenged with a intracerebrally injected, lethal dose of YF-17DD, and all 
vaccinated mice survived (irrespective of the live or inactivated vaccine virus). The 
authors are currently testing the immunogenicity of priming with pressure-inactivated 
17DD virus and boosting with the live virus vaccine, which, if successful, would be 
appropriate for the elderly travellers, as YF-17D viraemia is undetectable in subjects 
with pre-existent yellow fever immunity [18,26]. In addition, higher doses of inactivated 
YF-17D should also be tested in order to induce a better response.
Chapter 5
In chapter 5 we focus on subjects who failed to mount a protective immune response 
to 6 standard intramuscular hepatitis B vaccinations. The biological mechanism for 
this impaired response remains unidentified. We investigated whether stimulation of 
the immune response by application of a TLR7 agonist, imiquimod, on the skin prior 
to intradermal (ID) hepatitis B vaccination would benefit these non-responders (NR). 
Unfortunately, we found that imiquimod application did not enhance the humoral 
response. However, irrespective of imiquimod application, 70% of the NR developed 
a protective immune response after 3 ID hepatitis B vaccinations with 5 µg HBsAg. 
This is the first study demonstrating the induction of a protective immune response to 
additional intradermal hepatitis B vaccinations in individuals who failed to respond to 
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6 prior vaccinations. The presence of high avidity antibodies after the first ID dose 
suggests that the previous vaccinations did induce the development of a small number 
of antigen specific lymphocytes, although not enough for a measurable antibody 
response.
Since the mechanism of non-response to the hepatitis B vaccine is unknown, a rational 
approach to overcome this defective response remains challenging. Clearly, our 
approach to enhance antigen presentation with a TLR7 agonist was not effective. 
Several hypotheses have been investigated previously to explain non-responsiveness. 
Besides the well-known demographic and behavioural factors associated with non-
responsiveness, such as smoking, obesity, male gender and old age [29-31], genetic 
associations with non-responsiveness have been identified. The suggestion that 
MHC-linked genes may also control the human immune response to HBsAg was first 
made by Walker et al. who observed a significant excess of HLA-DR7 and a total 
absence of HLA-DR1 in HBsAg vaccinated low or non-responders [32]. Subsequent 
studies demonstrated that the HLA class II alleles HLA-DR3, -DR7, -DQ2 and -DP11 
are associated with low or non-responsiveness and HLA-DR1, -DR5, -DR2, -DQ5 and 
-DP4 are associated with strong humoral responses to HBsAg vaccination [33]. Since 
the involvement of MHC is likely to influence the development of the adaptive immune 
response against HBsAg, the following steps in the response have been investigated: 
antigen presentation by APC, T helper cell proliferation and regulatory T cell activation. 
The different steps towards an adaptive immune response following hepatitis B 
vaccination are illustrated in figure 1 [34].
A defect in epitope selection and presentation was not found in T cell-APC mixing 
experiments using responder T cells and non-responder APC [35-37]. However, in 
these experiments non-responder APC were only examined for their capacity to 
stimulate a recall response to HBsAg in vitro and therefore the role of these APC to 
induce a primary anti-HBs response in vivo is not determined. With respect to the 
results described in chapter 5, stimulating APC with imiquimod would be less likely to 
enhance the antibody production if the in vivo functionality of APC is comparable to 
the in vitro findings. Another limitation of these T cell-APC mixing experiments, is that 
they do not exclude a defect in the migration of APC towards the draining lymph node. 
Nonetheless, if this migration is antigen specific a positive effect of imiquimod would 
be expected, and if this is not antigen specific, which is more likely, one would expect 
a much wider range of immune deficiencies in hepatitis B non-responders.
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A ‘hole in the T cell repertoire’ as underlying defect in the hepatitis B vaccine response, 
meaning either the lack of T cells with receptors able to recognize HBsAg peptide-class 
II complexes or unresponsiveness when T cell receptors do recognize the antigen, 
was investigated by proliferating T cells of good responders and non-responders after 
stimulation with HBsAg [38-39]. Desombere et al. demonstrated that the T cell 
response of good responders to HBsAg vaccine was multispecific and polyclonal 
(numerous epitopes and restricting elements) whereas the T cell response of poor 
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Figure 1  Mechanistic diagram showing the different required steps for  
the induction of an adaptive immune response against HBsAg. 
Adapted from ref 34 
HBs-Ag = Hepatitis B surface antigen, MHC = major histocompatibility complex, Igs = immunoglobulins. 
The HBsAg is presented by MHC class II to T helper cells.
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and non-responders was paucispecific and oligoclonal (few epitopes and restricting 
elements). By using a panel of synthetic peptides representing selected sequences of 
the HBsAg, the specificities of each of these T cell lines were determined, and revealed 
that the majority of the identified T cell epitopes was located in and around the first 
hydrophobic transmembranous region of the HBsAg. This was observed in T cell lines 
from good and poor vaccine responders, without distinction [39]. These data, together 
with the diminished proliferation capacity and impaired IL-2, IL-10 and IFNg production 
of non-responder T cells to HBsAg demonstrated by Chedid et al. and Kardar et al. 
[38,40], suggest that the hyporesponsiveness to HBsAg may be caused by defective 
T cell recognition of HBsAg which is more likely due to a ‘hole in the repertoire’ than 
to inadequate antigen presentation by APC. 
Failure of T cells to respond to HBsAg may also be explained by a lack of antigen-
specific T cell help or by an excess of antigen-specific suppression mediated by 
regulatory T cells. Scarce data support this hypothesis, as increased numbers of 
CD4+CD25+FoxP3+ regulatory T cells were demonstrated in the blood of non- 
responders after normal hepatitis B vaccination, compared to high-responders [41]. 
Whether these regulatory T cells are HBsAg specific remains to be investigated. 
Although such ‘obstinate’ non-responders as described in chapter 5 were never studied 
before, the strategy to overcome nonresponse to HBsAg vaccine is the administration 
of additional doses demonstrated by Wismans et al. who showed that supplementary 
vaccination of healthy hypo- and non-responders after standard hepatitis B vaccination 
induced an anti-HBs titre greater than 10 IU/l in 38% after one and in 75% after three 
additional doses of 20 micrograms of hepatitis B vaccine given intramuscularly [42]. 
Others reported seroconversion in 61% of the revaccinated [43]. Our findings found 
70% seroconvertion of true non-responders after additional vaccinations. And the T cell 
proliferation, although decreased, after identical epitope stimulation in non-responders 
[39] also support this strategy. Non-response is evidently a multifactor mechanism, with 
a cumulative negative influence of different factors (e.g. age, weight, gender, smoking, 
HLA-profile) on the adaptive immune response. 
In line with our attempt to enhance this response with imiquimod, many other adjuvants 
are investigated, such as AS04 [44] which elicits a superior response in non-respond-
ers compared to the licensed vaccine, although the experimental vaccine contained 
40μg HBsAg and the licensed vaccine 20μg HBsAg. Also novel antigenic formulations 
(PreS/S) are tested in non-responders, and show that the boundaries of the immune 
response in these subjects can be stretched [45].
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Whether the ID route of HBs-antigen delivery is superior to the intramuscular route 
remains uncertain, as we have not included a control group of participants who 
received a similar low vaccine dose intramuscularly. On the other hand, the ID 
vaccination route has shown to be a potential vaccination route for several vaccine 
antigens [46] and could also have contributed to the high rate of seroprotection with 
high avidity antibody response in these NR. 
Prevention of travel-related diseases by vaccination – increasing vaccine 
dose availability
Chapter 6, 7 and 8 
The intradermal vaccination, described in chapter 5, used to immunise hepatitis B 
non-responders is a recently rediscovered possibility of vaccine dose reduction 
through augmented immune stimulation, that received much attention from vaccinolo-
gists [46-48]. By reducing the vaccine dose needed for immunisation, costs per 
vaccine dose decrease and vaccine stockpiles last longer, possibly leading to higher 
vaccine coverage. In chapters 6, 7 and 8 the intradermal vaccination as an immunity 
enhancing route of inoculation is studied for yellow fever, a live attenuated vaccine 
virus, and for rabies vaccine, an inactivated virus. 
Intradermal administration of reduced amounts of both vaccines, 1/5th of the yellow 
fever vaccine and 1/10th of the rabies vaccine, elicited protective immune responses. 
We have shown that in the case of yellow fever, the reduced dose injected intradermally 
is non-inferior to the subcutaneous dose, and that the reduced rabies vaccine dose 
elicits a protective response (in correspondence with WHO definitions of protection), 
but we have not demonstrated the superiority of the intradermal immunisation per se 
since no comparison was made between the reduced vaccine dose administered 
intradermally and the reduced dose administered by the conventional immunisation 
route
In support of the superiority of the intradermal route, Cubas et al. recently showed that 
intradermal inoculation of virus-like particles (VLPs) of simian-human immunodefi-
ciency (SHIV) in mice induced enhanced immune responses compared to 
intramuscular, intraperitoneal and subcutaneous inoculation. By optical imaging, the 
trafficking of the VLPs after immunisation was directly visualized, thereby showing 
that intradermal immunisation led to the largest level of lymph node involvement for 
the longest period of time, which correlated with the strongest humoral and cellular 
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immune responses [49]. These findings should now be investigated with respect to 
other antigenic formulations.
The immune response following intradermal immunisation is depicted in Figure 2. In 
response to the injected antigen, with or without adjuvant, immature DC’s residing at 
the site of vaccination (LC or dermal DC) undergo a maturation process that is 
characterised by expression of costimulatory molecules and inflammatory cytokines 
[50]. With respect to yellow fever, the in vivo sites of replication of YF-17D have been 
determined in cynomolgus macaques [28]. After subcutaneous inoculation, small 
amounts of 17D virus were found in the skin at the site of inoculation, in the draining 
lymph nodes and mesenteric lymph nodes at the peak of viraemia (day 3 for these 
primates). By day 7, liver, spleen, bone marrow, thymus and adrenal glands were 
found to harbour YF-17D. The spleen and lymph nodes remained positive for the virus 
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Figure 2  Schematic representation of intradermal immunisation and 
 subsequent initiation of adaptive immune response [after ref 46] 
DC = dendritic cell.
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up to 14 days after inoculation, and by day 46 the virus was undetectable. These data 
indicate that the attenuated vaccine virus has a tissue tropism similar to that of 
wild-type YF, and that the initial process of immune activation occurs between the site 
of inoculation and the draining lymph nodes, similar to inactivated vaccine antigens. 
Unlike inactivated antigens which are internalised and presented on MHC class II to 
CD4+ T cells, live virus particles such as YF-17D are classically presented by DC’s on 
MHC class I to CD8+ T cells. Nonetheless, the robust humoral response to YF-17D, 
besides the elaborate cellular response recently elicited [51,52] cannot be based on 
MHC class I presentation to CTL’s. The vaccine virus activates multiple subsets of 
DC’s by signalling through multiple TLRs, including TLR2, -7, -8, and -9, resulting in 
diverse types of adaptive immune responses [53]. This was confirmed by Gaucher et 
al. who showed an increase in proliferating (Ki67+) YF-specific CD4+ T cells (2.3 fold), 
CD8+ T cells (4.7 fold), non-T cell PBMCs containing monocytes and B cells (1.9 fold) 
and NK cells (1.6 fold) within the first 14 days after vaccination, returning to insignificant 
levels thereafter [52]. The higher magnitude of the CD8+ T cell proliferation could 
reflect the occurrence of the classical MHC class I presentation of live viral pathogens 
by DC’s. The cellular response following YF-17D inoculation has probably been un-
derestimated, since the antibody response has always been regarded the principal 
mediator of protection, based on protection by passive immunisation [54]. To support 
the hypothesis of the response being initiated at the site of inoculation, recent data 
show that YF-17D replicates in DC’s and is then rapidly processed [55]. The predilection 
of YF-17D for DC’s of the skin would not be unexpected, given the natural route of 
infection via  mosquito bites. Thus, YF-17D initiates a response via multiple TLR’s on 
cells of the innate immunity, thereby inducing a broad cellular and humoral response, 
beside the response initiated via replication in DC’s which prime naïve CTL’s.
Until today, the precise role of distinct DC subsets such as Langerhans cells, dermal 
DC’s, and plasmacytoid DC’s in the process of intradermal immunisation remains 
largely unknown. Besides the involvement of skin resident DC’s in the initial 
antigen-APC contact, circulating DC precursors can be recruited into the dermis upon 
intradermal vaccination with a soluble protein, via enhanced expression of chemokine 
receptor/ligand CCR6/CCL20 [56]. After the uptake and processing of antigens, the 
maturing DC’s migrate to the T cell rich areas of the draining lymph nodes, where they 
express a mature phenotype characterized by CD11cintermediate  to high and MHCIIhigh [50]. 
The role of migratory DC’s upon viral inoculation in the skin with different viruses is not 
uniform in the induction of CD8+ T cell responses, as shown by the following mice 
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experiments. For example, in response to Herpes Simplex virus (HSV) the migratory 
DC’s merely ferry viral antigens to the lymph node and immediately transfer the HSV 
antigens to CD8α+ DC’s residing in the lymph node for cross-presentation [57]. In 
contrast, He et al. showed that migratory skin DC’s did directly present lentivirus 
derived OVA to lymph node CD8+ T cells, without cross-presentation to lymph node 
resident DC’s [58]. Nonetheless, Allan et al. demonstrated that inhibition of migration 
of skin DC’s, impaired the CTL response in the induction of HSV antiviral immunity 
[57], thereby implicating the importance of migratory skin DC’s. 
Besides the trafficking of antigens through migrating DC’s, recent research has 
highlighted the additional role of direct lymphatic drainage of free soluble antigen 
within hours after inoculation. This free antigen flows through afferent lymphatics into 
the subcapsular sinuses of the draining lymph node and is taken up and processed 
by lymph node resident DC’s. After 24 hours, a 2nd antigen wave is delivered to the 
lymph node by influx of dermal DCs (not LCs) [59]. Even though the resident DCs 
were responsible for the initial T cell activation, the DCs that acquired antigen at the 
injection site and migrated to the lymph node were needed to sustain the expression 
of the IL-2 receptor on the T cells.
For the induction of the humoral response, generally the marker of success of 
vaccination, T cell-dependent B cell responses begin in the T cell-rich areas of the 
lymphoid organs, where DC’s present antigen to antigen-specific T cells in the context 
of MHC and costimulatory molecules.  The antigen-specific B cells then receive 
signals from the helper T cells, proliferate, and undergo isotype switching. Some of 
the activated B cells become extrafollicular antibody-secreting plasma cells while 
others enter germinal centres, where they undergo somatic mutation to generate 
high-affinity memory B cells and long-lived plasma cells [60,61]. The precise role 
played by TLRs and DC’s in the germinal-centre reaction and in the generation of 
memory B cells and long-lived plasma cells is poorly understood. Recently, activation 
of B cells independently of T cells was shown by free protein antigen (green fluorescent 
protein) flow to lymph nodes upon epidermal inoculation [62]. Regarding vaccine 
antigens, T cell independent activation of B cells has only been described for polysac-
charide antigens.
Several hypotheses have been postulated to explain the relative success of ID 
vaccination.	Firstly,	a	more	direct	antigen	–	APC	contact	could	lead	to	a	smaller	‘loss’	
of antigen in subcutaneous tissue or the blood circulation where possibly less APC’s 
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are present. This hypothesis is particularly attractive in the case of live attenuated 
viruses, which need to replicate intracellularly in order to induce a potent immune 
response. For soluble protein antigens, direct flow via the afferent lymphatic vessels 
could also contribute to the response [59,62]. Interestingly, it has been shown recently 
that locally activated mast cells can, via enhanced DC migration, augment the immune 
response to several vaccine antigens such as protein antigens and vaccinia, a live 
viral antigen [63]. In chapter 7 we describe the protective antibody response to YF-17D 
in chicken egg allergic individuals. Unfortunately, whether their antibody response 
was enhanced compared to non-allergic individuals could not be verified, as their 
response had not been measured at set time points.
Secondly, ID immunisation can trigger the activation and migration of dermal DCs, 
thereby amplifying the immune response [59]. In contrast, intramuscular immunisation 
enhances, via the bloodstream, the activation of plasmacytoid DCs (pDCs) which 
enter the lymph node via high endothelial venules, similar to B en T cells [64]. pDCs 
are activated through TLR7 and TLR9 signalling, leading to type 1 IFN secretion. Their 
functional capacity in terms of vaccination (i.e. antigen presentation and T cell priming) 
remains to be investigated. 
Finally, suggested by the findings of Cubas et al., a greater number of lymph nodes 
engaged upon ID immunisation might be attributed to the lymphatic structure in the 
intradermal zone. In the skin, lymphatic vessels form two plexuses [65]. The superficial 
plexus contains branches that drain vertically into larger lymphatic vessels located in 
the lower dermis and the superficial zone of the subcutaneous tissue. These deep 
lymphatic vessels contain numerous valves through which antigen can be taken up. 
In addition, the limited space in the dermis and relatively large volume inoculated, 
could affect the permeability of the lymph vessels and thereby increasing antigen 
uptake [46]. This argument of the volume of inoculation influencing the immune 
response has been suggested by Fox et al. [66], and should be considered when 
designing new trials studying the immunisation routes.
The growing interest in ID immunisation by vaccinologists has led to the development 
of many different technologies to accurately administer vaccine doses intradermally. 
These techniques include fine-gauge needles and microneedle arrays, as well as 
various types of needle free devices such as jet injectors, and patches. Novel 
technologies for ID delivery may simplify the logistics of vaccine administration, avoid 
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Reizigersgeneeskunde; Reizigers beter beschermen tegen infectieziekten
Inleiding
In een tijd waarin steeds meer wordt gereisd naar exotische bestemmingen, worden 
ook artsen in toenemende mate geconfronteerd met geïmporteerde infectieziekten die 
niet in hun dagelijkse praktijk voorkomen. Zo werd bijvoorbeeld in 2008 een Nederlandse 
vrouw in Uganda besmet met het Marburg virus, een zeer besmettelijk virus dat massale 
bloedingen, falende orgaanfuncties en uiteindelijk de dood tot gevolg kan hebben. 
De diagnose werd pas een paar dagen na opname in het ziekenhuis vermoed. Afgezien 
van deze zeer ernstige geïmporteerde infectieziekten, die over het algemeen zeldzaam 
zijn, krijgt 10% van de reizigers tijdens of kort na hun reis koorts, vaak ten gevolge van 
infecties van het maagdarmstelsel of de luchtwegen. 
Naast het opvangen van reizigers die ziek terugkeren, beoogt de reizigersgenees-
kunde ook de reiziger zo goed mogelijk te beschermen tegen mogelijke (infectie)
ziekten die voorkomen in het land van bestemming. Deze bescherming kan op 
verschillende niveaus plaatsvinden, waarvan enkele aspecten worden beschreven in 
dit proefschrift. Als model voor de bescherming van reizigers in bredere zin, kan het 
‘Zwitserse kaas model’ worden gehanteerd, dat in 2000 beschreven is door James 
Reason (figuur 1). Reason beschreef dit model als een systeem om menselijke fouten 
(ten gevolge van een falend systeem) te minimaliseren.
Dit model kan ook toegepast worden op de reizigersgeneeskunde. Voorbeelden van 
gevaren (hazards) zijn de omstandigheden waarin de reiziger verkeert en die hem of 
haar kwetsbaar maakt voor besmetting met micro-organismen (bacteriën, virussen, 
enz) die ziekte kunnen veroorzaken, en de gezondheidstoestand van de reiziger die 
kunnen maken dat ziekten ernstiger verlopen. Dit laatste is bijvoorbeeld het geval 
voor reizigers met een verminderde afweer. De verschillende kaasplakken staan 
model voor de barrières die men kan inbouwen om de kans op besmetting of op 
een ernstiger verloop van de ziekte te verkleinen. Waar deze bescherming faalt, 
bijvoorbeeld als een vaccin geen 100% bescherming biedt, vallen er gaten in de kaas. 
Uiteindelijk leidt de som van barrières en het falen van bescherming tot de kans op 
ziekte.
De taak van de reizigersgeneeskunde, zoals in andere takken van preventieve genees -
kunde, bestaat uit het optimaliseren van deze barrières en het identificeren van de gaten. 
In dit proefschrift worden een aantal onderzoeken beschreven die dit doel nastreven.
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Hoofdstuk 1. Langdurig verblijf in malaria gebied: voorkomen en zelf 
behandelen van malaria
In hoofdstuk 1 werd een malaria preventie programma geëvalueerd. Het programma 
bestond uit een educatieve training over malaria, een quiz bij aankomst in het land 
van bestemming, het verstrekken van antimuggenmaatregelen en malariaprofylaxe, 
testen om malaria bij zichzelf vast te stellen en een geneesmiddel om malaria te 
behandelen. Het programma werd uitgevoerd in een groep werknemers van 
oliebedrijven, die gedurende langere perioden in gebieden verbleven waar malaria 
voorkomt. Hoewel het programma verplicht was, hadden om logistieke redenen niet 
alle werknemers hieraan deelgenomen, wat de gelegenheid gaf het effect van het 
programma te onderzoeken. Het is bekend dat deze ‘langverblijvers’ de beschermende 
maatregelen tegen malaria niet goed opvolgen. Deze maatregelen omvatten het 
voorkomen van muggenbeten (malaria wordt door een mug overgebracht), en het 
innemen van medicatie die de vermenigvuldiging van de malariaparasiet in het 
lichaam remt. Zoals verwacht was de onderzoeksgroep therapieontrouw  (20% nam 
antimalariamiddelen ter voorkoming van malaria, tegenover 85% van de toeristen 
naar een malariagebied). Opvallend was echter dat deelname aan het programma dit 
gebruik verdubbelde (van 20% naar 55%). Voor het gebruik van antimuggenmaat-
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Figuur 1  Zwitserse kaas model van Reason. Hazards = gevaren, losses = 
schade of ziekte. De verschillende kaasplakken staan voor de 
 verschillende barrières (beschermende maatregelen). Deze zijn 
schematisch getekend, waarbij in de werkelijkheid de gaten in de 
verschillende plakken niet overlappen.
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regelen werd eenzelfde trend gezien, evenals een gunstige invloed van het programma 
op de kennis van de deelnemers over malaria. De mogelijkheid om zelf een test uit te 
voeren om malaria vast te stellen werd eveneens onderzocht. Er werd een daling van 
het aantal ziekenhuisopnames ten gevolge van malaria gezien bij deelnemers die het 
programma hadden gevolgd, wat duidt op een eerdere diagnose en behandeling van 
de ziekte en daardoor minder ernstig beloop. 
Een beperking van dit onderzoek was dat de diagnose malaria niet werd gecontroleerd, 
waardoor de feitelijke juistheid van de zelf-test niet gemeten kon worden. Deze test, 
indien correct uitgevoerd, zou een uitkomst bieden aan reizigers die symptomen van 
een malaria infectie hebben en niet direct medische hulp kunnen zoeken.
Hoofdstuk 2. Reizigers met verlaagde afweer: niertransplantatie patiënten
Deze niertransplantatiepatiënten krijgen afweeronderdrukkende medicatie om 
afstoting van hun getransplanteerde nier te voorkomen. In Hoofdstuk 2 werd 
onderzocht of deze patiënten met verlaagde afweer op reis gaan en hoe zij zich hierop 
voorbereidden. Ook werd onderzocht of zij gedurende de reis ziek werden. Een derde 
van de patiënten was in de voorgaande 5 jaar op reis geweest buiten West-Europa of 
Noord-Amerika. De helft van de patiënten die reisadvies hadden ingewonnen, deden 
dit bij hun transplantatie arts; hetgeen wijst op de belangrijke rol van deze arts bij de 
reisvoorlichting. Opvallend was, dat van de patiënten die ziek werden gedurende hun 
reis, 25% opgenomen werd in een ziekenhuis. Vergeleken met reizigers zonder af-
weerproblemen, waarvan 1% van de zieken wordt opgenomen, duidt dit op een 
verhoogde kans op een ernstiger beloop van ziekte ten gevolge van de transplantatie. 
Hierbij speelt mogelijk een rol dat deze niertransplantatiepatiënten eerder dan 
gezonden een ziekenhuis bezoeken bij symptomen van ziekte. Dit onderzoek toont 
aan dat de voorlichting van deze specifieke groep reizigers kan worden verbeterd 
door meer aandacht te schenken aan de voorbereiding van de reis, bijvoorbeeld door 
professioneel advies in te winnen. Hierbij is een belangrijke rol  weggelegd voor de 
behandelende specialist. Door het retrospectieve karakter van het onderzoek zijn de 
resultaten onderhevig aan de herinnering van de patiënten wat leidt tot een grotere 
onnauwkeurigheid (afgezien van de resultaten betreffende de ziekenhuisopname). 
Om deze onnauwkeurigheid uit te sluiten is prospectief onderzoek noodzakelijk.
Hoofdstuk 3. Reizigers met co-morbiditeit: diabetes mellitus
In dit hoofdstuk werd onderzocht of reizigers met suikerziekte (diabetes mellitus) een 
verhoogde kans hebben op het krijgen van reizigersdiarree. Dit werd namelijk in 
eerder retrospectief onderzoek beschreven, met als gevolg dat suikerpatiënten op 
Samenvatting
180
reis altijd antibiotica meekrijgen ter voorkoming van ernstige ontregeling van hun 
bloedsuikers ten gevolge van de diarree. Het onderzoek beschreven in hoofdstuk 3 
werd prospectief uitgevoerd, wat betekent dat de deelnemers tijdens hun reis dagelijks 
notitie maakten van het optreden van eventuele symptomen. Omdat het voorkomen 
van infectieziekten sterk afhangt van de reisbestemming en blootstelling aan micro-
organismen, werden naast de diabetische deelnemers ook hun (gezonde) reispartner 
geïncludeerd. Het belangrijkste resultaat van dit onderzoek was dat suikerpatiënten 
geen hogere kans hebben op het krijgen van reizigersdiarree dan hun gezonde 
reispartner. Slechts 2.4 en 4.3% (respectievelijk niet insuline afhankelijke en insuline 
afhankelijke diabeten) had een ontregeling van de bloedsuiker. Van deze deelnemers 
had de helft klachten van diarree. Ook bleek uit het onderzoek dat slechts 17% van de 
diabeten die diarree kregen de voorgeschreven antibiotica innam, wat het nut van het 
voorschrijven van deze antibiotica nog verder ter discussie stelt.
Hoofdstuk 4. Reizen op oudere leeftijd: implicaties voor vaccinatie met 
verzwakt levend vaccin
Met een toenemend aantal reizigers in de afgelopen jaren, neemt ook de groep 
oudere reizigers significant toe. Nu babyboomers de pensioengerechtigde leeftijd 
bereiken, relatief gezond en vaak niet onbemiddeld zijn, zullen meer en meer ouderen 
ook verre reizen gaan maken. Deze groep vormt een extra uitdaging om ze weer 
gezond terug te laten keren naar huis. Afgezien van logistieke maatregelen met 
betrekking tot geneesmiddelen, verzekeringen enz., neemt het vermogen om 
beschermende afweer op te bouwen na vaccinatie af met het ouder worden. 
Om deze afweer te verhogen zou bijvoorbeeld de dosis van het vaccin verhoogd 
kunnen worden.
Voor het gele koorts vaccin geldt nog een ander probleem. Het gele koorts vaccin bevat 
levend gelekoortsvirus, dat verzwakt is en dus in principe geen ziekte kan veroorzaken. 
Na vaccinatie vermenigvuldigt het virus zich in het lichaam. De afweerreactie die 
daarop volgt en het virus opruimt, zorgt voor een levenslange bescherming tegen de 
ziekte gele koorts. In de afgelopen jaren werden er wereldwijd tientallen gevallen 
beschreven waarbij personen na toediening van het gele koorts vaccin de ziekte gele 
koorts ontwikkelden. Waarschijnlijk zag het vaccinvirus een kans zich veel meer te 
vermenigvuldigen dan normaal. Uit eerder onderzoek bleek een hogere leeftijd een 
onafhankelijke risicofactor te zijn voor het ontwikkelen van deze bijwerking. 
In hoofdstuk 4 werd onderzocht of dit het gevolg was van een tragere  afweerreactie bij 
ouderen waardoor het vaccin virus zich dus langer en meer kan vermenigvuldigen. 
Een groep jongeren (gemiddelde leeftijd 22) en een groep ouderen (gemiddelde leeftijd 
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65) werden gevaccineerd en op dezelfde tijdstippen werd de afweer tegen gele koorts 
gemeten. Uit dit onderzoek bleek dat de beschermende afweer (uitgedrukt in antistoffen) 
in ouderen inderdaad later opkomt.
Hoofdstuk 5. Verlaagde respons op vaccinatie: hepatitis B vaccinatie
Hepatitis B virus kan een chronische ontsteking van de lever veroorzaken wat 
uiteindelijk tot leverkanker kan leiden. Omdat dit virus via seksuele weg of bloed wordt 
overdragen en  personen op reis een verhoogd risicogedrag vertonen waardoor ze 
geïnfecteerd kunnen worden met het virus, worden reizigers in veel landen 
laagdrempelig gevaccineerd tegen het hepatitis B virus. In Nederland  worden 
reizigers die veelvuldig reizen of lange reizen gaan maken gevaccineerd.
Afgezien van reizigers worden in Nederland verschillende beroepsgroepen, waaronder 
medisch en paramedisch personeel, gevaccineerd tegen hepatitis B, omdat zij in 
contact kunnen komen met gecontamineerd patiëntenmateriaal. Helaas maakt 5 tot 
10% van de gezonde personen geen afweerstoffen (anti-hepatitis B antistoffen) na 
vaccinatie. Er is nog geen duidelijke verklaring gevonden voor het uitblijven van deze 
reactie op het vaccin. Wel zijn mannelijk geslacht, roken, hogere leeftijd en overgewicht 
geassocieerd met een slechtere afweerrespons. In hoofdstuk 5 werd onderzocht of 
met een afweerstimulerende crème (imiquimod) deze reactie alsnog op te wekken 
viel. De crème wordt gebruikt voor de behandeling van (genitale) wratten, waarbij het 
virus dat deze wratten veroorzaakt (humaan papilloma virus) door gespecialiseerde 
witte bloedcellen (dendritische cellen) in de huid naar de lymfeklier wordt getranspor-
teerd en er zo een volledige afweerreactie ontstaat. De crème activeert deze 
dendritische cellen waardoor de afweerreactie wordt gestimuleerd. In het onderzoek 
werd het hepatitis B vaccin in de huid (intradermaal) geïnjecteerd, onmiddellijk nadat 
de crème op de huid was aangebracht. Om het effect van de crème te onderzoeken 
werd één groep met crème gevaccineerd en een groep zonder. Er werd geen verschil 
gemeten tussen beiden groepen. Wat wel opviel was dat 70% van de proefpersonen, 
die na 6 eerdere hepatitis B vaccinaties (in de spier) geen beschermende afweerreactie 
hadden ontwikkeld, dat na intra dermale vaccinatie wel deden. 
De reden voor het uitblijven van een betere respons na stimulatie met de crème kan zijn 
dat de afweercellen die gestimuleerd worden niet de cellen zijn die verantwoordelijk zijn 
voor de slechte afweerrespons. Verder is het mogelijk dat het effect van de crème virus-
specifiek is, en dus wel geobserveerd wordt bij infecties met humaan papilloma virus, 
maar niet bij andere virussen of virusdeeltjes. Het feit dat 70% van de deelnemers 
(ongeacht de onderzoeksgroep) een beschermende respons ontwikkelde leidt tot de 
hypothese dat uiteindelijk iedereen afweer tegen dit vaccin kan opbouwen, mits er 
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voldoende (qua dosis of frequentie) gevaccineerd wordt. Dit is aannemelijk, aangezien 
de kwaliteit van de antistoffen, uitgedrukt in de sterkte van de binding aan het ingeënte 
hepatitis B eiwit, al na de eerste vaccinatie hoog was. 
De superioriteit van het eenmalig aanbrengen van de afweerstimulerende crème kon in 
deze groep niet worden aangetoond omdat de bescherming in de controlegroep veel 
hoger bleek dan verwacht. De grootte van de onderzoeks populatie was dus te klein om 
een verschil tussen de controlegroep (zonder crème) en de interventiegroep (met 
crème) aan te tonen. De superioriteit van de vaccinatie in de huid ten opzichte van de 
conventionele vaccinatie werd niet aangetoond, aangezien geen controle groep werd 
geïncludeerd waarbij dezelfde dosis in de spier werd geïnjecteerd.
Hoofdstuk 6 en 7. Gele koorts vaccin dosisverlaging: vaccinatie in de huid
Het gele koorts vaccin dat in hoofdstuk 5 reeds ter sprake kwam, is een levend verzwakt 
vaccin dat toegediend wordt aan reizigers naar tropisch Afrika en Zuid-Amerika. In de 
natuur wordt het virus overgebracht door muggen, en infectie bij de mens kan lever-
ontsteking, multi-orgaanfalen en uiteindelijk de dood tot gevolg hebben. De enige 
bescherming tegen gele koorts is vaccinatie, aangezien er geen geneesmiddel tegen 
de ziekte bestaat. Het vaccin is een levend verzwakt virus dat op kippeneieren wordt 
gekweekt. Het is een bewerkelijk productieproces waardoor ten tijde van epidemieën 
gemakkelijk vaccinschaarste kan ontstaan. De wereldgezondheidsorganisatie verhoogt 
ieder jaar  de voorraad gele koortsvaccin om tijdig te kunnen reageren op jaarlijkse 
epidemieën door middel van vaccinatiecampagnes. 
In Hoofdstuk 6 wordt in een vergelijkend gerandomiseerd onderzoek aangetoond dat 
de intradermale vaccinatie met  1/5de van de normale vaccindosis (0.1ml) een 
evenwaardige afweerreactie tot gevolg had als vaccinatie  van 0.5ml via de 
conventionele subcutane (onder de huid) weg. Door in tijden van schaarte intradermaal 
in plaats van subcutaan te vaccineren, kan de voorraad gele koorts vaccin theoretisch 
vervijfvoudigd worden.
Het onderzoek beschreven in hoofdstuk 6 is het eerste onderzoek waarin aangetoond 
werd dat intradermale vaccinatie met een kleine dosis gele koorts virus een 
evenwaardige beschermende afweerrepons tot gevolg heeft. Het succes van deze 
spaarzame vaccinatiemethode wordt toegeschreven aan de aanwezigheid van 
specifieke witte bloedcellen (dendritische cellen) in de bovenste lagen van de huid, 
die de vaccindeeltjes efficiënt kunnen afbreken en presenteren aan de afweercellen in 
de lymfeklieren, waar uiteindelijk de afweerreactie tegen het virus ontstaat. De 
subcutane (onder de huid) en intramusculaire (in de spier) vaccinaties maken mogelijk 
minder aanspraak op deze gespecialiseerde dendritische cellen, waardoor meer 
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vaccin ‘verloren’ gaat. Onlangs is in muizen aangetoond, dat als fluorescerende 
deeltjes in de huid werden ingespoten er meer en langer deeltjes werden teruggevonden 
in de lymfeklieren, dan wanneer de fluorescerende deeltjes onder de huid, in de spier 
of in de buikholte werden ingespoten. Dit onderzoek ondersteunt onze bevindingen.
Hoofdstuk 8. Rabiës vaccin dosisverlaging: vaccinatie in de huid
Zoals in hoofdstuk 8 beschreven voor de gele koorts vaccinatie, werd ook de 
intradermale vaccinatie van rabiës (hondsdolheid) vaccin onderzocht. Evenals gele 
koorts, wekt dit vaccin (een dood vaccin) na toediening in de huid een goede 
afweerrespons op. Daarnaast bleek ook een intradermale rabiës revaccinatie (booster) 
effectief. Een booster is een vaccinatie die het afweergeheugen aanspreekt, na een 
eerdere (primaire) vaccinatie, waarbij snel een zeer hoge afweerrespons tot stand 
komt. De intradermale rabiësvaccinatie biedt een uitkomst voor het dure vaccin dat 
geïndiceerd is voor reizigers die langdurige en avontuurlijke reizen maken. Hierbij is 
de kans om door een dolle hond, of ander zoogdier besmet met hondsdolheidvirus, 
gebeten te worden zodanig dat vaccinatie vóór de reis sterk aangeraden wordt. 
Vanwege de kostenreductie door dosisverlaging kiezen meer reizigers ervoor om zich 
via intradermale weg te laten vaccineren. De intradermale rabiësvaccinatie wordt om 
financiële redenen op ruime schaal toegepast in ontwikkelingslanden. 
De intradermale vaccinatie als methode om een effectieve afweerrespons op te 
bouwen wordt de laatste jaren uitvoerig onderzocht met betrekking tot de verschillende 
vaccins, zoals gele koorts en rabiës, maar ook met betrekking tot de methode van 
intradermaal vaccineren. Voorbeelden hiervan zijn bijvoorbeeld vaccinatie met zeer 
kleine naaldjes, of vaccinatie met een pleister, waarbij het vaccin door de huid wordt 
opgenomen. Deze nieuwe methoden kunnen de toediening en daarmee de 
implementatie van de intradermale vaccinatie stimuleren. 
Beschouwing en conclusie
Bescherming van reizigers tegen infectieziekten kan op verschillende niveaus worden 
nagestreefd. Het Zwitserse kaasmodel, zoals beschreven in de inleiding van deze 
samenvatting, geeft weer dat op elk niveau fouten kunnen optreden die kunnen leiden 
tot ziekte. In dit proefschrift staan verschillende onderzoeken beschreven die kunnen 
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LC Langerhans cell
LUMC Leiden University Medical Centre
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PCECV Purified Chick Embryo Cell Vaccine
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List of abbreviations
186
SOT Solid Organ Transplant 
TLR Toll like Receptor
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